Anti-erbb3 antibodies

ABSTRACT

Monoclonal antibodies that bind and inhibit activation of epidermal growth factor receptor related member ErbB3/HER3 are disclosed. The antibodies can be used to treat cell proliferative diseases and disorders, including certain forms of cancer, associated with activation of ErbB3/HER3.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. patent application Ser. No. 15/448,164, filed Mar. 2, 2017, which is a divisional of U.S. patent application Ser. No. 14/987,374, filed Jan. 4, 2016, now U.S. Pat. No. 9,598,498, which is a divisional of U.S. patent application Ser. No. 13/919,582, filed Jun. 17, 2013, now U.S. Pat. No. 9,228,021, which is a divisional of U.S. patent application Ser. No. 13/082,852 filed Apr. 8, 2011, now U.S. Pat. No. 8,481,687, which claims priority to and the benefit of U.S. Provisional Patent Application No. 61/322,712, filed Apr. 9, 2010; the entire contents of each of which is incorporated herein by reference.

FIELD OF THE INVENTION

The field of the invention is molecular biology, immunology and oncology. More particularly, the field is humanized antibodies that bind human ErbB3/HER3.

BACKGROUND

HER3/c-ErbB3 (referred to herein as ErbB3) is a member of the epidermal growth factor receptor (EGFR) family. ErbB3 binds neuregulin/heregulin (NRG/HRG). Receptors in the EGFR family are single transmembrane receptors with an intracellular tyrosine kinase domain. While the other EGFR family members, i.e., EGFR/HER1/ErbB1, HER2/ErbB2, and HER4/ErbB4, each have tyrosine kinase activity, ErbB3 has little or no tyrosine kinase activity, and thus is “kinase-dead.”

The extracellular domain (ECD) of the EGFR family contains four domains. Domains 1 and 3 (also known as domains L1 and L2) are responsible for ligand binding. Cysteine-rich domains 2 and 4 (also known as domains C1 and C2) are involved in dimerization with receptor partners. Upon ligand binding, the ECD undergoes conformational changes. The interaction of domains 2 and 4, which maintains the tethered (inactive) conformation of the receptor, is relieved, and an extended (active) conformation is adopted. The extended conformation favors dimerization with other receptor partners. HER2/ErbB2 is the only exception to this general rule, i.e., Her2-ECD is constitutively in the extended conformation. No ligand for HER2 has been identified thus far.

Because ErbB3 lacks an intrinsic kinase activity, it must dimerize with another active tyrosine kinase receptor to be activated by tyrosine phosphorylation. Dimerization can occur between two different receptors (heterodimerization), e.g., ErbB3 and EGFR/HER1/ErbB1, HER2/ErbB2, or HER4/ErbB4. Recently, ErbB3 was also shown to dimerize with MET. Upon association with another tyrosine kinase receptor, ErbB3 is activated by phosphorylation of at least nine tyrosine residues in the ErbB3 intracellular domain, and then rapidly associates with adaptors or downstream signaling molecules. Six of the ErbB3 phosphorylated tyrosine residues associate directly with the p85 subunit of Phosphatidylinositol 3-Kinase (PIK3), which results in activation of the cellular survival pathway controlled by the PI3K/Akt axis. Constitutive activation of ErbB3 by unregulated dimerization and/or unregulated phosphorylation of ErbB3 can lead to certain cancers.

Overexpression of ErbB3 is associated with poor prognosis in various carcinomas (e.g., breast, ovarian, prostate, colorectal, pancreatic, gastric, and head and neck cancers). Overexpression of ErbB3 also correlates with local to distal metastasis in lung, gastric, and colorectal cancers, and bone invasion in prostate cancer (Sithanandam et al., 2008, CANCER GENE THERAPY 15:413). Overexpression of ErbB3 has been linked to resistance to several cancer treatments, including treatment with EGFR tyrosine kinase inhibitors in non-small cell lung cancer (NSCLC) and head and neck cancers, treatment with Her2 inhibitor in breast cancers, and treatment with radiotherapy in pancreatic cancers. Moreover, overexpression of NRG, a ligand for ErbB3, was also linked to resistance to EGFR tyrosine kinase inhibitor treatment. Chen et al. describe the use of anti-ErbB3 monoclonal antibodies that inhibit NRG function and show growth inhibitory activity against breast and ovarian cancer cells (Chen et al., 1996, J. BIOL. CHEM. 271: 7620).

There is a need for improved anti-ErbB3 antibodies that can be used as therapeutic agents.

SUMMARY

The invention is based on the discovery of a family of antibodies that specifically bind human ErbB3. The antibodies contain ErbB3 binding sites based on CDRs that specifically bind human ErbB3. When used as therapeutic agents, the antibodies are engineered, e.g., humanized, to reduce or eliminate an immune response when administered to a human patient.

The antibodies disclosed herein prevent or inhibit the activation of human ErbB3. In some embodiments, the antibodies prevent ErbB3 from binding to a ligand, e.g., NRG/HRG, thereby neutralizing the biological activity of ErbB3. In other embodiments, the anti-ErbB3 antibodies inhibit ErbB3 dimerization, thereby neutralizing the biological activity of ErbB3. The antibodies disclosed herein can be used to inhibit the proliferation of tumor cells in vitro or in vivo. When administered to a human cancer patient (or an animal model such as a mouse model), the antibodies inhibit or reduce tumor growth in the human patient (or animal model).

These and other aspects and advantages of the invention are illustrated by the following figures, detailed description and claims. As used herein, “including” means without limitation, and examples cited are non-limiting.

DESCRIPTION OF THE DRAWINGS

The invention can be more completely understood with reference to the following drawings.

FIG. 1 (prior art) is a schematic representation of a typical antibody.

FIG. 2 is a schematic diagram showing the amino acid sequence of the complete immunoglobulin heavy chain variable region of the antibodies denoted as 04D01, 09D03, 11G01, 12A07, 18H02, 22A02, and 24C05. The amino acid sequences for each antibody are aligned against one another, and Complementary Determining Sequences (CDR) (Kabat definition), CDR₁, CDR₂, and CDR₃, are identified in boxes. The unboxed sequences represent framework (FR) sequences.

FIG. 3 is a schematic diagram showing the CDR₁, CDR₂, and CDR₃ sequences (Kabat definition) for each of the immunoglobulin heavy chain variable region sequences in FIG. 2.

FIG. 4 is a schematic diagram showing the amino acid sequence of the complete immunoglobulin light chain variable region of antibodies 04D01, 09D03, 11G01, 12A07, 18H02, 22A02, and 24C05. The amino acid sequences for each antibody are aligned against one another, and CDR₁, CDR₂, and CDR₃ sequences (Kabat definition) are identified in boxes. The unboxed sequences represent framework (FR) sequences.

FIG. 5 is a schematic diagram showing the CDR₁, CDR₂, and CDR₃ sequences (Kabat definition) for each of the immunoglobulin light chain variable region sequences in FIG. 4.

FIGS. 6A and 6B are graphs summarizing results from an experiment to measure the neutralization activity of negative control (murine IgG (Δ)) and anti-ErbB3 monoclonal antibodies 04D01 (▪), 12A07 (o), 18H02 (⋄), 22A02 (⋅) and 24C05 (□) to inhibit NRG1-β1 binding to hErbB3 (FIG. 6A) and to measure the enhanced binding of NRG1-β1 to rhErbB3 by the anti-ErbB3 mAb 09D03 (▴) and 11G01 (*) (FIG. 6B).

FIG. 7 is a graph summarizing results from an experiment to measure the neutralization activity of negative control (murine IgG) and anti-ErbB3 monoclonal antibodies 04D01, 09D03, 11G01, 12A07, 18H02, 22A02 and 24C05 to inhibit NRG1-α1 binding to rhErbB3.

FIG. 8 is a graph summarizing results from an experiment to measure the cell surface recognition of the anti-ErbB3 antibodies of the chimeric protein Her2/3d2 expressed at the surface of CHO cells.

FIG. 9 is a graph summarizing results from an experiment to measure the anti-proliferation activity of negative control IgG (murine IgG (A)) and anti-ErbB3 monoclonal antibodies 04D01 (▪), 09D03 (▾), 11G01 (♦), 12A07 (o), 18H02 (⋄), 22A02 (⋅) and 24C05 (□) in BaF/3 cells expressing Her2 and ErbB3 in presence of NRG1-β1.

FIG. 10 is a graph summarizing results from an experiment to measure the anti-proliferation activity of anti-ErbB3 monoclonal antibodies 04D01 (▪), 09D03(▾), 11G01 (♦), 12A07 (o), 18H02 (⋄), 22A02 (⋅) and 24C05 (□) in MCF7 cells in the presence of NRG1-β1.

FIG. 11 is a graph summarizing results from an experiment to measure the anti-proliferation activity of negative control (murine IgG) and anti-ErbB3 monoclonal antibodies 04D01, 09D03, 11G01, 12A07, 18H02, 22A02 and 24C05 in SKBR-3 cells treated with 5 μg/ml of antibodies in the presence of serum.

FIG. 12 is graph summarizing results from an experiment to measure the inhibitory activity of negative control IgG and anti-ErbB3 monoclonal antibodies 04D01, 09D03, 11G01, 12A07, 18H02, 22A02 and 24C05 on the phosphorylation of ErbB3 induced by NRG in SKBR-3 cells. No antibody/no ligand and no antibody controls are also shown.

FIGS. 13A and 13B are graphs representing results from an experiment to measure the inhibitory activity of anti-ErbB3 monoclonal antibodies 04D01, 09D03, 11G01, 12A07, 18H02, 22A02 and 24C05 on the phosphorylation of Akt in response to NRG1-131 in MCF7 cells (FIG. 13A) and in DU145 cells (FIG. 13B) as determined by ELISA. No antibody/no ligand and no antibody controls are also shown.

FIG. 14 is a graph summarizing results from an experiment to measure the tumor inhibitory activity of the anti-ErbB3 antibodies 04D01 (Δ), 09D03 (*), 11G01 (□), 12A07 (▴), 18H02 (⋅), 22A02 (□), 24C05 (o) and a human IgG control (- -▪- -) dosed at 20 mg/kg in a BxPC3 pancreatic tumor xenograft model in CB17 SCID mice (vehicle control, PBS (♦)).

FIG. 15 is a schematic diagram showing the amino acid sequences of the complete heavy chain variable region of 24C05 and the complete humanized heavy chain variable regions denoted as Sh24C05 Hv3-7, Sh24C05 Hv3-11, Sh24C05 Hv3-11 N62S, Sh24C05 Hv3-21, Sh24C05 Hv3-23, Sh24C05 Hv3-30, and Hu24C05 HvA. The amino acid sequences for each heavy chain variable regions are aligned against one another, and Complementary Determining Sequences (CDR) (Kabat definition), CDR₁, CDR₂, and CDR₃, are identified in boxes. The unboxed sequences represent framework (FR) sequences.

FIG. 16 is a schematic diagram showing the amino acid sequences of the complete light chain variable region of 24C05 and the complete humanized light chain variable regions denoted as Sh24C05 Kv1-9, Sh24C05 Kv1-16, Sh24C05 Kv1-17, Sh24C05 Kv1-33, Sh24C05 Kv1-39, and Hu24C05 KvA. The amino acid sequences for each light chain variable regions are aligned against one another, and CDR₁, CDR₂, and CDR₃ sequences (Kabat definition) are identified in boxes. The unboxed sequences represent framework (FR) sequences.

FIG. 17 are Biacore sensorgrams representing results from an experiment to measure the kinetic values of anti-ErbB3 monoclonal antibodies, Sh24C05-31 N62S-IgG1, Ab #6, U1-53, and U1-59.

FIG. 18A is a graph summarizing results from an experiment to measure the neutralization activity of negative control (human IgG (□)) and anti-ErbB3 monoclonal antibodies Sh24C05-25 N62S-IgG1 (▴), Sh24C05-25 N62S-IgG2 (Δ), Sh24C05-31 N62S-IgG1(⋅) and Sh24C05-31 N62S-IgG2 (o). FIG. 18B is a graph summarizing results from an experiment to measure the neutralization activity of human IgG (□) and anti-ErbB3 monoclonal antibodies Ab #6 IgG2 (▾), U1-53 (⋄) and U1-59 (□).

FIG. 19A is a graph summarizing results from an experiment to measure the inhibitory activity of negative control (human IgG (□)) and anti-ErbB3 monoclonal antibodies Sh24C05-25 N62S-IgG1 (▴), Sh24C05-25 N62S-IgG2 (Δ), Sh24C05-31 N62S-IgG1 (⋅) and Sh24C05-31 N62S-IgG2 (o) in BaF/3 cells expressing Her2 and ErbB3 in the presence of NRG1-β1. FIG. 19B is a graph summarizing results from an experiment to measure the inhibitory activity of human IgG (□) and anti-ErbB3 monoclonal antibodies Sh24C05-31 N62S-IgG1(⋅), Ab #6 IgG2 (∇), U1-53 (□) and U1-59 (▪) in BaF/3 cells expressing Her2 and ErbB3 in the presence of NRG1-β1.

FIG. 20 is a graph summarizing results from an experiment to measure the inhibitory activity of negative control (human IgG) and anti-ErbB3 monoclonal antibodies Sh24C05-25 N62S-IgG1, Sh24C05-25 N62S-IgG2, Sh24C05-31 N62S-IgG1, and Sh24C05-31 N62S-IgG2 on the steady state phosphorylation of ErbB3 in growing SKBR-3 cells.

FIG. 21 is a graph summarizing results from an experiment to measure the degradation of ErbB3 receptor by negative control (human IgG) and anti-ErbB3 monoclonal antibodies Sh24C05-25 N62S-IgG1, Sh24C05-25 N62S-IgG2, Sh24C05-31 N62S-IgG1, and Sh24C05-31 N62S-IgG2 in growing SKBR-3 cells.

FIG. 22 is a graph summarizing the results from an experiment to measure tumor inhibitory activity of a human IgG, murine IgG, or anti-ErbB3 monoclonal antibodies dosed at 2 mg/kg in a BxPC3 pancreatic tumor xenograft model in CB17 SCID mice (murine 24C05 (Δ), Sh24C05-31 N62S IgG1 (⋅), Sh24C05-31 N62S IgG2 (♦), Sh24C05-25 N62S IgG1(▴), Sh24C05-25 N62S IgG2 (▪), vehicle control (□), murine IgG (x), and human IgG (⋄)).

FIG. 23A is a graph summarizing the results from an experiment to measure tumor inhibitory activity of a murine IgG or anti-ErbB3 monoclonal antibodies dosed at 5 mg/kg in a Calu-3 non-small cell lung cancer xenograft model in NCR nude mice (vehicle control (□), murine IgG (x), Sh24C05-31 N62S IgG1 (▴), Ab #6 IgG2 (⋅), and U1-59 (▪)).

FIG. 23B is a graph summarizing the results from an experiment to measure tumor inhibitory activity of a murine IgG or anti-ErbB3 monoclonal antibodies dosed at 10 mg/kg in a Calu-3 non-small cell lung cancer xenograft model in NCR nude mice (vehicle control (□), murine IgG (x), Sh24C05-31 N62S IgG1 (▴), Ab #6 IgG2 (⋅), and U1-59 (▪)).

FIG. 23C is a graph summarizing the results from an experiment to measure tumor inhibitory activity of a murine IgG or anti-ErbB3 monoclonal antibodies dosed at 20 mg/kg in a Calu-3 non-small cell lung cancer xenograft model in NCR nude mice (vehicle control (□), murine IgG (x), Sh24C05-31 N62S IgG1 (▴), Ab #6 IgG2 (⋅), and U1-59 (□)).

FIG. 24 is a graph summarizing the results from an experiment to measure tumor inhibitory activity of a human IgG, murine or anti-ErbB3 monoclonal antibodies in a MDA-MB-453 breast cancer xenograft model in NOD SCID mice (vehicle control (□), human IgG (x), Sh24C05-31 N62S IgG1 dosed at 5 mg/kg (⋄), Sh24C05-31 N62S IgG1 dosed at 10 mg/kg (Δ), Sh24C05-31 N62S IgG1 dosed at 20 mg/kg (▴), Ab #6 IgG2 dosed at 10 mg/kg (⋅), and U1-59 dosed at 10 mg/kg (▪)).

DETAILED DESCRIPTION

The ErbB3 antibodies disclosed herein are based on the antigen binding sites of certain monoclonal antibodies selected for their ability to neutralize the biological activity of human ErbB3 polypeptides. The antibodies contain immunoglobulin variable region CDR sequences that define a binding site for ErbB3. In some embodiments, the antibodies prevent ErbB3 from binding to a ligand, e.g., NRG/HRG, thereby neutralizing the biological activity of ErbB3. In other embodiments, the anti-ErbB3 antibodies inhibit ErbB3 dimerization, thereby neutralizing the biological activity of ErbB3. In still other embodiments, the anti-ErbB3 antibodies inhibit phosphorylation of ErbB3 and downstream signaling.

Because of the neutralizing activity of these antibodies, they are useful for inhibiting the growth and/or proliferation of certain cancer cells and tumors. The antibodies can be engineered to minimize or eliminate an immune response when administered to a human patient. In some embodiments, the antibodies are fused or conjugated to other moieties, such as detectable labels or effector molecules such as small molecule toxins.

I. Antibodies that Bind ErbB3

In some embodiments, the antibody comprises: (a) an immunoglobulin heavy chain variable region comprising the structure CDR_(H1)-CDR_(H2)-CDR_(H3) and (b) immunoglobulin light chain variable region, wherein the heavy chain variable region and the light chain variable region together define a single binding site for binding human ErbB3. A CDR_(H1) comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 5 (04D01), SEQ ID NO:15 (09D03), SEQ ID NO: 25 (11G01), SEQ ID NO: 34 (12A07), SEQ ID NO: 41 (18H02), SEQ ID NO: 51 (22A02), SEQ ID NO: 57 (24C05), and SEQ ID NO: 75 (24C05); a CDR_(H2) comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 6 (04D01), SEQ ID NO:16 (09D03), SEQ ID NO: 26 (11G01), SEQ ID NO: 35 (12A07), SEQ ID NO: 42 (18H02), SEQ ID NO: 52 (22A02), SEQ ID NO: 58 (24C05), and SEQ ID NO: 148 (Sh24C05 Hv3-11 N62S); and a CDR_(H3) comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 7 (04D01), SEQ ID NO: 17 (09D03), SEQ ID NO: 27 (11G01), SEQ ID NO: 36 (12A07, 22A02), SEQ ID NO: 43 (18H02), and SEQ ID NO: 59 (24C05). Throughout the specification a particular SEQ ID NO. is followed in parentheses by the antibody that was the origin of that sequence. For example, “SEQ ID NO: 5 (04D01)” means that SEQ ID NO: 5 comes from antibody 04D01.

In some embodiments, the antibody comprises an immunoglobulin heavy chain variable region comprising a CDR_(H1) comprising the amino acid sequence of SEQ ID NO: 5 (04D01), a CDR_(H2) comprising the amino acid sequence of SEQ ID NO: 6 (04D01), and a CDR_(H3) comprising the amino acid sequence of SEQ ID NO: 7 (04D01).

In some embodiments, the antibody comprises an immunoglobulin heavy chain variable region comprising a CDR_(H1) comprising the amino acid sequence of SEQ ID NO: 15 (09D03), a CDR_(H2) comprising the amino acid sequence of SEQ ID NO: 16 (09D03), and a CDR_(H3) comprising the amino acid sequence of SEQ ID NO: 17 (09D03).

In some embodiments, the antibody comprises an immunoglobulin heavy chain variable region comprising a CDR_(H1) comprising the amino acid sequence of SEQ ID NO: 25 (11G01), a CDR_(H2) comprising the amino acid sequence of SEQ ID NO: 26 (11G01), and a CDR_(H3) comprising the amino acid sequence of SEQ ID NO: 27 (11G01).

In some embodiments, the antibody comprises an immunoglobulin heavy chain variable region comprising a CDR_(H1) comprising the amino acid sequence of SEQ ID NO: 34 (12A07), a CDR_(H2) comprising the amino acid sequence of SEQ ID NO: 35 (12A07), and a CDR_(H3) comprising the amino acid sequence of SEQ ID NO: 36 (12A07, 22A02).

In some embodiments, the antibody comprises an immunoglobulin heavy chain variable region comprising a CDR_(H1) comprising the amino acid sequence of SEQ ID NO: 41 (18H02), a CDR_(H2) comprising the amino acid sequence of SEQ ID NO: 42 (18H02), and a CDR_(H3) comprising the amino acid sequence of SEQ ID NO: 43 (18H02).

In some embodiments, the antibody comprises an immunoglobulin heavy chain variable region comprising a CDR_(H1) comprising the amino acid sequence of SEQ ID NO: 51 (22A02), a CDR_(H3) comprising the amino acid sequence of SEQ ID NO: 52 (22A02), and a CDR_(H3) comprising the amino acid sequence of SEQ ID NO: 36 (12A07, 22A02).

In some embodiments, the antibody comprises an immunoglobulin heavy chain variable region comprising a CDR_(H1) comprising the amino acid sequence of SEQ ID NO: 57 (24C05) or SEQ ID NO: 75 (24C05), a CDR_(H2) comprising the amino acid sequence of SEQ ID NO: 58 (24C05), and a CDR_(H3) comprising the amino acid sequence of SEQ ID NO: 59 (24C05).

In certain embodiments, the antibody comprises an immunoglobulin heavy chain variable region comprising a CDR_(H1) comprising the amino acid sequence of SEQ ID NO: 57 (24C05), a CDR_(H2) comprising the amino acid sequence of SEQ ID NO: 58 (24C05), and a CDR_(H3) comprising the amino acid sequence of SEQ ID NO: 59 (24C05).

In other embodiments, the antibody comprises an immunoglobulin heavy chain variable region comprising a CDR_(H1) comprising the amino acid sequence of SEQ ID NO: 75 (24C05), a CDR_(H2) comprising the amino acid sequence of SEQ ID NO: 58 (24C05), and a CDR_(H3) comprising the amino acid sequence of SEQ ID NO: 59 (24C05).

In certain embodiments, the antibody comprises an immunoglobulin heavy chain variable region a CDR_(H1) comprising the amino acid sequence of SEQ ID NO: 57 (24C05) or SEQ ID NO: 75 (24C05), a CDR_(H2) comprising the amino acid sequence of SEQ ID NO: 148 (Sh24C05 Hv3-11 N62S), and a CDR_(H3) comprising the amino acid sequence of SEQ ID NO: 59 (24C05).

Preferably, the CDR_(H1), CDR_(H2), and CDR_(H3) sequences are interposed between human or humanized immunoglobulin FRs. The antibody can be an intact antibody or an antigen-binding antibody fragment.

In some embodiments, the antibody comprises (a) an immunoglobulin light chain variable region comprising the structure CDR_(L1)-CDR_(L2)-CDR_(L3), and (b) an immunoglobulin heavy chain variable region, wherein the IgG light chain variable region and the IgG heavy chain variable region together define a single binding site for binding human ErbB3. A CDR_(L1) comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 8 (04D01, 12A07, 22A02), SEQ ID NO: 18 (09D03), SEQ ID NO: 28 (11G01), SEQ ID NO: 44 (18H02), and SEQ ID NO: 60 (24C05); a CDR_(L2) comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 9 (04D01, 11G01, 12A07, 22A02), SEQ ID NO: 19 (09D03), SEQ ID NO: 45 (18H02), and SEQ ID NO: 61 (24C05); and a CDR_(L3) comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 10 (04D01, 12A07, 22A02), SEQ ID NO: 20 (09D03), SEQ ID NO: 29 (11G01), SEQ ID NO: 46 (18H02), and SEQ ID NO: 62 (24C05).

In some embodiments, the antibody comprises an immunoglobulin light chain variable region comprising: a CDR_(L1) comprising the amino acid sequence of SEQ ID NO: 8 (04D01, 12A07, 22A02); a CDR_(L2) comprising the amino acid sequence of SEQ ID NO: 9 (04D01, 11G01, 12A07, 22A02); and a CDR_(L3) comprising the amino acid sequence of SEQ ID NO: 10 (04D01, 12A07, 22A02).

In some embodiments, the antibody comprises an immunoglobulin light chain variable region comprising: a CDR_(L1) comprising the amino acid sequence of SEQ ID NO: 18 (09D03); a CDR_(L2) comprising the amino acid sequence of SEQ ID NO: 19 (09D03); and a CDR_(L3) comprising the amino acid sequence of SEQ ID NO: 20 (09D03).

In some embodiments, the antibody comprises an immunoglobulin light chain variable region comprising: a CDR_(L1) comprising the amino acid sequence of SEQ ID NO: 28 (11G01); a CDR_(L2) comprising the amino acid sequence of SEQ ID NO: 9 (04D01, 11G01, 12A07, 22A02); and a CDR_(L3) comprising the amino acid sequence of SEQ ID NO: 29 (11G01).

In some embodiments, the antibody comprises an immunoglobulin light chain variable region comprising: a CDR_(L1) comprising the amino acid sequence of SEQ ID NO: 44 (18H02); a CDR_(L2) comprising the amino acid sequence of SEQ ID NO: 45 (18H02); and a CDR_(L3) comprising the amino acid sequence of SEQ ID NO: 46 (18H02).

In one embodiment, the antibody comprises an immunoglobulin light chain variable region comprising: a CDR_(L1) comprising the amino acid sequence of SEQ ID NO: 60 (24C05); a CDR_(L2) comprising the amino acid sequence of SEQ ID NO: 61 (24C05); and a CDR_(L3) comprising the amino acid sequence of SEQ ID NO: 62 (24C05).

Preferably, the CDR_(L1), CDR_(L2), and CDR_(L3) sequences are interposed between human or humanized immunoglobulin FRs. The antibody can be an intact antibody or an antigen-binding antibody fragment.

In some embodiments, the antibody comprises: (a) an IgG heavy chain variable region comprising the structure CDR_(H1)-CDR_(H2)-CDR_(H3) and (b) an IgG light chain variable region comprising the structure CDR_(L1)-CDR_(L2)-CDR_(L3), wherein the heavy chain variable region and the light chain variable region together define a single binding site for binding human ErbB3. The CDR_(H1) is an amino acid sequence selected from the group consisting of SEQ ID NO: 5 (04D01), SEQ ID NO:15 (09D03), SEQ ID NO: 25 (11G01), SEQ ID NO: 34 (12A07), SEQ ID NO: 41 (18H02), SEQ ID NO: 51 (22A02), SEQ ID NO: 57 (24C05), and SEQ ID NO: 75 (24C05); the CDR_(H2) is an amino acid sequence selected from the group consisting of SEQ ID NO: 6 (04D01), SEQ ID NO:16 (09D03), SEQ ID NO: 26 (11G01), SEQ ID NO: 35 (12A07), SEQ ID NO: 42 (18H02), SEQ ID NO: 52 (22A02), SEQ ID NO: 58 (24C05), and SEQ ID NO: 148 (Sh24C05 Hv3-11 N62S); and the CDR_(H3) is an amino acid sequence selected from the group consisting of SEQ ID NO: 7 (04D01), SEQ ID NO: 17 (09D03), SEQ ID NO: 27 (11G01), SEQ ID NO: 36 (12A07, 22A02), SEQ ID NO: 43 (18H02), and SEQ ID NO: 59 (24C05). The CDR_(L1) is an amino acid sequence selected from the group consisting of SEQ ID NO: 8 (04D01, 12A07, 22A02), SEQ ID NO: 18 (09D03), SEQ ID NO: 28 (11G01), SEQ ID NO: 44 (18H02), and SEQ ID NO: 60 (24C05); the CDR_(L2) is an amino acid sequence selected from the group consisting of SEQ ID NO: 9 (04D01, 11G01, 12A07, 22A02), SEQ ID NO: 19 (09D03), SEQ ID NO: 45 (18H02), and SEQ ID NO: 61 (24C05); and the CDR_(L3) is an amino acid sequence selected from the group consisting of SEQ ID NO: 10 (04D01, 12A07, 22A02), SEQ ID NO: 20 (09D03), SEQ ID NO: 29 (11G01), SEQ ID NO: 46 (18H02), and SEQ ID NO: 62 (24C05).

In another embodiment, the antibody comprises an immunoglobulin heavy chain variable region selected from the group consisting of SEQ ID NO: 2 (04D01), SEQ ID NO: 12 (09D03), SEQ ID NO: 22 (11G01), SEQ ID NO: 31 (12A07), SEQ ID NO: 38 (18H02), SEQ ID NO: 48 (22A02), SEQ ID NO: 54 (24C05), and SEQ ID NO: 154 (Sh24C05 Hv3-11 N62S), and an immunoglobulin light chain variable region selected from the group consisting of SEQ ID NO: 4 (04D01), SEQ ID NO: 14 (09D03), SEQ ID NO: 24 (11G01), SEQ ID NO: 33 (12A07), SEQ ID NO: 40 (18H02), SEQ ID NO: 50 (22A02), SEQ ID NO: 56 (24C05), SEQ ID NO: 166 (Sh24C05 Kv1-16), and SEQ ID NO: 168 (Sh24C05 Kv1-17).

In another embodiment, the antibody comprises an immunoglobulin heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 2 (04D01), and an immunoglobulin light chain variable region comprising the amino acid sequence of SEQ ID NO: 4 (04D01).

In another embodiment, the antibody comprises an immunoglobulin heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 12 (09D03), and an immunoglobulin light chain variable region comprising the amino acid sequence of SEQ ID NO: 14 (09D03).

In another embodiment, the antibody comprises an immunoglobulin heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 22 (11G01), and an immunoglobulin light chain variable region comprising the amino acid sequence of SEQ ID NO: 24 (11G01).

In another embodiment, the antibody comprises an immunoglobulin heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 31 (12A07), and an immunoglobulin light chain variable region comprising the amino acid sequence of SEQ ID NO: 33 (12A07).

In another embodiment, the antibody comprises an immunoglobulin heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 38 (18H02), and an immunoglobulin light chain variable region comprising the amino acid sequence of SEQ ID NO: 40 (18H02).

In another embodiment, the antibody comprises an immunoglobulin heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 48 (22A02), and an immunoglobulin light chain variable region comprising the amino acid sequence of SEQ ID NO: 50 (22A02).

In another embodiment, the antibody comprises an immunoglobulin heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 54 (24C05), and an immunoglobulin light chain variable region comprising the amino acid sequence of SEQ ID NO: 56 (24C05).

In another embodiment, the antibody comprises an immunoglobulin heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 154 (Sh24C05 Hv3-11 N62S), and an immunoglobulin light chain variable region comprising the amino acid sequence of SEQ ID NO: 166 (Sh24C05 Kv1-16).

In another embodiment, the antibody comprises an immunoglobulin heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 154 (Sh24C05 Hv3-11 N62S), and an immunoglobulin light chain variable region comprising the amino acid sequence of SEQ ID NO: 168 (Sh24C05 Kv1-17).

In other embodiments, the antibody comprises (i) an immunoglobulin heavy chain selected from the group consisting of SEQ ID NO: 109 (04D01), SEQ ID NO: 113 (09D03), SEQ ID NO: 117 (11G01), SEQ ID NO: 121 (12A07), SEQ ID NO: 125 (18H02), SEQ ID NO: 129 (22A07), SEQ ID NO: 133 (24C05), SEQ ID NO: 190 (Sh24C05 Hv3-11 N62S IgG1), and SEQ ID NO: 192 (Sh24C05 Hv3-11 N62S IgG2), and (ii) an immunoglobulin light chain selected from the group consisting of SEQ ID NO: 111 (04D01), SEQ ID NO: 115 (09D03), SEQ ID NO: 119 (11G01), SEQ ID NO: 123 (12A07), SEQ ID NO: 127 (18H02), SEQ ID NO: 131 (22A07), SEQ ID NO: 135 (24C05), SEQ ID NO: 204 (Sh24C05 Kv1-16 kappa), and SEQ ID NO: 206 (Sh24C05 Kv1-17 kappa).

In another embodiment, the antibody comprises an immunoglobulin heavy chain comprising the amino acid sequence of SEQ ID NO: 109 (04D01), and an immunoglobulin light chain comprising the amino acid sequence of SEQ ID NO: 111 (04D01).

In another embodiment, the antibody comprises an immunoglobulin heavy chain comprising the amino acid sequence of SEQ ID NO: 113 (09D03), and an immunoglobulin light chain comprising the amino acid sequence of SEQ ID NO: 115 (09D03).

In another embodiment, the antibody comprises an immunoglobulin heavy chain comprising the amino acid sequence of SEQ ID NO: 117 (11G01), and an immunoglobulin light chain comprising the amino acid sequence of SEQ ID NO: 119 (11G01).

In another embodiment, the antibody comprises an immunoglobulin heavy chain comprising the amino acid sequence of SEQ ID NO: 121 (12A07), and an immunoglobulin light chain comprising the amino acid sequence of SEQ ID NO: 123 (12A07).

In another embodiment, the antibody comprises an immunoglobulin heavy chain comprising the amino acid sequence of SEQ ID NO: 125 (18H02), and an immunoglobulin light chain comprising the amino acid sequence of SEQ ID NO: 127 (18H02).

In another embodiment, the antibody comprises an immunoglobulin heavy chain comprising the amino acid sequence of SEQ ID NO: 129 (22A02), and an immunoglobulin light chain comprising the amino acid sequence of SEQ ID NO: 131 (22A02).

In another embodiment, the antibody comprises an immunoglobulin heavy chain comprising the amino acid sequence of SEQ ID NO: 133 (24C05), and an immunoglobulin light chain comprising the amino acid sequence of SEQ ID NO: 135 (24C05).

In another embodiment, the antibody comprises an immunoglobulin heavy chain comprising the amino acid sequence of SEQ ID NO: 190 (Sh24C05 Hv3-11 N62S IgG1), and an immunoglobulin light chain comprising the amino acid sequence of SEQ ID NO: 204 (Sh24C05 Kv1-16 kappa).

In another embodiment, the antibody comprises an immunoglobulin heavy chain comprising the amino acid sequence of SEQ ID NO: 192 (Sh24C05 Hv3-11 N62S IgG2), and an immunoglobulin light chain comprising the amino acid sequence of SEQ ID NO: 204 (Sh24C05 Kv1-16 kappa).

In another embodiment, the antibody comprises an immunoglobulin heavy chain comprising the amino acid sequence of SEQ ID NO: 190 (Sh24C05 Hv3-11 N62S IgG1), and an immunoglobulin light chain comprising the amino acid sequence of SEQ ID NO: 206 (Sh24C05 Kv1-17 kappa).

In another embodiment, the antibody comprises an immunoglobulin heavy chain comprising the amino acid sequence of SEQ ID NO: 192 (Sh24C05 Hv3-11 N62S IgG2), and an immunoglobulin light chain comprising the amino acid sequence of SEQ ID NO: 206 (Sh24C05 Kv1-17 kappa).

As used herein, unless otherwise indicated, the term “antibody” means an intact antibody (e.g., an intact monoclonal antibody) or antigen-binding fragment of a antibody (e.g., an antigen-binding fragment of a monoclonal antibody), including an intact antibody or antigen-binding fragment that has been modified, engineered, or chemically conjugated. Examples of antibodies that have been modified or engineered include chimeric antibodies, humanized antibodies, and multispecific antibodies (e.g., bispecific antibodies). Examples of antigen-binding fragments include Fab, Fab′, (Fab′)₂, Fv, single chain antibodies (e.g., scFv), minibodies, and diabodies. An example of a chemically conjugated antibody is an antibody conjugated to a toxin moiety.

FIG. 1 shows a schematic representation of an intact monoclonal antibody that contains four polypeptide chains. Two of the polypeptide chains are called immunoglobulin heavy chains (H chains), and two of the polypeptide chains are called immunoglobulin light chains (L chains). The immunoglobulin heavy and light chains are connected by an interchain disulfide bond. The immunoglobulin heavy chains are connected by interchain disulfide bonds. A light chain consists of one variable region (V_(L) in FIG. 1) and one constant region (C_(L) in FIG. 1). The heavy chain consists of one variable region (V_(H) in FIG. 1) and at least three constant regions (CH₁, CH₂ and CH₃ in FIG. 1). The variable regions determine the specificity of the antibody.

Each variable region contains three hypervariable regions known as complementarity determining regions (CDRs) flanked by four relatively conserved regions known as framework regions (FRs). The three CDRs, referred to as CDR₁, CDR₂, and CDR₃, contribute to the antibody binding specificity.

In certain embodiments, an isolated antibody that binds human ErbB3 comprises an immunoglobulin heavy chain variable region comprising an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, or 99% identical to the entire variable region or the framework region sequence of SEQ ID NO: 2 (04D01), SEQ ID NO: 12 (09D03), SEQ ID NO: 22 (11G01), SEQ ID NO: 31 (12A07), SEQ ID NO: 38 (18H02), SEQ ID NO: 48 (22A02), SEQ ID NO: 54 (24C05), and SEQ ID NO: 154 (Sh24C05 Hv3-11 N62S).

In certain embodiments, an isolated antibody that binds human ErbB3 comprises an immunoglobulin light chain variable region comprising an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, or 99% identical to the entire variable region or the framework region sequence of SEQ ID NO: 4 (04D01), SEQ ID NO: 14 (09D03), SEQ ID NO: 24 (11G01), SEQ ID NO: 33 (12A07), SEQ ID NO: 40 (18H02), SEQ ID NO: 50 (22A02), SEQ ID NO: 56 (24C05), SEQ ID NO: 166 (Sh24C05 Kv1-16), and SEQ ID NO: 168 (Sh24C05 Kv1-17).

In each of the foregoing embodiments, it is contemplated herein that immunoglobulin heavy chain variable region sequences and/or light chain variable region sequences that together bind human ErbB3 may contain amino acid alterations (e.g., at least 1, 2, 3, 4, 5, or 10 amino acid substitutions, deletions, or additions) in the framework regions of the heavy and/or light chain variable regions.

In some embodiments, an isolated antibody binds hErbB3 with a K_(D) of 350 pM, 300 pM, 250 pM, 200 pM, 150 pM, 100 pM, 75 pM, 50 pM, 20 pM, 10 pM or lower. Unless otherwise specified, K_(D) values are determined by surface plasmon resonance methods. The surface plasmon resonance methods can be performed using the conditions described, for example, in Examples 3 and 12, where the measurements were performed at 25° C. and 37° C., respectively.

In some embodiments, the antibodies inhibit hErbB3 binding to NRG1-β1. For example, the antibodies can have an IC₅₀ (concentration at 50% of maximum inhibition) of about 5 nM, 2 nM or lower, when assayed using the protocols described in Examples 4 and 13.

II. Production of Antibodies

Methods for producing antibodies disclosed herein are known in the art. For example, DNA molecules encoding light chain variable regions and heavy chain variable regions can be chemically synthesized using the sequence information provided herein. Synthetic DNA molecules can be ligated to other appropriate nucleotide sequences, including, e.g., constant region coding sequences, and expression control sequences, to produce conventional gene expression constructs encoding the desired antibodies. Production of defined gene constructs is within routine skill in the art. Alternatively, the sequences provided herein can be cloned out of hybridomas by conventional hybridization techniques or polymerase chain reaction (PCR) techniques, using synthetic nucleic acid probes whose sequences are based on sequence information provided herein, or prior art sequence information regarding genes encoding the heavy and light chains of murine antibodies in hybridoma cells.

Nucleic acids encoding the antibodies disclosed herein can be incorporated (ligated) into expression vectors, which can be introduced into host cells through conventional transfection or transformation techniques. Exemplary host cells are E. coli cells, Chinese hamster ovary (CHO) cells, HeLa cells, baby hamster kidney (BHK) cells, monkey kidney cells (COS), human hepatocellular carcinoma cells (e.g., Hep G2), and myeloma cells that do not otherwise produce IgG protein. Transformed host cells can be grown under conditions that permit the host cells to express the genes that encode the immunoglobulin light and/or heavy chain variable regions.

Specific expression and purification conditions will vary depending upon the expression system employed. For example, if a gene is to be expressed in E. coli, it is first cloned into an expression vector by positioning the engineered gene downstream from a suitable bacterial promoter, e.g., Trp or Tac, and a prokaryotic signal sequence. The expressed secreted protein accumulates in refractile or inclusion bodies, and can be harvested after disruption of the cells by French press or sonication. The refractile bodies then are solubilized, and the proteins refolded and cleaved by methods known in the art.

If a DNA construct encoding an antibody disclosed herein is to be expressed in eukayotic host cells, e.g., CHO cells, it is first inserted into an expression vector containing a suitable eukaryotic promoter, a secretion signal, IgG enhancers, and various introns. This expression vector optionally contains sequences encoding all or part of a constant region, enabling an entire, or a part of, a heavy and/or light chain to be expressed. In some embodiments, a single expression vector contains both heavy and light chain variable regions to be expressed.

The gene construct can be introduced into eukaryotic host cells using conventional techniques. The host cells express V_(L) or V_(H) fragments, V_(L)-V_(H) heterodimers, V_(H)-V_(L) or V_(L)-V_(H) single chain polypeptides, complete heavy or light immunoglobulin chains, or portions thereof, each of which may be attached to a moiety having another function (e.g., cytotoxicity). In some embodiments, a host cell is transfected with a single vector expressing a polypeptide expressing an entire, or part of, a heavy chain (e.g., a heavy chain variable region) or a light chain (e.g., a light chain variable region). In other embodiments, a host cell is transfected with a single vector encoding (a) a polypeptide comprising a heavy chain variable region and a polypeptide comprising a light chain variable region, or (b) an entire immunoglobulin heavy chain and an entire immunoglobulin light chain. In still other embodiments, a host cell is co-transfected with more than one expression vector (e.g., one expression vector expressing a polypeptide comprising an entire, or part of, a heavy chain or heavy chain variable region, and another expression vector expressing a polypeptide comprising an entire, or part of, a light chain or light chain variable region).

A method of producing a polypeptide comprising an immunoglobulin heavy chain variable region or a polypeptide comprising an immunoglobulin light chain variable region may comprise growing a host cell transfected with an expression vector under conditions that permits expression of the polypeptide comprising the immunoglobulin heavy chain variable region or the polypeptide comprising the immunoglobulin light chain variable region. The polypeptide comprising a heavy chain variable region or the polypeptide comprising the light chain variable region then may be purified using techniques well known in the art, e.g., affinity tags such as glutathione-S-transferase (GST) and histidine tags.

A method of producing a monoclonal antibody that binds human ErbB3, or an antigen-binding fragment of the antibody, may comprise growing a host cell transfected with: (a) an expression vector that encodes a complete or partial immunoglobulin heavy chain, and a separate expression vector that encodes a complete or partial immunoglobulin light chain; or (b) a single expression vector that encodes both chains (e.g., complete or partial chains), under conditions that permit expression of both chains. The intact antibody (or antigen-binding fragment) can be harvested and purified using techniques well known in the art, e.g., Protein A, Protein G, affinity tags such as glutathione-S-transferase (GST) and histidine tags. It is within ordinary skill in the art to express the heavy chain and the light chain from a single expression vector or from two separate expression vectors.

III. Modifications to the Antibodies

Methods for reducing or eliminating the antigenicity of antibodies and antibody fragments are known in the art. When the antibodies are to be administered to a human, the antibodies preferably are “humanized” to reduce or eliminate antigenicity in humans. Preferably, a humanized antibody has the same or substantially the same affinity for the antigen as the non-humanized mouse antibody from which it was derived.

In one humanization approach, chimeric proteins are created in which mouse immunoglobulin constant regions are replaced with human immunoglobulin constant regions. See, e.g., Morrison et al., 1984, PROC. NAT. ACAD. SCI. 81:6851-6855, Neuberger et al., 1984, NATURE 312:604-608; U.S. Pat. No. 6,893,625 (Robinson); U.S. Pat. No. 5,500,362 (Robinson); and U.S. Pat. No. 4,816,567 (Cabilly).

In an approach known as CDR grafting, the CDRs of the light and heavy chain variable regions are grafted into frameworks from another species. For example, murine CDRs can be grafted into human FRs. In some embodiments, the CDRs of the light and heavy chain variable regions of an anti-ErbB3 antibody are grafted onto human FRs or consensus human FRs. To create consensus human FRs, FRs from several human heavy chain or light chain amino acid sequences are aligned to identify a consensus amino acid sequence. CDR grafting is described in U.S. Pat. No. 7,022,500 (Queen); U.S. Pat. No. 6,982,321 (Winter); U.S. Pat. No. 6,180,370 (Queen); U.S. Pat. No. 6,054,297 (Carter); U.S. Pat. No. 5,693,762 (Queen); U.S. Pat. No. 5,859,205 (Adair); U.S. Pat. No. 5,693,761 (Queen); U.S. Pat. No. 5,565,332 (Hoogenboom); U.S. Pat. No. 5,585,089 (Queen); U.S. Pat. No. 5,530,101 (Queen); Jones et al. (1986) NATURE 321: 522-525; Riechmann et al. (1988) NATURE 332: 323-327; Verhoeyen et al. (1988) SCIENCE 239: 1534-1536; and Winter (1998) FEBS LETT 430: 92-94.

In an approach called “SUPERHUMANIZATION™,” human CDR sequences are chosen from human germline genes, based on the structural similarity of the human CDRs to those of the mouse antibody to be humanized. See, e.g., U.S. Pat. No. 6,881,557 (Foote); and Tan et al., 2002, J. IMMUNOL 169:1119-1125.

Other methods to reduce immunogenicity include “reshaping,” “hyperchimerization,” and “veneering/resurfacing.” See, e.g., Vaswami et al., 1998, ANNALS OF ALLERGY, ASTHMA, & IMMUNOL. 81:105; Roguska et al., 1996, PROT. ENGINEER 9:895-904; and U.S. Pat. No. 6,072,035 (Hardman). In the veneering/resurfacing approach, the surface accessible amino acid residues in the murine antibody are replaced by amino acid residues more frequently found at the same positions in a human antibody. This type of antibody resurfacing is described, e.g., in U.S. Pat. No. 5,639,641 (Pedersen).

Another approach for converting a mouse antibody into a form suitable for medical use in humans is known as ACTIVMAB™ technology (Vaccinex, Inc., Rochester, N.Y.), which involves a vaccinia virus-based vector to express antibodies in mammalian cells. High levels of combinatorial diversity of IgG heavy and light chains are said to be produced. See, e.g., U.S. Pat. No. 6,706,477 (Zauderer); U.S. Pat. No. 6,800,442 (Zauderer); and U.S. Pat. No. 6,872,518 (Zauderer).

Another approach for converting a mouse antibody into a form suitable for use in humans is technology practiced commercially by KaloBios Pharmaceuticals, Inc. (Palo Alto, Calif.). This technology involves the use of a proprietary human “acceptor” library to produce an “epitope focused” library for antibody selection.

Another approach for modifying a mouse antibody into a form suitable for medical use in humans is HUMAN ENGINEERING™ technology, which is practiced commercially by XOMA (US) LLC. See, e.g., PCT Publication No. WO 93/11794 and U.S. Pat. Nos. 5,766,886; 5,770,196; 5,821,123; and 5,869,619.

Any suitable approach, including any of the above approaches, can be used to reduce or eliminate human immunogenicity of an antibody disclosed herein.

Methods of making multispecific antibodies are known in the art. Multi-specific antibodies include bispecific antibodies. Bispecific antibodies are antibodies that have binding specificities for at least two different epitopes. Exemplary bispecific antibodies bind to two different epitopes of the antigen of interest. Bispecific antibodies can be prepared as full length antibodies or antibody fragments (e.g., F(ab′)2 bispecific antibodies and diabodies) as described, for example, in Milstein et al., NATURE 305:537-539 (1983), WO 93/08829, Traunecker et al., EMBO J., 10:3655-3659 (1991), WO 94/04690, Suresh et al., METHODS IN ENZYMOLOGY, 121:210 (1986), WO96/27011, Brennan et al., SCIENCE, 229: 81 (1985), Shalaby et al., J. EXP. MED., 175: 217-225 (1992), Kostelny et al., J. IMMUNOL., 148(5):1547-1553 (1992), Hollinger et al., PNAS, 90:6444-6448, Gruber et al., J. IMMUNOL., 152:5368 (1994), Wu et al., NAT. BIOTECHNOL., 25(11): 1290-1297, U.S. Patent Publication No. 2007/0071675, and Bostrom et al., SCIENCE 323:1640-1644 (2009).

In some embodiments, the antibody is conjugated to an effector agent such as a small molecule toxin or a radionuclide using standard in vitro conjugation chemistries. If the effector agent is a polypeptide, the antibody can be chemically conjugated to the effector or joined to the effector as a fusion protein. Construction of fusion proteins is within ordinary skill in the art.

IV. Use of the Antibodies

The antibodies disclosed herein can be used to treat various forms of cancer, e.g., breast, ovarian, prostate, cervical, colorectal, lung (e.g., non-small cell lung cancer), pancreatic, gastric, skin, kidney, head and neck, and schwannoma cancers. The cancer cells are exposed to a therapeutically effective amount of the antibody so as to inhibit or reduce proliferation of the cancer cell. In some embodiments, the antibodies inhibit cancer cell proliferation by at least 40%, 50%, 60%, 70%, 80%, 90%, 95%, 98%, 99%, or 100%.

In some embodiments, the antibody inhibits or reduces proliferation of a tumor cell by inhibiting binding of human ErbB3 to an ErbB3 ligand, e.g., Neuregulin/Heregulin especially NRGβ1/NRG1-β1/NRGβ1/HRGβ1 and NRGα1/NRG1-α1/NRGα1/HRGα1. The antibody can be used in a method to inhibit tumor growth in a human patient. The method comprises administering to the patient a therapeutically effective amount of the antibody.

Cancers associated with ErbB3 overexpression and/or activation include breast cancer, ovarian cancer, prostate cancer, cervical cancer, lung cancer (e.g., non-small cell lung cancer), some forms of brain cancer (e.g., schwannoma), melanomas, skin, kidney, and gastrointestinal cancers (e.g., colorectal, pancreatic, gastric, head and neck).

As used herein, “treat, “treating” and “treatment” mean the treatment of a disease in a mammal, e.g., in a human. This includes: (a) inhibiting the disease, i.e., arresting its development; and (b) relieving the disease, i.e., causing regression of the disease state; and (c) curing the disease.

Generally, a therapeutically effective amount of active component is in the range of 0.1 mg/kg to 100 mg/kg, e.g., 1 mg/kg to 100 mg/kg, 1 mg/kg to 10 mg/kg. The amount administered will depend on variables such as the type and extent of disease or indication to be treated, the overall health of the patient, the in vivo potency of the antibody, the pharmaceutical formulation, and the route of administration. The initial dosage can be increased beyond the upper level in order to rapidly achieve the desired blood-level or tissue level. Alternatively, the initial dosage can be smaller than the optimum, and the daily dosage may be progressively increased during the course of treatment. Human dosage can be optimized, e.g., in a conventional Phase I dose escalation study designed to run from 0.5 mg/kg to 20 mg/kg. Dosing frequency can vary, depending on factors such as route of administration, dosage amount and the disease being treated. Exemplary dosing frequencies are once per day, once per week and once every two weeks. A preferred route of administration is parenteral, e.g., intravenous infusion. Formulation of monoclonal antibody-based drugs is within ordinary skill in the art. In some embodiments, the monoclonal antibody is lyophilized and reconstituted in buffered saline at the time of administration.

For therapeutic use, an antibody preferably is combined with a pharmaceutically acceptable carrier. As used herein, “pharmaceutically acceptable carrier” means buffers, carriers, and excipients suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio. The carrier(s) should be “acceptable” in the sense of being compatible with the other ingredients of the formulations and not deleterious to the recipient. Pharmaceutically acceptable carriers include buffers, solvents, dispersion media, coatings, isotonic and absorption delaying agents, and the like, that are compatible with pharmaceutical administration. The use of such media and agents for pharmaceutically active substances is known in the art.

Pharmaceutical compositions containing antibodies disclosed herein can be presented in a dosage unit form and can be prepared by any suitable method. A pharmaceutical composition should be formulated to be compatible with its intended route of administration. Examples of routes of administration are intravenous (IV), intradermal, inhalation, transdermal, topical, transmucosal, and rectal administration. A preferred route of administration for monoclonal antibodies is IV infusion. Useful formulations can be prepared by methods well known in the pharmaceutical art. For example, see Remington's Pharmaceutical Sciences, 18th ed. (Mack Publishing Company, 1990). Formulation components suitable for parenteral administration include a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as EDTA; buffers such as acetates, citrates or phosphates; and agents for the adjustment of tonicity such as sodium chloride or dextrose.

For intravenous administration, suitable carriers include physiological saline, bacteriostatic water, Cremophor EL™ (BASF, Parsippany, N.J.) or phosphate buffered saline (PBS). The carrier should be stable under the conditions of manufacture and storage, and should be preserved against microorganisms. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyetheylene glycol), and suitable mixtures thereof.

Pharmaceutical formulations preferably are sterile. Sterilization can be accomplished, for example, by filtration through sterile filtration membranes. Where the composition is lyophilized, filter sterilization can be conducted prior to or following lyophilization and reconstitution.

EXAMPLES

The following Examples are merely illustrative and are not intended to limit the scope or content of the invention in any way.

Example 1—Production of Anti-hErbB3 Monoclonal Antibodies

Immunizations, fusions, and primary screens were conducted at Maine Biotechnology Services Inc. following the Repetitive Immunization Multiple Sites (RIMMS) protocol. Three AJ mice and three Balb/c mice were immunized with recombinant human ErbB3/Fc (R&D Systems, Cat. No. 348-RB). Two sets of immunization were performed with either cleaved rhErbB3 (Immunization A) or with cleaved rhErbB3 cross-linked to its ligand, recombinant human NRG1-β1/HRG1-β1-EGF domain (R&D Systems, Cat. No. 396-HB) (Immunization B). Two AJ mice per immunization with sera displaying high anti-ErbB3 activity by Enzyme Linked Immunosorbent Assay (ELISA) were chosen for subsequent fusion. Spleens and lymph nodes from the appropriate mice were harvested. B-cells then were harvested and fused with a myeloma line. Fusion products were serially diluted onto forty 96-well plates to near clonality. A total of 5280 supernatants from the resulting fusions were screened for binding to recombinant rhErbB3/Fc, using ELISA. The same supernatants were also screened for their binding to human ErbB3 overexpressed in CHO cells (by Mesoscale electrochemiluminescence assay). Three hundred supernatants identified as containing antibodies against ErbB3 were further characterized by in vitro biochemical and cell-based assays as discussed below. A panel of hybridomas was selected, and the hybridomas were subcloned and expanded. Hybridoma cell lines were transferred to BioXCell (formerly Bio-Express) for antibody expression and purification by affinity chromatography on Protein G resin under standard conditions.

Anti-hErbB3 monoclonal antibody 04D01 was generated from Immunization A described above. Anti-hErbB3 monoclonal antibodies 09D03, 11G01, 12A07, 18H02, 22A02 and 24C05 were generated from Immunization B described above.

Example 2—Sequence Analysis of Anti-hErbB3 Monoclonal Antibodies

The light-chain isotype and heavy chain isotype of each monoclonal antibody in Example 1 was determined using the IsoStrip™ Mouse Monoclonal Antibody Isotyping Kit according the manufacturer's instructions (Roche Applied Science). All antibodies were determined to be Kappa light chain and IgG1 or IgG2b IgG heavy chain.

The heavy and light chain variable regions of the mouse monoclonal antibodies were sequenced using 5′ RACE (Rapid Amplification of cDNA Ends). Total RNA was extracted from each monoclonal hybridoma cell line using the RNeasy® Miniprep kit according to the vendor's instructions (Qiagen). Full-length first strand cDNA containing 5′ ends was generated using either the GeneRacer™ Kit (Invitrogen) or SMARTer™ RACE cDNA Amplification Kit (Clontech) according to the manufacturer's instructions using random primers for 5′ RACE.

The variable regions of the Kappa and Heavy (IgG1or IgG2b) IgG chains were amplified by PCR, using KOD Hot Start Polymerase (Novagen) or Advantage 2 Polymerase Mix (Clontech) according to the manufacturer's instructions. For amplification of 5′ cDNA ends in conjunction with the GeneRacer™ Kit, the GeneRacer™ 5′ Primer, 5′ cgactggagcacgaggacactga 3′ (SEQ ID NO: 136) (Invitrogen) was used as a 5′ primer. For amplification of 5′ cDNA ends in conjunction with the SMARTer™ RACE cDNA Amplification Kit, the Universal Primer Mix A primer (Clontech), a mix of 5′CTAATACGACTCACTATAGGGCAAGCAGTGGTATCAACGCAGAGT 3′ (SEQ ID NO: 137) and 5′ CTAATACGACTCACTATAGGGC 3′ (SEQ ID NO: 138), was used as a 5′ primer. Heavy chain variable regions were amplified using the above 5′ primers and a 3′ IgG1 Constant Region specific primer, either 5′ TATGCAAGGCTTACAACCACA 3′ (SEQ ID NO: 139) or 5′ GCCAGTGGATAGACAGATGGGGGTGTCG 3′ (SEQ ID NO: 140). IgG2b sequences were amplified with either 5′ AGGACAGGGGTTGATTGTTGA 3′ (SEQ ID NO: 141), 5′ GGCCAGTGGATAGACTGATGGGGGTGTTGT 3′ (SEQ ID NO: 142), or 5′ GGAGGAACCAGTTGTATCTCCACACCCA 3′ (SEQ ID NO: 143). Kappa chain variable regions were amplified with the above 5′ primers and a 3′ Kappa Constant Region specific primer, either 5′ CTCATTCCTGTTGAAGCTCTTGACAAT 3′ (SEQ ID NO: 144) or 5′ CGACTGAGGCACCTCCAGATGTT 3′ (SEQ ID NO: 145).

Individual PCR products were isolated by agarose gel electrophoresis and purified using the Qiaquick® Gel Purification kit according to the manufacturer's instructions (Qiagen). The PCR products were subsequently cloned into the pCR®4Blunt plasmid using the Zero Blunt® TOPO® PCR Cloning Kit according to the manufacturer's instructions (Invitrogen) and transformed into DH5-α bacteria (Invitrogen) through standard molecular biology techniques. Plasmid DNA isolated from transformed bacterial clones was sequenced using M13 Forward (5′ GTAAAACGACGGCCAGT 3′) (SEQ ID NO: 146) and M13 Reverse primers (5′ CAGGAAACAGCTATGACC 3′) (SEQ ID NO: 147) by Beckman Genomics, using standard dideoxy DNA sequencing methods to identify the sequence of the variable region sequences. The sequences were analyzed using Vector NTI software (Invitrogen) and the IMGT/V-Quest software to identify and confirm variable region sequences.

The nucleic acid sequences encoding and the protein sequences defining variable regions of the murine monoclonal antibodies are summarized below (amino terminal signal peptide sequences are not shown). CDR sequences (Kabat definition) are shown in bold/underlined in the amino acid sequences.

Nucleic Acid Sequence Encoding the Heavy Chain Variable Region of the 04D01 Antibody (SEQ ID NO: 1)

1 caggtccaac tgcagcagcc tggggctgaa ctggtgaggc ctgggacttc agtgaagttg 61 tcctgcaagg cttctggcta caccttcacc agccactggt tgcactgggt gaagcagagg 121 cctggacaag gccttgagtg gatcggagtg cttgatcctt ctgattttta tagtaactac 181 aatcaaaact tcaagggcaa ggccacattg actgtagaca catcctccag cacagcctac 241 atgcagctca gcagcctgac atctgaggac tctgcggtct attactgtgc acgaggccta 301 ctatccgggg actatgctat ggactactgg ggtcaaggaa cctcagtcac cgtctcctca

Protein Sequence Defining the Heavy Chain Variable Region of the 04D01 Antibody (SEQ ID NO: 2)

1 qvqlqqpgae lvrpgtsvkl sckasgytft  shwlh wvkqr pgqglewig v   ldpsdfysny 61 nqnfkg katl tvdtssstay mqlssltsed savyycar gl   lsgdyamdy w gqgtsvtvss

Nucleic Acid Sequence Encoding the Kappa Chain Variable Region of the 04D01 Antibody (SEQ ID NO: 3)

1 gatgttttga tgacccaaat tccactctcc ctgcctgtca gtcttggaga tcaagcctcc 61 atctcttgca gatctagtca gagcattgta catagtaatg gaaacaccta tttagaatgg 121 tacctgcaga aaccaggcca gtctccaaag tccctgatct acaaagtttc taaccgattt 181 tctggggtcc cagacaggtt cagtggcagt ggatcaggga cagatttcac actcaagatc 241 agcagagtgg aggctgagga tctgggagtt tattactgct ttcaaggttc atatgttccg 301 tggacgttcg gtggaggcac caagctggaa atcaaa

Protein Sequence Defining the Kappa Chain Variable Region of the 04D01 Antibody (SEQ ID NO: 4)

1 dvlmtgipls lpvslgdgas isc rss q siv   hsngntyle w ylqkpggspk sliy kvsnrf 61 s gvpdrfsgs gsgtdftlki srveaedlgv yyc f q gsyvp   wt fgggtkle ik

Nucleic Acid Sequence Encoding the Heavy Chain Variable Region of the 09D03 Antibody (SEQ ID NO: 11)

1 caggttactc taaaagagtc tggccctggg atattgcggc cctcccagac cctcagtctg 61 acttgttctt tctctgggtt ttcactgagc acttttggtt tgagtgtagg ctggattcgt 121 cagccttcag ggaagggtct ggagtggctg gcacacattt ggtgggatga tgataagtac 181 tataacccag cccttaagag tcggctcaca atctccaagg atacctccaa aaaccaggta 241 ttcctcaaga tcgccaatgt ggacactgca gatactgcca catactactg tgctcgaata 301 ggggcggacg cccttccttt tgactactgg ggccaaggca ccactctcac agtctcctca

Protein Sequence Defining the Heavy Chain Variable Region of the 09D03 Antibody (SEQ ID NO: 12)

1 qvtlkesgpg ilrpsqtlsl tcsfsgfsls  tfglsvg wir qpsgkglewl a hiwwdddky 61 ynpalks rlt iskdtsknqv flkianvdta dtatyycar i   gadalpfdy w gqgttltvss

Nucleic Acid Sequence Encoding the Kappa Chain Variable Region of the 09D03 Antibody (SEQ ID NO: 13)

1 gatattgtgt tgactcagac tgcaccctct gtacctgtca ctcctggaga gtcagtatcc 61 atctcctgca ggtctagtaa gagtctcctg catagtaatg gcaacactta cttgtattgg 121 ttcctgcaga ggccaggcca gtctcctcag ctcctgatat atcggatgtc caaccttgcc 181 tcaggagtcc cagacaggtt cagtggcagt gggtcaggaa ctgctttcac actgagaatc 241 gtagagtgg aggctgagga tgtgggtgtt tattactgta tgcaacatct agaatatcct 301 ttcacgttcg gctcggggac aaagttggaa ataaaa

Protein Sequence Defining the Kappa Chain Variable Region of the 09D03 Antibody (SEQ ID NO: 14)

1 divltqtaps vpvtpgesys isc rssksll   hsngntyly w flqrpgqspq lliy rmsnla 61 s gvpdrfsgs gsgtaftlri srveaedvgv yyc m q hleyp   ft fgsgtkle ik

Nucleic Acid Sequence Encoding the Heavy Chain Variable Region of the 11G01 Antibody (SEQ ID NO: 21)

1 caggttcagc tgcaacagtc tgacgctgag ttggtgaaac ctggagcttc agtgaagata 61 tcctgcaagg tttctggcta caccttcact gaccatatta ttcactggat gaagcagagg 121 cctgaacagg gcctggaatg gattggatat atttatccta gagatggtta tattaagtac 181 aatgagaagt tcaagggcaa ggccacattg actgcagaca aatcctccag cacagcctac 241 atgcaggtca acagcctgac atctgaggac tctgcagtct atttctgtgc aaggggttac 301 tattatgcta tggactactg gggtcaagga acctcagtca ccgtctcctc a

Protein Sequence Defining the Heavy Chain Variable Region of the 11G01 Antibody (SEQ ID NO: 22)

1 qvqlqqsdae lvkpgasvki sckvsgytft  dhiih wmkqr peqglewig y   iyprdgyiky 61 nekfkg katl tadkssstay mqvnsltsed savyfca gy   yyamdy wgqg tsvtvss

Nucleic Acid Sequence Encoding the Kappa Chain Variable Region of the 11G01 Antibody (SEQ ID NO: 23)

1 gatgttttga tgacccaaac tccactctcc ctgcctgtca gtcttggaga tcaagcctcc 61 atctcttgca gatctagtca gagcattgta catagtattg gaaacaccta tttagaatgg 121 tacctgcaga aaccaggcca gtctccaaag ctcctgatct acaaagtttc caaccgattt 181 tctggggtcc cagagaggtt cagtggcagt ggatcaggga cagatttcac actcaagatc 241 agcagagtgg aggctgagga tctgggagtt tattactgct ttcaaggttc acatgttcca 301 ttcacgttcg gctcggggac aaagttggaa ataaaa

Protein Sequence Defining the Kappa Chain Variable Region of the 11G01 Antibody (SEQ ID NO: 24)

1 dvlmtqtpls lpvslgdqas isc rssqsiv   hsigntyle w ylqkpgqspk lliy kvsnrf 61 s gvperfsgs gsgtdftlki srveaedlgv yyc fqgshvp   ft fgsgtkle ik

Nucleic Acid Sequence Encoding the Heavy Chain Variable Region of the 12A07 Antibody (SEQ ID NO: 30)

1 caggtccaac tgctgcagcc tggggctgag ctggtgaggc ctgggacttc agtgaagttg 61 tcctgcaaga cttctggcta caccttctcc agctactgga tgcactgggt aaagcagagg 121 cctggacaag gccttgagtg gatcggaatg attgatcctt ctgatgttta tactaactac 181 aatccaaagt tcaagggcaa ggccacattg actgttgaca catcctccag cacagcctac 241 atgcagctca gcagcctgac atctgaggac tctgcggtct attactgtgc aagaaactac 301 tctggggact actggggcca aggcaccact ctcacagtct cctca

Protein Sequence Defining the Heavy Chain Variable Region of the 12A07 Antibody (SEQ ID NO: 31)

1 qvqllqpgae lvrpgtsvkl scktsgytfs  sywmh wvkqr pgqglewig m   idpsdvytny 61 npkfkg katl tvdtssstay mqlssltsed savyycar ny   sgdy wgqgtt ltvss

Nucleic Acid Sequence Encoding the Kappa Chain Variable Region of the 12A07 Antibody (SEQ ID NO: 32)

1 gatgttttga tgacccaaat tccactctcc ctgcctgtca gtcttggaga tcaagcctcc 61 atctcttgta gatctagtca gagcattgtc catagtaatg gaaacaccta tttagaatgg 121 tacctgcaga aaccaggcca gtctccaaag ctcctgatct acaaagtttc caaccgattt 181 tctggggtcc cagacaggtt cagtggcagt ggatcaggga cagatttcac actcaagatc 241 agcagagtgg aggctgagga tctgggagtt tattactgct ttcaaggttc atatgttccg 301 tggacgttcg gtggaggcac caagctggaa atcaaa

Protein Sequence Defining the Kappa Chain Variable Region of the 12A07 Antibody (SEQ ID NO: 33)

1 dvlmtqipls lpvslgdqas isc rssqsiv   hsngntyle w ylqkpgqspk lliy kvsnrf 61 s gvpdrfsgs gsgtdftlki srveaedlgv yyc fqgsyvp   wt fgggtkle ik

Nucleic Acid Sequence Encoding the Heavy Chain Variable Region of the 18H02 Antibody (SEQ ID NO: 37)

1 cagatccagt tggtacagtc tggacctgaa ctgaagaagc ctggagaggc agtcaagatc 61 tcctgcaagt cttctgggta taccttcaca acctatggaa tgagctgggt gaaacaggct 121 ccaggaaggg ctttaaagtg gatgggctgg ataaacacct actctggagt gccaacatat 181 gctgatgact tcaagggacg gtttgccttc tctttggaat cctctgccag cactgcctat 241 ttgcagatca acaacctcaa aaatgaggac acggctacat atttctgtgc aagagggagg 301 gatggttacc aagtggcctg gtttgcttac tggggccaag ggacgctggt cactgtctct 361 gca

Protein Sequence Defining the Heavy Chain Variable Region of the 18H02 Antibody (SEQ ID NO: 38)

1 qiqlvqsgpe lkkpgeavki sckssgytft  tygms wvkqa pgralkwmg w   intysgvpty 61 addfkg rfaf slessastay lqinnlkned tatyfcar gr   dgyqvawfay  wgqgtlvtvs 121 a

Nucleic Acid Sequence Encoding the Kappa Chain Variable Region of the 18H02 Antibody (SEQ ID NO: 39)

1 gaaacaactg tgacccagtc tccagcatcc ctgtccatgg ctataggaga taaagtcacc 61 atcagatgca taaccagcac tgatattgat gatgatatga actggttcca gcagaagcca 121 ggggaacctc ctaagctcct tatttcagaa ggcaatactc ttcgtcctgg agtcccatcc 181 cgattctccg gcagtggcta tggtacagat tttattttta caattgaaaa catgctctct 241 gaagatgttg cagattacta ctgtttgcaa agtgataact tgccgtacac gttcggaggg 301 gggaccaagc tggaaataaa a

Protein Sequence Defining the Kappa Chain Variable Region of the 18H02 Antibody (SEQ ID NO: 40)

1 ettvtqspas lsmaigdkvt irc itstdid ddmn wfqqkp geppkllis e gntlrp gvps 61 rfsgsgygtd fiftienmls edvadyyc lq sdnlpyt fgg gtkleik

Nucleic Acid Sequence Encoding the Heavy Chain Variable Region of the 22A02 Antibody (SEQ ID NO: 47)

1 caggtccaac tgcagcagcc tggggctgag ctggtgaggc ctgggacttc agtgaagttg 61 tcctgcaagg cttctggcta caccttcacc aactactgga tgcactgggt aaagcagagg 121 cctggacaag gccttgagtg gatcggaatg attgatcctt ctgatagtta tactaactac 181 aatccaaagt tcaagggtaa ggccacattg actgtagaca catcctccag cacagcctac 241 atgcagctca gcagcctgac atctgaggac tctgcggtct attactgtgc aagaaactac 301 tctggggact actggggcca aggcaccact ctcacagtct cctca

Protein Sequence Defining the Heavy Chain Variable Region of the 22A02 Antibody (SEQ ID NO: 48)

1 qvqlqqpgae lvrpgtsvkl sckasgytft  nywmh wvkqr pgqglewig m   idpsdsytny 61 npkfkg katl tvdtssstay mqlssltsed savyycar ny   sgdy wgqgtt ltvss

Nucleic Acid Sequence Encoding the Kappa Chain Variable Region of the 22A02 Antibody (SEQ ID NO: 49)

1 gatgttttga tgacccaaac tccactctcc ctgcctgtca gtcttggaga tcaagcctcc 61 atctcttgca gatctagtca gagcattgta catagtaatg gaaacaccta tttagaatgg 121 tacctgcaga aaccaggcca gtctccaaag ctcctgatct acaaagtttc caaccgattt 181 tctggggtcc cagacaggtt cagtggcagt ggatcaggga cagatttcac actcaagatc 241 agcagagtgg aggctgagga tctgggagtt tattattgct ttcaaggttc atatgttccg 301 tggacgttcg gtggaggcac caagctggaa atcaaa

Protein Sequence Defining the Kappa Chain Variable Region of the 22A02 Antibody (SEQ ID NO: 50)

1 dvlmtgtpls lpvslgdqas isc rssqsiv   hsngntyle w ylqkpgqspk lliy kvsnrf 61 s gvpdrfsgs gsgtdftlki srveaedlgv yyc fqgsyvp   wt fgggtkle ik

Nucleic Acid Sequence Encoding the Heavy Chain Variable Region of the 24C05 Antibody (SEQ ID NO: 53)

1 gaggtgcagc tggtggaatc tgggggaggc ttagtgaagc ctggagggtc cctgaaactc 61 tcctgtgcag cctctggatt cactttcagt gactatgcca tgtcttgggt tcgccagact 121 ccggaaaaga ggctggagtg ggtcgcaacc attagtgatg gtggtactta cacctactat 181 ccagacaatg taaagggccg attcaccatc tccagagaca atgccaagaa caacctgtac 241 ctgcaaatga gccatctgaa gtctgaggac acagccatgt attactgtgc aagagaatgg 301 ggtgattacg acggatttga ctactggggc caaggcacca ctctcacagt ctcctcg

Protein Sequence Defining the Heavy Chain Variable Region of the 24C05 Antibody (SEQ ID NO: 54)

1 evqlvesggg lvkpggslkl scaasgftfs  dyams wvrqt pekrlewva t   isdggtytyy 61 pdnvkg rfti srdnaknnly lqmshlksed tamyycar ew   gdydgfdy wg qgttltvss

Nucleic Acid Sequence Encoding the Kappa Chain Variable Region of the 24C05 Antibody (SEQ ID NO: 55)

  1 gacatccaga tgacccagtc tccatcctcc ttatctgcct ctctgggaga aagagtcagt  61 ctcacttgtc gggcaagtca ggaaattagt ggttacttaa gctggcttca gcagaaacca 121 gatggaacta ttaaacgcct gatctacgcc gcatccactt tagattctgg tgtcccaaaa 181 aggttcagtg gcagtaggtc tgggtcagat tattctctca ccatcggcag ccttgagtct 241 gaagatcttg cagactatta ctgtctacaa tatgatagtt atccgtacac gttcggaggg 301 gggaccaagc tggaaataaa a

Protein Sequence Defining the Kappa Chain Variable Region of the 24C05 Antibody (SEQ ID NO: 56)

 1 diqmtqspss lsaslgervs ltc ras q eis   gyls wlqqkp dgtikrliy a   astlds gvpk 61 rfsgsrsgsd ysltigsles edladyyc lq   ydsypyt fgg gtkleik

The amino acid sequences defining the immunoglobulin heavy chain variable regions for the antibodies produced in Example 1 are aligned in FIG. 2. Amino terminal signal peptide sequences (for proper expression/secretion) are not shown. CDR₁, CDR₂, and CDR₃ (Kabat definition) are identified by boxes. FIG. 3 shows an alignment of the separate CDR₁, CDR₂, and CDR₃ sequences for each antibody.

The amino acid sequences defining the immunoglobulin light chain variable regions for the antibodies in Example 1 are aligned in FIG. 4. Amino terminal signal peptide sequences (for proper expression/secretion) are not shown. CDR₁, CDR₂ and CDR₃ are identified by boxes. FIG. 5 shows an alignment of the separate CDR₁, CDR₂, and CDR₃ sequences for each antibody.

Table 1 is a concordance chart showing the SEQ ID NO. of each sequence discussed in this Example.

TABLE 1 SEQ. ID NO. Nucleic Acid or Protein 1 04D01 Heavy Chain Variable Region-nucleic acid 2 04D01 Heavy Chain Variable Region-protein 3 04D01 Light (kappa) Chain Variable Region-nucleic acid 4 04D01 Light (kappa) Chain Variable Region-protein 5 04D01 Heavy Chain CDR₁ 6 04D01 Heavy Chain CDR₂ 7 04D01 Heavy Chain CDR₃ 8 04D01 Light (kappa) Chain CDR₁ 9 04D01 Light (kappa) Chain CDR₂ 10 04D01 Light (kappa) Chain CDR₃ 11 09D03 Heavy Chain Variable Region-nucleic acid 12 09D03 Heavy Chain Variable Region-protein 13 09D03 Light (kappa) Chain Variable Region-nucleic acid 14 09D03 Light (kappa) Chain Variable Region-protein 15 09D03 Heavy Chain CDR₁ 16 09D03 Heavy Chain CDR₂ 17 09D03 Heavy Chain CDR₃ 18 09D03 Light (kappa) Chain CDR₁ 19 09D03 Light (kappa) Chain CDR₂ 20 09D03 Light (kappa) Chain CDR₃ 21 11G01 Heavy Chain Variable Region-nucleic acid 22 11G01 Heavy Chain Variable Region-protein 23 11G01 Light (kappa) Chain Variable Region-nucleic acid 24 11G01 Light (kappa) Chain Variable Region-protein 25 11G01 Heavy Chain CDR₁ 26 11G01 Heavy Chain CDR₂ 27 11G01 Heavy Chain CDR₃ 28 11G01 Light (kappa) Chain CDR₁ 9 11G01 Light (kappa) Chain CDR₂ 29 11G01 Light (kappa) Chain CDR₃ 30 12A07 Heavy Chain Variable Region-nucleic acid 31 12A07 Heavy Chain Variable Region-protein 32 12A07 Light (kappa) Chain Variable Region-nucleic acid 33 12A07 Light (kappa) Chain Variable Region-protein 34 12A07 Heavy Chain CDR₁ 35 12A07 Heavy Chain CDR₂ 36 12A07 Heavy Chain CDR₃ 8 12A07 Light (kappa) Chain CDR₁ 9 12A07 Light (kappa) Chain CDR₂ 10 12A07 Light (kappa) Chain CDR₃ 37 18H02 Heavy Chain Variable Region-nucleic acid 38 18H02 Heavy Chain Variable Region-protein 39 18H02 Light (kappa) Chain Variable Region-nucleic acid 40 18H02 Light (kappa) Chain Variable Region-protein 41 18H02 Heavy Chain CDR₁ 42 18H02 Heavy Chain CDR₂ 43 18H02 Heavy Chain CDR₃ 44 18H02 Light (kappa) Chain CDR₁ 45 18H02 Light (kappa) Chain CDR₂ 46 18H02 Light (kappa) Chain CDR₃ 47 22A02 Heavy Chain Variable Region-nucleic acid 48 22A02 Heavy Chain Variable Region-protein 49 22A02 Light (kappa) Chain Variable Region-nucleic acid 50 22A02 Light (kappa) Chain Variable Region-protein 51 22A02 Heavy Chain CDR₁ 52 22A02 Heavy Chain CDR₂ 36 22A02 Heavy Chain CDR₃ 8 22A02 Light (kappa) Chain CDR₁ 9 22A02 Light (kappa) Chain CDR₂ 10 22A02 Light (kappa) Chain CDR₃ 53 24C05 Heavy Chain Variable Region-nucleic acid 54 24C05 Heavy Chain Variable Region-protein 55 24C05 Light (kappa) Chain Variable Region-nucleic acid 56 24C05 Light (kappa) Chain Variable Region-protein 57 24C05 Heavy Chain CDR₁ 58 24C05 Heavy Chain CDR₂ 59 24C05 Heavy Chain CDR₃ 60 24C05 Light (kappa) Chain CDR₁ 61 24C05 Light (kappa) Chain CDR₂ 62 24C05 Light (kappa) Chain CDR₃

Mouse monoclonal antibody heavy chain CDR sequences (Kabat, Chothia, and IMGT definitions) are shown in Table 2.

TABLE 2 CDR1 CDR2 CDR3 Kabat 04D01 SHWLH VLDPSDFYSNYNQN GLLSGDYAMDY (SEQ ID FKG (SEQ ID NO: NO: 5) (SEQ ID NO: 6) 7) 09D03 TFGLSVG HIWWDDDKYYNPA IGADALPFDY (SEQ ID LKS (SEQ ID NO: NO: 15) (SEQ ID NO: 16) 17) 11G01 DHIIH YIYPRDGYIKYNEK GYYYAMDY (SEQ ID FKG (SEQ ID NO: NO: 25) (SEQ ID NO: 26) 27) 12A07 SYWMH MIDPSDVYTNYNPK NYSGDY (SEQ ID FKG (SEQ ID NO: NO: 34) (SEQ ID NO: 35) 36) 18H02 TYGMS WINTYSGVPTYADD GRDGYQVAWFAY (SEQ ID FKG (SEQ ID NO: NO: 41) (SEQ ID NO: 42) 43) 22A02 NYWMH MIDPSDSYTNYNPK NYSGDY (SEQ ID FKG (SEQ ID NO: NO: 51) (SEQ ID NO: 52) 36) 24C05 DYAMS TISDGGTYTYYPDN EWGDYDGFDY (SEQ ID VKG (SEQ ID NO: NO: 57) (SEQ ID NO: 58) 59) Chothia 04D01 GYTFTSH DPSDFY GLLSGDYAMDY (SEQ ID (SEQ ID NO: 64) (SEQ ID NO: NO: 63) 7) 09D03 GFSLSTFGL WWDDD IGADALPFDY (SEQ ID (SEQ ID NO: 66) (SEQ ID NO: NO: 65) 17) 11G01 GYTFTDH YPRDGY GYYYAMDY (SEQ ID (SEQ ID NO: 68) (SEQ ID NO: NO: 67) 27) 12A07 GYTFSSY DPSDVY NYSGDY (SEQ ID (SEQ ID NO: 70) (SEQ ID NO: NO: 69) 36) 18H02 GYTFTTY NTYSGV GRDGYQVAWFAY (SEQ ID (SEQ ID NO: 72) (SEQ ID NO: NO: 71) 43) 22A02 GYTFTNY DPSDSY NYSGDY (SEQ ID (SEQ ID NO: 74) (SEQ ID NO: NO: 73) 36) GFTFSDY SDGGTY EWGDYDGFDY 24C05 (SEQ ID (SEQ ID NO: 76) (SEQ ID NO: NO: 75) 59) IMGT 04D01 GYTFTSHW LDPSDFYS ARGLLSGDYAM (SEQ ID (SEQ ID NO: 78) DY (SEQ ID NO: 77) NO: 79) 09D03 GFSLSTFGLS IWWDDDK ARIGADALPFDY (SEQ ID (SEQ ID NO: 81) (SEQ ID NO: NO: 80) 82) 11G01 GYTFTDHI IYPRDGYI ARGYYYAMDY (SEQ ID (SEQ ID NO: 84) (SEQ ID NO: NO: 83) 85) 12A07 GYTFSSYW IDPSDVYT ARNYSGDY (SEQ ID (SEQ ID NO: 87) (SEQ ID NO: NO: 86) 88) 18H02 GYTFTTYG INTYSGVP ARGRDGYQVAWF (SEQ ID (SEQ ID NO: 90) AY (SEQ ID NO: 89) NO: 91) 22A02 GYTFTNYW IDPSDSYT ARNYSGDY (SEQ ID (SEQ ID NO: 93) (SEQ ID NO: NO: 92) 88) 24C05 GFTFSDYA ISDGGTYT AREWGDYDGFDY (SEQ ID (SEQ ID NO: 95) (SEQ ID NO: NO: 94) 96)

Mouse monoclonal antibody Kappa light chain CDR sequences (Kabat, Chothia, and IMGT definitions) are shown in Table 3.

TABLE 3 CDR1 CDR2 CDR3 Kabat/Chothia 04D01 RSSQSIVHSNGNTYLE KVSNRFS FQGSYVPWT (SEQ ID NO: 8) (SEQ ID (SEQ ID NO: 10) NO: 9) 09D03 RSSKSLLHSNGNTYLY RMSNLAS MQHLEYPFT (SEQ ID NO: 18) (SEQ ID (SEQ ID NO: 20) NO: 19) 11G01 RSSQSIVHSIGNTYLE KVSNRFS FQGSHVPFT (SEQ ID NO: 28) (SEQ ID (SEQ ID NO: 29) NO: 9) 12A07 RSSQSIVHSNGNTYLE KVSNRFS FQGSYVPWT (SEQ ID NO: 8) (SEQ ID (SEQ ID NO: 10) NO: 9) 18H02 ITSTDIDDDMN EGNTLRP LQSDNLPYT (SEQ ID NO: 44) (SEQ ID (SEQ ID NO: 46) NO: 45) 22A02 RSSQSIVHSNGNTYLE KVSNRFS FQGSYVPWT (SEQ ID NO: 8) (SEQ ID (SEQ ID NO: 10) NO: 9) 24C05 RASQEISGYLS AASTLDS LQYDSYPYT (SEQ ID NO: 60) (SEQ ID (SEQ ID NO: 62) NO: 61) IMGT 04D01 QSIVHSNGNTY KVS FQGSYVPWT (SEQ ID NO: 97) (SEQ ID NO: 10) 09D03 KSLLHSNGNTY RMS MQHLEYPFT (SEQ ID NO: 98) (SEQ ID NO: 20) 11G01 QSIVHSIGNTY KVS FQGSHVPFT (SEQ ID NO: 99) (SEQ ID NO: 29) 12A07 QSIVHSNGNTY KVS FQGSYVPWT (SEQ ID NO: 97) (SEQ ID NO: 10) 18H02 TDIDDD EGN LQSDNLPYT (SEQ ID NO: 100) (SEQ ID NO: 46) 22A02 QSIVHSNGNTY KVS FQGSYVPWT (SEQ ID NO: 97) (SEQ ID NO: 10) 24C05 QEISGY AAS LQYDSYPYT (SEQ ID NO: 101) (SEQ ID NO: 62)

In Tables 2 and 3, the longest CDR sequences for the immunoglobulin heavy chain and light chain are shown in bold.

To create the complete heavy or kappa chain antibody sequences, each variable sequence above is combined with its respective constant region. For example, a complete heavy chain comprises a heavy variable sequence followed by the murine IgG1 or IgG2b heavy chain constant sequence and a complete kappa chain comprises a kappa variable sequence followed by the murine kappa light chain constant sequence.

Nucleic Acid Sequence Encoding the Murine IgG1 Heavy Chain Constant Region (SEQ ID NO: 102)

  1 gccaaaacga cacccccatc tgtctatcca ctggcccctg gatctgctgc ccaaactaac  61 tccatggtga ccctgggatg cctggtcaag ggctatttcc ctgagccagt gacagtgacc 121 tggaactctg gatccctgtc cagcggtgtg cacaccttcc cagctgtcct gcagtctgac 181 ctctacactc tgagcagctc agtgactgtc ccctccagca cctggcccag ccagaccgtc 241 acctgcaacg ttgcccaccc ggccagcagc accaaggtgg acaagaaaat tgtgcccagg 301 gattgtggtt gtaagccttg catatgtaca gtcccagaag tatcatctgt cttcatcttc 361 cccccaaagc ccaaggatgt gctcaccatt actctgactc ctaaggtcac gtgtgttgtg 421 gtagacatca gcaaggatga tcccgaggtc cagttcagct ggtttgtaga tgatgtggag 481 gtgcacacag ctcagacgca accccgggag gagcagttca acagcacttt ccgctcagtc 541 agtgaacttc ccatcatgca ccaggactgg ctcaatggca aggagttcaa atgcagggtc 601 aacagtgcag ctttccctgc ccccatcgag aaaaccatct ccaaaaccaa aggcagaccg 661 aaggctccac aggtgtacac cattccacct cccaaggagc agatggccaa ggataaagtc 721 agtctgacct gcatgataac agacttcttc cctgaagaca ttactgtgga gtggcagtgg 781 aatgggcagc cagcggagaa ctacaagaac actcagccca tcatggacac agatggctct 841 tacttcgtct acagcaagct caatgtgcag aagagcaact gggaggcagg aaatactttc 901 acctgctctg tgttacatga gggcctgcac aaccaccata ctgagaagag cctctcccac 961 tctcctggta aa

Protein Sequence Defining the Murine IgG1 Heavy Chain Constant Region (SEQ ID NO: 103)

  1 akttppsvyp lapgsaaqtn smvtlgclvk gyfpepvtvt wnsgslssgv htfpavlqsd  61 lytlsssvtv psstwpsqtv tcnvahpass tkvdkkivpr dcgckpcict vpevssvfif 121 ppkpkdvlti tltpkvtcvv vdiskddpev qfswfvddve vhtaqtqpre eqfnstfrsv 181 selpimhqdw lngkefkcrv nsaafpapie ktisktkgrp kapqvytipp pkeqmakdkv 241 sltcmitdff peditvewqw ngqpaenykn tqpimdtdgs yfvysklnvq ksnweagntf 301 tcsvlheglh nhhtekslsh spgk

Nucleic Acid Sequence Encoding the Murine IgG2b Heavy Chain Constant Region (SEQ ID NO: 104)

  1 gccaaaacaa cacccccatc agtctatcca ctggcccctg ggtgtggaga tacaactggt  61 tcctctgtga ctctgggatg cctggtcaag ggctacttcc ctgagtcagt gactgtgact 121 tggaactctg gatccctgtc cagcagtgtg cacaccttcc cagctctcct gcagtctgga 181 ctctacacta tgagcagctc agtgactgtc ccctccagca cctggccaag tcagaccgtc 241 acctgcagcg ttgctcaccc agccagcagc accacggtgg acaaaaaact tgagcccagc 301 gggcccattt caacaatcaa cccctgtcct ccatgcaagg agtgtcacaa atgcccagct 361 cctaacctcg agggtggacc atccgtcttc atcttccctc caaatatcaa ggatgtactc 421 atgatctccc tgacacccaa ggtcacgtgt gtggtggtgg atgtgagcga ggatgaccca 481 gacgtccaga tcagctggtt tgtgaacaac gtggaagtac acacagctca gacacaaacc 541 catagagagg attacaacag tactatccgg gtggtcagca ccctccccat ccagcaccag 601 gactggatga gtggcaagga gttcaaatgc aaggtcaaca acaaagacct cccatcaccc 661 atcgagagaa ccatctcaaa aattaaaggg ctagtcagag ctccacaagt atacatcttg 721 ccgccaccag cagagcagtt gtccaggaaa gatgtcagtc tcacttgcct ggtcgtgggc 781 ttcaaccctg gagacatcag tgtggagtgg accagcaatg ggcatacaga ggagaactac 841 aaggacaccg caccagtcct agactctgac ggttcttact tcatatatag caagctcaat 901 atgaaaacaa gcaagtggga gaaaacagat tccttctcat gcaacgtgag acacgagggt 961 ctgaaaaatt actacctgaa gaagaccatc tcccggtctc cgggtaaa

Protein Sequence Defining the Murine IgG2b Heavy Chain Constant Region (SEQ ID NO: 105)

  1 akttppsvyp lapgcgdttg ssvtlgclvk gyfpesvtvt wnsgslsssv htfpallqsg  61 lytmsssvtv psstwpsqtv tcsvahpass ttvdkkleps gpistinpcp pckechkcpa 121 pnleggpsvf ifppnikdvl misltpkvtc vvvdvseddp dvqiswfvnn vevhtaqtqt 181 hredynstir vvstlpiqhq dwmsgkefkc kvnnkdlpsp iertiskikg lvrapqvyil 241 pppaeqlsrk dvsltclvvg fnpgdisvew tsnghteeny kdtapvldsd gsyfiyskln 301 mktskwektd sfscnvrheg lknyylkkti srspgk

Nucleic Acid Sequence Encoding the Murine Kappa Light Chain Constant Region (SEQ ID NO: 106)

  1 cgggctgatg ctgcaccaac tgtatccatc ttcccaccat ccagtgagca gttaacatct  61 ggaggtgcct cagtcgtgtg cttcttgaac aacttctacc ccagagacat caatgtcaag 121 tggaagattg atggcagtga acgacaaaat ggtgtcctga acagttggac tgatcaggac 181 agcaaagaca gcacctacag catgagcagc accctcacat tgaccaagga cgagtatgaa 241 cgacataaca gctatacctg tgaggccact cacaagacat caacttcacc cattgtcaag 301 agcttcaaca ggaatgagtg t

Protein Sequence Defining the Murine Kappa Light Chain Constant Region (SEQ ID NO: 107)

 1 radaaptvsi fppsseqlts ggasvvcfln nfyprdinvk wkidgserqn gvlnswtdqd 61 skdstysmss tltltkdeye rhnsytceat hktstspivk sfnrnec

The following sequences represent the actual or contemplated full length heavy and light chain sequences (i.e., containing both the variable and constant regions sequences) for each antibody described in this Example. Signal sequences for proper secretion of the antibodies are also included at the 5′ end of the DNA sequences or the amino terminal end of the protein sequences. The variable region sequences can be ligated to other constant region sequences, to produce active full length IgG heavy and light chains.

Nucleic Acid Sequence Encoding the Full Length Heavy Chain Sequence (Heavy Chain Variable Region and IgG1 Constant Region) of 04D01 (SEQ ID NO: 108)

  1 atgggatgga gctgtatcat tgtcctcttg gtatcaacag ctacaggtgt ccactcccag  61 gtccaactgc agcagcctgg ggctgaactg gtgaggcctg ggacttcagt gaagttgtcc 121 tgcaaggctt ctggctacac cttcaccagc cactggttgc actgggtgaa gcagaggcct 181 ggacaaggcc ttgagtggat cggagtgctt gatccttctg atttttatag taactacaat 241 caaaacttca agggcaaggc cacattgact gtagacacat cctccagcac agcctacatg 301 cagctcagca gcctgacatc tgaggactct gcggtctatt actgtgcacg aggcctacta 361 tccggggact atgctatgga ctactggggt caaggaacct cagtcaccgt ctcctcagcc 421 aaaacgacac ccccatctgt ctatccactg gcccctggat ctgctgccca aactaactcc 481 atggtgaccc tgggatgcct ggtcaagggc tatttccctg agccagtgac agtgacctgg 541 aactctggat ccctgtccag cggtgtgcac accttcccag ctgtcctgca gtctgacctc 601 tacactctga gcagctcagt gactgtcccc tccagcacct ggcccagcca gaccgtcacc

 661 tgcaacgttg cccacccggc cagcagcacc aaggtggaca agaaaattgt gcccagggat  721 tgtggttgta agccttgcat atgtacagtc ccagaagtat catctgtctt catcttcccc  781 ccaaagccca aggatgtgct caccattact ctgactccta aggtcacgtg tgttgtggta  841 gacatcagca aggatgatcc cgaggtccag ttcagctggt ttgtagatga tgtggaggtg  901 cacacagctc agacgcaacc ccgggaggag cagttcaaca gcactttccg ctcagtcagt  961 gaacttccca tcatgcacca ggactggctc aatggcaagg agttcaaatg cagggtcaac 1021 agtgcagctt tccctgcccc catcgagaaa accatctcca aaaccaaagg cagaccgaag 1081 gctccacagg tgtacaccat tccacctccc aaggagcaga tggccaagga taaagtcagt 1141 ctgacctgca tgataacaga cttcttccct gaagacatta ctgtggagtg gcagtggaat 1201 gggcagccag cggagaacta caagaacact cagcccatca tggacacaga tggctcttac 1261 ttcgtctaca gcaagctcaa tgtgcagaag agcaactggg aggcaggaaa tactttcacc 1321 tgctctgtgt tacatgaggg cctgcacaac caccatactg agaagagcct ctcccactct 1381  cctggtaaa

Protein Sequence Defining the Full Length Heavy Chain Sequence (Heavy Chain Variable Region and IgG1 Constant Region) of 04D01 (SEQ ID NO: 109)

  1 mgwsciivll vstatgvhsq vqlqqpgael vrpgtsvkls ckasgytfts hwlhwvkqrp  61 gqglewigvl dpsdfysnyn qnfkgkatlt vdtssstaym qlssltseds avyycargll 121 sgdyamdywg qgtsvtvssa kttppsvypl apgsaaqtns mvtlgclvkg yfpepvtvtw 181 nsgslssgvh tfpavlqsdl ytlsssvtvp sstwpsqtvt cnvahpasst kvdkkivprd 241 cgckpcictv pevssvfifp pkpkdvltit ltpkvtcvvv diskddpevq fswfvddvev 301 htaqtqpree qfnstfrsvs elpimhqdwl ngkefkcrvn saafpapiek tisktkgrpk 361 apqvytippp keqmakdkvs ltcmitdffp editvewqwn gqpaenyknt qpimdtdgsy 421 fvysklnvqk snweagntft csvlheglhn hhtekslshs pgk

Nucleic Acid Sequence Encoding the Full Length Light Chain Sequence (Kappa Chain Variable Region and Constant Region) of 04D01 (SEQ ID NO: 110)

  1 atgaagttgc ctgttaggct gttggtgctg atgttctgga ttcctgcttc cagcagtgat  61 gttttgatga cccaaattcc actctccctg cctgtcagtc ttggagatca agcctccatc 121 tcttgcagat ctagtcagag cattgtacat agtaatggaa acacctattt agaatggtac 181 ctgcagaaac caggccagtc tccaaagtcc ctgatctaca aagtttctaa ccgattttct 241 ggggtcccag acaggttcag tggcagtgga tcagggacag atttcacact caagatcagc 301 agagtggagg ctgaggatct gggagtttat tactgctttc aaggttcata tgttccgtgg 361 acgttcggtg gaggcaccaa gctggaaatc aaacgggctg atgctgcacc aactgtatcc 421 atcttcccac catccagtga gcagttaaca tctggaggtg cctcagtcgt gtgcttcttg 481 aacaacttct accccagaga catcaatgtc aagtggaaga ttgatggcag tgaacgacaa 541 aatggtgtcc tgaacagttg gactgatcag gacagcaaag acagcaccta cagcatgagc 601 agcaccctca cattgaccaa ggacgagtat gaacgacata acagctatac ctgtgaggcc 661 actcacaaga catcaacttc acccattgtc aagagcttca acaggaatga gtgt

Protein Sequence Defining the Full Length Light Chain Sequence (Kappa Chain Variable Region and Constant Region) of 04D01 (SEQ ID NO: 111)

  1 mklpvrllvl mfwipasssd vlmtqiplsl pvslgdqasi scrssqsivh sngntylewy  61 lqkpgqspks liykvsnrfs gvpdrfsgsg sgtdftlkis rveaedlgvy ycfqgsyvpw 121 tfgggtklei kradaaptvs ifppsseqlt sggasvvcfl nnfyprdinv kwkidgserq 181 ngvlnswtdq dskdstysms stltltkdey erhnsytcea thktstspiv ksfnrnec

Nucleic Acid Sequence Encoding the Full Length Heavy Chain Sequence (Heavy Chain Variable Region and IgG2b Constant Region) of 09D03 (SEQ ID NO: 112)

   1 atgggcaggc ttacttcttc attcctgtta ctgattgtcc ctgcatatgt cctgtcccag   61 gttactctaa aagagtctgg ccctgggata ttgcggccct cccagaccct cagtctgact  121 tgttctttct ctgggttttc actgagcact tttggtttga gtgtaggctg gattcgtcag  181 ccttcaggga agggtctgga gtggctggca cacatttggt gggatgatga taagtactat  241 aacccagccc ttaagagtcg gctcacaatc tccaaggata cctccaaaaa ccaggtattc  301 ctcaagatcg ccaatgtgga cactgcagat actgccacat actactgtgc tcgaataggg  361 gcggacgccc ttccttttga ctactggggc caaggcacca ctctcacagt ctcctcagcc  421 aaaacaacac ccccatcagt ctatccactg gcccctgggt gtggagatac aactggttcc  481 tccgtgacct ctgggtgcct ggtcaagggg tacttccctg agccagtgac tgtgacttgg  541 aactctggat ccctgtccag cagtgtgcac accttcccag ctctcctgca gtctggactc  601 tacactatga gcagctcagt gactgtcccc tccagcacct ggccaagtca gaccgtcacc  661 tgcagcgttg ctcacccagc cagcagcacc acggtggaca aaaaacttga gcccagcggg  721 cccatttcaa caatcaaccc ctgtcctcca tgcaaggagt gtcacaaatg cccagctcct  781 aacctcgagg gtggaccatc cgtcttcatc ttccctccaa atatcaagga tgtactcatg  841 atctccctga cacccaaggt cacgtgtgtg gtggtggatg tgagcgagga tgacccagac  901 gtccagatca gctggtttgt gaacaacgtg gaagtacaca cagctcagac acaaacccat  961 agagaggatt acaacagtac tatccgggtg gtcagcaccc tccccatcca gcaccaggac 1021 tggatgagtg gcaaggagtt caaatgcaag gtgaacaaca aagacctccc atcacccatc 1081 gagagaacca tctcaaaaat taaagggcta gtcagagctc cacaagtata cactttgccg 1141 ccaccagcag agcagttgtc caggaaagat gtcagtctca cttgcctggt cgtgggcttc 1201 aaccctggag acatcagtgt ggagtggacc agcaatgggc atacagagga gaactacaag 1261 gacaccgcac cagttcttga ctctgacggt tcttacttca tatatagcaa gctcaatatg 1321 aaaacaagca agtgggagaa aacagattcc ttctcatgca acgtgagaca cgagggtctg 1381 aaaaattact acctgaagaa gaccatctcc cggtctccgg gtaaa

Protein Sequence Defining the Full Length Heavy Chain Sequence (Heavy Chain Variable Region and IgG2b Constant Region) of 09D03 (SEQ ID NO: 113)

  1 mgrltssfll livpayvlsq vtlkesgpgi lrpsqtlslt csfsgfslst fglsvgwirq  61 psgkglewla hiwwdddkyy npalksrlti skdtsknqvf lkianvdtad tatyycarig 121 adalpfdywg qgttltvssa kttppsvypl apgcgdttgs svtsgclvkg yfpepvtvtw 181 nsgslsssvh tfpallgsgl ytmsssvtvp sstwpsqtvt csvahpasst tvdkklepsg 241 pistinpcpp ckechkcpap nleggpsvfi fppnikdvlm isltpkvtcv vvdvseddpd 301 vqiswfvnnv evhtaqtqth redynstirv vstlpiqhqd wmsgkefkck vnnkdlpspi 361 ertiskikgl vrapqvytlp ppaeqlsrkd vsltclvvgf npgdisvewt snghteenyk 421 dtapvldsdg syfiysklnm ktskwektds fscnvrhegl knyylkktis rspgk

Nucleic Acid Sequence Encoding the Full Length Light Chain Sequence (Kappa Chain Variable Region and Constant Region) of 09D03 (SEQ ID NO: 114)

  1 atgaggtgcc tagctgagtt cctggggctg cttgtgctct ggatccctgg agccattggg  61 gatattgtgt tgactcagac tgcaccctct gtacctgtca ctcctggaga gtcagtatcc 121 atctcctgca ggtctagtaa gagtctcctg catagtaatg gcaacactta cttgtattgg 181 ttcctgcaga ggccaggcca gtctcctcag ctcctgatat atcggatgtc caaccttgcc 241 tcaggagtcc cagacaggtt cagtggcagt gggtcaggaa ctgctttcac actgagaatc 301 agtagagtgg aggctgagga tgtgggtgtt tattactgta tgcaacatct agaatatcct 361 ttcacgttcg gctcggggac aaagttggaa ataaaacggg ctgatgctgc accaactgta 421 tccatcttcc caccatccag tgagcagtta acatctggag gtgcctcagt cgtgtgcttc 481 ttgaacaact tctaccccag agacatcaat gtcaagtgga agattgatgg cagtgaacga 541 caaaatggtg tcctgaacag ttggactgat caggacagca aagacagcac ctacagcatg 601 agcagcaccc tcacattgac caaggacgag tatgaacgac ataacagcta tacctgtgag 661 gccactcaca agacatcaac ttcacccatt gtcaagagct tcaacaggaa tgagtgt

Protein Sequence Defining the Full Length Light Chain Sequence (Kappa Chain Variable Region and Constant Region) of 09D03 (SEQ ID NO: 115)

  1 mrclaeflgl lvlwipgaig divltqtaps vpvtpgesvs iscrssksll hsngntylyw  61 flqrpggspq lliyrmsnla sgvpdrfsgs gsgtaftlri srveaedvgv yycmqhleyp 121 ftfgsgtkle ikradaaptv sifppsseql tsggasvvcf lnnfyprdin vkwkidgser 181 qngvlnswtd qdskdstysm sstltltkde yerhnsytce athktstspi vksfnrnec

Nucleic Acid Sequence Encoding the Full Length Heavy Chain Sequence (Heavy Chain Variable Region and IgG1 Constant Region) of 11G01 (SEQ ID NO: 116)

   1 atggaatgga gctgggtctc tctcttcttc ctgtcagtaa ctacaggtgt ccactcccag   61 gttcagctgc aacagtctga cgctgagttg gtgaaacctg gagcttcagt gaagatatcc  121 tgcaaggttt ctggctacac cttcactgac catattattc actggatgaa gcagaggcct  181 gaacagggcc tggaatggat tggatatatt tatcctagag atggttatat taagtacaat  241 gagaagttca agggcaaggc cacattgact gcagacaaat cctccagcac agcctacatg  301 caggtcaaca gcctgacatc tgaggactct gcagtctatt tctgtgcaag gggttactat  361 tatgctatgg actactgggg tcaaggaacc tcagtcaccg tctcctcagc caaaacgaca  421 cccccatctg tctatccact ggcccctgga tctgctgccc aaactaactc catggtgacc  481 ctgggatgcc tggtcaaggg ctatttccct gagccagtga cagtgacctg gaactctgga  541 tccctgtcca gcggtgtgca caccttccca gctgtcctgc agtctgacct ctacactctg  601 agcagctcag tgactgtccc ctccagcacc tggcccagcc agaccgtcac ctgcaacgtt  661 gcccacccgg ccagcagcac caaggtggac aagaaaattg tgcccaggga ttgtggttgt  721 aagccttgca tatgtacagt cccagaagta tcatctgtct tcatcttccc cccaaagccc  781 aaggatgtgc tcaccattac tctgactcct aaggtcacgt gtgttgtggt agacatcagc  841 aaggatgatc ccgaggtcca gttcagctgg tttgtagatg atgtggaggt gcacacagct  901 cagacgcaac cccgggagga gcagttcaac agcactttcc gctcagtcag tgaacttccc  961 atcatgcacc aggactggct caatggcaag gagttcaaat gcagggtcaa cagtgcagct 1021 ttccctgccc ccatcgagaa aaccatctcc aaaaccaaag gcagaccgaa ggctccacag 1081 gtgtacacca ttccacctcc caaggagcag atggccaagg ataaagtcag tctgacctgc 1141 atgataacag acttcttccc tgaagacatt actgtggagt ggcagtggaa tgggcagcca 1201 gcggagaact acaagaacac tcagcccatc atggacacag atggctctta cttcgtctac 1261 agcaagctca atgtgcagaa gagcaactgg gaggcaggaa atactttcac ctgctctgtg 1321 ttacatgagg gcctgcacaa ccaccatact gagaagagcc tctcccactc tcctggtaaa

Protein Sequence Defining the Full Length Heavy Chain Sequence (Heavy Chain Variable Region and IgG1 Constant Region) of 11G01 (SEQ ID NO: 117)

  1 mewswvslff lsvttgvhsq vqlqqsdael vkpgasvkis ckvsgytftd hiihwmkqrp  61 eqglewigyi yprdgyikyn ekfkgkatlt adkssstaym qvnsltseds avyfcargyy 121 yamdywgqgt svtvssaktt ppsvyplapg saaqtnsmvt lgclvkgyfp epvtvtwnsg 181 slssgvhtfp avlqsdlytl sssvtvpsst wpsqtvtcnv ahpasstkvd kkivprdcgc 241 kpcictvpev ssvfifppkp kdvltitltp kvtcvvvdis kddpevqfsw fvddvevhta 301 qtqpreeqfn stfrsvselp imhqdwlngk efkcrvnsaa fpapiektis ktkgrpkapq 361 vytipppkeq makdkvsltc mitdffpedi tvewqwngqp aenykntqpi mdtdgsyfvy 421 sklnvqksnw eagntftcsv lheglhnhht ekslshspgk 

Nucleic Acid Sequence Encoding the Full Length Light Chain Sequence (Kappa Chain Variable Region and Constant Region) of 11G01 (SEQ ID NO: 118)

  1 atgaagttgc ctgttaggct gttggtgctg atgttctgga ttcctgcttc cagaagtgat  61 gttttgatga cccaaactcc actctccctg cctgtcagtc ttggagatca agcctccatc 121 tcttgcagat ctagtcagag cattgtacat agtattggaa acacctattt agaatggtac 181 ctgcagaaac caggccagtc tccaaagctc ctgatctaca aagtttccaa ccgattttct 241 ggggtcccag agaggttcag tggcagtgga tcagggacag atttcacact caagatcagc 301 agagtggagg ctgaggatct gggagtttat tactgctttc aaggttcaca tgttccattc 361 acgttcggct cggggacaaa gttggaaata aaacgggctg atgctgcacc aactgtatcc 421 atcttcccac catccagtga gcagttaaca tctggaggtg cctcagtcgt gtgcttcttg 481 aacaacttct accccaaaga catcaatgtc aagtggaaga ttgatggcag tgaacgacaa 541 aatggcgtcc tgaacagttg gactgatcag gacagcaaag acagcaccta cagcatgagc 601 agcaccctca cgttgaccaa ggacgagtat gaacgacata acagctatac ctgtgaggcc 661 actcacaaga catcaacttc acccattgtc aagagcttca acaggaatga gtgt

Protein Sequence Defining the Full Length Light Chain Sequence (Kappa Chain Variable Region and Constant Region) of 11G01 (SEQ ID NO: 119)

  1 mklpvrllvl mfwipasrsd vlmtqtplsl pvslgdqasi scrssqsivh signtylewy  61 lqkpgqspkl liykvsnrfs gvperfsgsg sgtdftlkis rveaedlgvy ycfqgshvpf 121 tfgsgtklei kradaaptvs ifppsseqlt sggasvvcfl nnfypkdinv kwkidgserq 181 ngvlnswtdq dskdstysms stltltkdey erhnsytcea thktstspiv ksfnrnec

Nucleic Acid Sequence Encoding the Full Length Heavy Chain Sequence (Heavy Chain Variable Region and IgG1 Constant Region) of 12A07 (SEQ ID NO: 120)

   1 atgggatgga gctgtatcat tgtcctcttg gtatcaacag ctacatgtgt ccactcccag   61 gtccaactgc tgcagcctgg ggctgagctg gtgaggcctg ggacttcagt gaagttgtcc  121 tgcaagactt ctggctacac cttctccagc tactggatgc actgggtaaa gcagaggcct  181 ggacaaggcc ttgagtggat cggaatgatt gatccttctg atgtttatac taactacaat  241 ccaaagttca agggcaaggc cacattgact gttgacacat cctccagcac agcctacatg  301 cagctcagca gcctgacatc tgaggactct gcggtctatt actgtgcaag aaactactct  361 ggggactact ggggccaagg caccactctc acagtctcct cagccaaaac gacaccccca  421 tctgtctatc cactggcccc tggatctgct gcccaaacta actccatggt gaccctggga  481 tgcctggtca agggctattt ccctgagcca gtgacagtga cctggaactc tggatccctg  541 tccagcggtg tgcacacctt cccagctgtc ctgcagtctg acctctacac tctgagcagc  601 tcagtgactg tcccctccag cacctggccc agccagaccg tcacctgcaa cgttgcccac  661 ccggccagca gcaccaaggt ggacaagaaa attgtgccca gggattgtgg ttgtaagcct  721 tgcatatgta cagtcccaga agtatcatct gtcttcatct tccccccaaa gcccaaggat  781 gtgctcacca ttactctgac tcctaaggtc acgtgtgttg tggtagacat cagcaaggat  841 gatcccgagg tccagttcag ctggtttgta gatgatgtgg aggtgcacac agctcagacg  901 caaccccggg aggagcagtt caacagcact ttccgctcag tcagtgaact tcccatcatg  961 caccaggact ggctcaatgg caaggagttc aaatgcaggg tcaacagtgc agctttccct 1021 gcccccatcg agaaaaccat ctccaaaacc aaaggcagac cgaaggctcc acaggtgtac 1081 accattccac ctcccaagga gcagatggcc aaggataaag tcagtctgac ctgcatgata 1141 acagacttct tccctgaaga cattactgtg gagtggcagt ggaatgggca gccagcggag 1201 aactacaaga acactcagcc catcatggac acagatggct cttacttcgt ctacagcaag 1261 ctcaatgtgc agaagagcaa ctgggaggca ggaaatactt tcacctgctc tgtgttacat 1321 gagggcctgc acaaccacca tactgagaag agcctctccc actctcctgg taaa

Protein Sequence Defining the Full Length Heavy Chain Sequence (Heavy Chain Variable Region and IgG1 Constant Region) of 12A07 (SEQ ID NO: 121)

  1 mgwsciivll vstatcvhsq vqllqpgael vrpgtsvkls cktsgytfss ywmhwvkqrp  61 gqglewigmi dpsdvytnyn pkfkgkatlt vdtssstaym qlssltseds avyycarnys 121 gdywgqgttl tvssakttpp svyplapgsa aqtnsmvtlg clvkgyfpep vtvtwnsgsl 181 ssgvhtfpav lqsdlytlss svtvpsstwp sqtvtcnvah passtkvdkk ivprdcgckp 241 cictvpevss vfifppkpkd vltitltpkv tcvvvdiskd dpevqfswfv ddvevhtaqt 301 qpreeqfnst frsvselpim hqdwlngkef kcrvnsaafp apiektiskt kgrpkapqvy 361 tipppkeqma kdkvsltcmi tdffpeditv ewqwngqpae nykntqpimd tdgsyfvysk 421 lnvqksnwea gntftcsvlh eglhnhhtek slshspgk

Nucleic Acid Sequence Encoding the Full Length Light Chain Sequence (Kappa Chain Variable Region and Constant Region) of 12A07 (SEQ ID NO: 122)

  1 atgaagttgc ctgttaggct gttggtgctg atgttctgga ttcctgcttc cagcagtgat  61 gttttgatga cccaaattcc actctccctg cctgtcagtc ttggagatca agcctccatc 121 tcttgtagat ctagtcagag cattgtccat agtaatggaa acacctattt agaatggtac 181 ctgcagaaac caggccagtc tccaaagctc ctgatctaca aagtttccaa ccgattttct 241 ggggtcccag acaggttcag tggcagtgga tcagggacag atttcacact caagatcagc 301 agagtggagg ctgaggatct gggagtttat tactgctttc aaggttcata tgttccgtgg 361 acgttcggtg gaggcaccaa gctggaaatc aaacgggctg atgctgcacc aactgtatcc 421 atcttcccac catccagtga gcagttaaca tctggaggtg cctcagtcgt gtgcttcttg 481 aacaacttct accccagaga catcaatgtc aagtggaaga ttgatggcag tgaacgacaa 541 aatggtgtcc tgaacagttg gactgatcag gacagcaaag acagcaccta cagcatgagc 601 agcaccctca cattgaccaa ggacgagtat gaacgacata acagctatac ctgtgaggcc 661 actcacaaga catcaacttc acccattgtc aagagcttca acaggaatga gtgt

Protein Sequence Defining the Full Length Light Chain Sequence (Kappa Chain Variable Region and Constant Region) of 12A07 (SEQ ID NO: 123)

  1 mklpvrllvl mfwipasssd vlmtqiplsl pvslgdqasi scrssqsivh sngntylewy  61 lqkpgqspkl liykvsnrfs gvpdrfsgsg sgtdftlkis rveaedlgvy ycfqgsyvpw 121 tfgggtklei kradaaptvs ifppsseqlt sggasvvcfl nnfyprdinv kwkidgserq 181 ngvlnswtdq dskdstysms stltltkdey erhnsytcea thktstspiv ksfnrnec

Nucleic Acid Sequence Encoding the Full Length Heavy Chain Sequence (Heavy Chain Variable Region and IgG1 Constant Region) of 18H02 (SEQ ID NO: 124)

   1 atgggttggc tgtggaactt gctattcctg atggcagctg cccaaagtgc ccaagcacag   61 atccagttgg tacagtctgg acctgaactg aagaagcctg gagaggcagt caagatctcc  121 tgcaagtctt ctgggtatac cttcacaacc tatggaatga gctgggtgaa acaggctcca  181 ggaagggctt taaagtggat gggctggata aacacctact ctggagtgcc aacatatgct  241 gatgacttca agggacggtt tgccttctct ttggaatcct ctgccagcac tgcctatttg  301 cagatcaaca acctcaaaaa tgaggacacg gctacatatt tctgtgcaag agggagggat  361 ggttaccaag tggcctggtt tgcttactgg ggccaaggga cgctggtcac tgtctctgca  421 gccaaaacga cacccccatc tgtctatcca ctggcccctg gatctgctgc ccaaactaac  481 tccatggtga ccctgggatg cctggtcaag ggctatttcc ctgagccagt gacagtgacc  541 tggaactctg gatccctgtc cagcggtgtg cacaccttcc cagctgtcct gcagtctgac  601 ctctacactc tgagcagctc agtgactgtc ccctccagca cctggcccag ccagaccgtc  661 acctgcaacg ttgcccaccc ggccagcagc accaaggtgg acaagaaaat tgtgcccagg  721 gattgtggtt gtaagccttg catatgtaca gtcccagaag tatcatctgt cttcatcttc  781 cccccaaagc ccaaggatgt gctcaccatt actctgactc ctaaggtcac gtgtgttgtg  841 gtagacatca gcaaggatga tcccgaggtc cagttcagct ggtttgtaga tgatgtggag  901 gtgcacacag ctcagacgca accccgggag gagcagttca acagcacttt ccgctcagtc  961 agtgaacttc ccatcatgca ccaggactgg ctcaatggca aggagttcaa atgcagggtc 1021 aacagtgcag ctttccctgc ccccatcgag aaaaccatct ccaaaaccaa aggcagaccg 1081 aaggctccac aggtgtacac cattccacct cccaaggagc agatggccaa ggataaagtc 1141 agtctgacct gcatgataac agacttcttc cctgaagaca ttactgtgga gtggcagtgg 1201 aatgggcagc cagcggagaa ctacaagaac actcagccca tcatggacac agatggctct 1261 tacttcgtct acagcaagct caatgtgcag aagagcaact gggaggcagg aaatactttc 1321 acctgctctg tgttacatga gggcctgcac aaccaccata ctgagaagag cctctcccac 1381 tctcctggta aatga

Protein Sequence Defining the Full Length Heavy Chain Sequence (Heavy Chain Variable Region and IgG1 Constant Region) of 18H02 (SEQ ID NO: 125)

  1 mgwlwnllfl maaaqsaqaq iqlvqsgpel kkpgeavkis ckssgytftt ygmswvkqap  61 gralkwmgwi ntysgvptya ddfkgrfafs lessastayl qinnlknedt atyfcargrd 121 gyqvawfayw gqgtivtvsa akttppsvyp lapgsaaqtn smvtlgclvk gyfpepvtvt 181 wnsgslssgv htfpavlqsd lytlsssvtv psstwpsqtv tcnvahpass tkvdkkivpr 241 dcgckpcict vpevssvfif ppkpkdvlti tltpkvtcvv vdiskddpev qfswfvddve 301 vhtaqtqpre eqfnstfrsv selpimhqdw lngkefkcrv nsaafpapie ktisktkgrp 361 kapqvytipp pkeqmakdkv sltcmitdff peditvewqw ngqpaenykn tqpimdtdgs 421 yfvysklnvq ksnweagntf tcsvlheglh nhhtekslsh spgk

Nucleic Acid Sequence Encoding the Full Length Light Chain Sequence (Kappa Chain Variable Region and Constant Region) of 18H02 (SEQ ID NO: 126)

  1 atgttctcac tagctcttct cctcagtctt cttctcctct gtgtctctga ttctagggca  61 gaaacaactg tgacccagtc tccagcatcc ctgtccatgg ctataggaga taaagtcacc 121 atcagatgca taaccagcac tgatattgat gatgatatga actggttcca gcagaagcca 181 ggggaacctc ctaagctcct tatttcagaa ggcaatactc ttcgtcctgg agtcccatcc 241 cgattctccg gcagtggcta tggtacagat tttattttta caattgaaaa catgctctct 301 gaagatgttg cagattacta ctgtttgcaa agtgataact tgccgtacac gttcggaggg 361 gggaccaagc tggaaataaa acgggctgat gctgcaccaa ctgtatccat cttcccacca 421 tccagtgagc agttaacatc tggaggtgcc tcagtcgtgt gcttcttgaa caacttctac 481 cccagagaca tcaatgtcaa gtggaagatt gatggcagtg aacgacaaaa tggtgtcctg 541 aacagttgga ctgatcagga cagcaaagac agcacctaca gcatgagcag caccctcaca 601 ttgaccaagg acgagtatga acgacataac agctatacct gtgaggccac tcacaagaca 661 tcaacttcac ccattgtcaa gagcttcaac aggaatgagt gttag

Protein Sequence Defining the Full Length Light Chain Sequence (Kappa Chain Variable Region and Constant Region) of 18H02 (SEQ ID NO: 127)

  1 mfslalllsl lllcvsdsra ettvtqspas lsmaigdkvt ircitstdid ddmnwfqqkp  61 geppkllise gntlrpgvps rfsgsgygtd fiftienmls edvadyyclq sdnlpytfgg 121 gtkleikrad aaptvsifpp sseqltsgga svvcflnnfy prdinvkwki dgserqngvl 181 nswtdqdskd stysmsstlt ltkdeyerhn sytceathkt stspivksfn rnec

Nucleic Acid Sequence Encoding the Full Length Heavy Chain Sequence (Heavy Chain Variable Region and IgG1 Constant Region) of 22A02 (SEQ ID NO: 128)

   1 atgggatgga gctgtatcat tgtcctcttg gtatcaacag ctacaggtgt ccactcccag   61 gtccaactgc agcagcctgg ggctgagctg gtgaggcctg ggacttcagt gaagttgtcc  121 tgcaaggctt ctggctacac cttcaccaac tactggatgc actgggtaaa gcagaggcct  181 ggacaaggcc ttgagtggat cggaatgatt gatccttctg atagttatac taactacaat  241 ccaaagttca agggtaaggc cacattgact gtagacacat cctccagcac agcctacatg  301 cagctcagca gcctgacatc tgaggactct gcggtctatt actgtgcaag aaactactct  361 ggggactact ggggccaagg caccactctc acagtctcct cagccaaaac gacaccccca  421 tctgtctatc cactggcccc tggatctgct gcccaaacta actccatggt gaccctggga  481 tgcctggtca agggctattt ccctgagcca gtgacagtga cctggaactc tggatccctg  541 tccagcggtg tgcacacctt cccagctgtc ctgcagtctg acctctacac tctgagcagc  601 tcagtgactg tcccctccag cacctggccc agccagaccg tcacctgcaa cgttgcccac  661 ccggccagca gcaccaaggt ggacaagaaa attgtgccca gggattgtgg ttgtaagcct  721 tgcatatgta cagtcccaga agtatcatct gtcttcatct tccccccaaa gcccaaggat  781 gtgctcacca ttactctgac tcctaaggtc acgtgtgttg tggtagacat cagcaaggat  841 gatcccgagg tccagttcag ctggtttgta gatgatgtgg aggtgcacac agctcagacg  901 caaccccggg aggagcagtt caacagcact ttccgctcag tcagtgaact tcccatcatg  961 caccaggact ggctcaatgg caaggagttc aaatgcaggg tcaacagtgc agctttccct 1021 gcccccatcg agaaaaccat ctccaaaacc aaaggcagac cgaaggctcc acaggtgtac 1081 accattccac ctcccaagga gcagatggcc aaggataaag tcagtctgac ctgcatgata 1141 acagacttct tccctgaaga cattactgtg gagtggcagt ggaatgggca gccagcggag 1201 aactacaaga acactcagcc catcatggac acagatggct cttacttcgt ctacagcaag 1261 ctcaatgtgc agaagagcaa ctgggaggca ggaaatactt tcacctgctc tgtgttacat 1321 gagggcctgc acaaccacca tactgagaag agcctctccc actctcctgg taaa

Protein Sequence Defining the Full Length Heavy Chain Sequence (Heavy Chain Variable Region and IgG1 Constant Region) of 22A02 (SEQ ID NO: 129)

  1 mgwsciivll vstatgvhsq vqlqqpgael vrpgtsvkls ckasgytftn ywmhwvkqrp  61 gqglewigmi dpsdsytnyn pkfkgkatlt vdtssstaym qlssltseds avyycarnys 121 gdywgqgttl tvssakttpp svyplapgsa aqtnsmvtlg clvkgyfpep vtvtwnsgsl 181 ssgvhtfpav lqsdlytlss svtvpsstwp sqtvtcnvah passtkvdkk ivprdcgckp 241 cictvpevss vfifppkpkd vltitltpkv tcvvvdiskd dpevqfswfv ddvevhtaqt 301 qpreeqfnst frsvselpim hqdwlngkef kcrvnsaafp apiektiskt kgrpkapqvy 361 tipppkeqma kdkvsltcmi tdffpeditv ewqwngqpae nykntqpimd tdgsyfvysk 421 lnvqksnwea gntftcsvlh eglhnhhtek slshspgk

Nucleic Acid Sequence Encoding the Full Length Light Chain Sequence (Kappa Chain Variable Region and Constant Region) of 22A02 (SEQ ID NO: 130)

  1 atgaagttgc ctgttaggct gttggtgctg atgttctgga ttcctgcttc cagcagtgat  61 gttttgatga cccaaactcc actctccctg cctgtcagtc ttggagatca agcctccatc 121 tcttgcagat ctagtcagag cattgtacat agtaatggaa acacctattt agaatggtac 181 ctgcagaaac caggccagtc tccaaagctc ctgatctaca aagtttccaa ccgattttct 241 ggggtcccag acaggttcag tggcagtgga tcagggacag atttcacact caagatcagc 301 agagtggagg ctgaggatct gggagtttat tattgctttc aaggttcata tgttccgtgg 361 acgttcggtg gaggcaccaa gctggaaatc aaacgggctg atgctgcacc aactgtatcc 421 atcttcccac catccagtga gcagttaaca tctggaggtg cctcagtcgt gtgcttcttg 481 aacaacttct accccagaga catcaatgtc aagtggaaga ttgatggcag tgaacgacaa 541 aatggtgtcc tgaacagttg gactgatcag gacagcaaag acagcaccta cagcatgagc 601 agcaccctca cattgaccaa ggacgagtat gaacgacata acagctatac ctgtgaggcc 661 actcacaaga catcaacttc acccattgtc aagagcttca acaggaatga gtgt

Protein Sequence Defining the Full Length Light Chain Sequence (Kappa Chain Variable Region and Constant Region) of 22A02 (SEQ ID NO: 131)

  1 mklpvrllvl mfwipasssd vlmtqtplsl pvslgdqasi scrssqsivh sngntylewy  61 lqkpgqspkl liykvsnrfs gvpdrfsgsg sgtdftlkis rveaedlgvy ycfqgsyvpw 121 tfgggtklei kradaaptvs ifppsseqlt sggasvvcfl nnfyprdinv kwkidgserq 181 ngvlnswtdq dskdstysms stltltkdey erhnsytcea thktstspiv ksfnrnec

Nucleic Acid Sequence Encoding the Full Length Heavy Chain Sequence (Heavy Chain Variable Region and IgG1 Constant Region) of 24C05 (SEQ ID NO: 132)

   1 atgaacttcg ggctcagctt gatgttcctt gtccttgtct taaaaggtgt ccagtgtgag   61 gtgcagctgg tggaatctgg gggaggctta gtgaagcctg gagggtccct gaaactctcc  121 tgtgcagcct ctggattcac tttcagtgac tatgccatgt cttgggttcg ccagactccg  181 gaaaagaggc tggagtgggt cgcaaccatt agtgatggtg gtacttacac ctactatcca  241 gacaatgtaa agggccgatt caccatctcc agagacaatg ccaagaacaa cctgtacctg  301 caaatgagcc atctgaagtc tgaggacaca gccatgtatt actgtgcaag agaatggggt  361 gattacgacg gatttgacta ctggggccaa ggcaccactc tcacagtctc ctcggccaaa  421 acgacacccc catctgtcta tccactggcc cctggatctg ctgcccaaac taactccatg  481 gtgaccctgg gatgcctggt caagggctat ttccctgagc cagtgacagt gacctggaac  541 tctggatccc tgtccagcgg tgtgcacacc ttcccagctg tcctgcagtc tgacctctac  601 actctgagca gctcagtgac tgtcccctcc agcacctggc ccagccagac cgtcacctgc  661 aacgttgccc acccggccag cagcaccaag gtggacaaga aaattgtgcc cagggattgt  721 ggttgtaagc cttgcatatg tacagtccca gaagtatcat ctgtcttcat cttcccccca  781 aagcccaagg atgtgctcac cattactctg actcctaagg tcacgtgtgt tgtggtagac  841 atcagcaagg atgatcccga ggtccagttc agctggtttg tagatgatgt ggaggtgcac  901 acagctcaga cgcaaccccg ggaggagcag ttcaacagca ctttccgctc agtcagtgaa  961 cttcccatca tgcaccagga ctggctcaat ggcaaggagt tcaaatgcag ggtcaacagt 1021 gcagctttcc ctgcccccat cgagaaaacc atctccaaaa ccaaaggcag accgaaggct 1081 ccacaggtgt acaccattcc acctcccaag gagcagatgg ccaaggataa agtcagtctg 1141 acctgcatga taacagactt cttccctgaa gacattactg tggagtggca gtggaatggg 1201 cagccagcgg agaactacaa gaacactcag cccatcatgg acacagatgg ctcttacttc 1261 gtctacagca agctcaatgt gcagaagagc aactgggagg caggaaatac tttcacctgc 1321 tctgtgttac atgagggcct gcacaaccac catactgaga agagcctctc ccactctcct 1381 ggtaaa

Protein Sequence Defining the Full Length Heavy Chain Sequence (Heavy Chain Variable Region and IgG1 Constant Region) of 24C05 (SEQ ID NO: 133)

  1 mnfglslmfl vlvlkgvqce vqlvesgggl vkpggslkls caasgftfsd yamswvrqtp  61 ekrlewvati sdggtytyyp dnvkgrftis rdnaknnlyl qmshlksedt amyycarewg 121 dydgfdywgq gttltvssak ttppsvypla pgsaaqtnsm vtlgclvkgy fpepvtvtwn 181 sgslssgvht fpavlqsdly tlsssvtvps stwpsqtvtc nvahpasstk vdkkivprdc 241 gckpcictvp evssvfifpp kpkdvltitl tpkvtcvvvd iskddpevqf swfvddvevh 301 taqtqpreeq fnstfrsvse lpimhqdwln gkefkcrvns aafpapiekt isktkgrpka 361 pqvytipppk eqmakdkvsl tcmitdffpe ditvewqwng qpaenykntq pimdtdgsyf 421 vysklnvqks nweagntftc svlheglhnh htekslshsp gk

Nucleic Acid Sequence Encoding the Full Length Light Chain Sequence (Kappa Chain Variable Region and Constant Region) of 24C05 (SEQ ID NO: 134)

  1 atggacatga gggttcctgc tcacgttttt ggcttcttgt tgctctggtt tccaggtacc  61 agatgtgaca tccagatgac ccagtctcca tcctccttat ctgcctctct gggagaaaga 121 gtcagtctca cttgtcgggc aagtcaggaa attagtggtt acttaagctg gcttcagcag 181 aaaccagatg gaactattaa acgcctgatc tacgccgcat ccactttaga ttctggtgtc 241 ccaaaaaggt tcagtggcag taggtctggg tcagattatt ctctcaccat cggcagcctt 301 gagtctgaag atcttgcaga ctattactgt ctacaatatg atagttatcc gtacacgttc 361 ggagggggga ccaagctgga aataaaacgg gctgatgctg caccaactgt atccatcttc 421 ccaccatcca gtgagcagtt aacatctgga ggtgcctcag tcgtgtgctt cttgaacaac 481 ttctacccca gagacatcaa tgtcaagtgg aagattgatg gcagtgaacg acaaaatggt 541 gtcctgaaca gttggactga tcaggacagc aaagacagca cctacagcat gagcagcacc 601 ctcacattga ccaaggacga gtatgaacga cataacagct atacctgtga ggccactcac 661 aagacatcaa cttcacccat tgtcaagagc ttcaacagga atgagtgt

Protein Sequence Defining the Full Length Light Chain Sequence (Kappa Chain Variable Region and Constant Region) of 24C05 (SEQ ID NO: 135)

  1 mdmrvpahvf gflllwfpgt rcdiqmtqsp sslsaslger vsltcrasqe isgylswlqq  61 kpdgtikrli yaastldsgv pkrfsgsrsg sdysltigsl esedladyyc lqydsypytf 121 gggtkleikr adaaptvsif ppsseqltsg gasvvcflnn fyprdinvkw kidgserqng 181 vlnswtdqds kdstysmsst ltltkdeyer hnsytceath ktstspivks fnrnec

For convenience, Table 4 provides a concordance chart showing the correspondence between the full length sequences of the antibodies discussed in this Example with those presented in the Sequence Listing.

TABLE 4 SEQ ID NO. Nucleic Acid or Protein 108 04D01 Heavy Variable + IgG1 Constant-nucleic acid 109 04D01 Heavy Variable + IgG1 Constant-protein 110 04D01 Kappa Variable + Constant-nucleic acid 111 04D01 Kappa Variable + Constant-protein 112 09D03 Heavy Variable + IgG2b Constant-nucleic acid 113 09D03 Heavy Variable + IgG2b Constant-protein 114 09D03 Kappa Variable + Constant-nucleic acid 115 09D03 Kappa Variable + Constant-protein 116 11G01 Heavy Variable + IgG1 Constant-nucleic acid 117 11G01 Heavy Variable + IgG1 Constant-protein 118 11G01 Kappa Variable + Constant-nucleic acid 119 11G01 Kappa Variable + Constant-protein 120 12A07 Heavy Variable + IgG1 Constant-nucleic acid 121 12A07 Heavy Variable + IgG1 Constant-protein 122 12A07 Kappa Variable + Constant-nucleic acid 123 12A07 Kappa Variable + Constant-protein 124 18H02 Heavy Variable + IgG1 Constant-nucleic acid 125 18H02 Heavy Variable + IgG1 Constant-protein 126 18H02 Kappa Variable + Constant-nucleic acid 127 18H02 Kappa Variable + Constant-protein 128 22A02 Heavy Variable + IgG1 Constant-nucleic acid 129 22A02 Heavy Variable + IgG1 Constant-protein 130 22A02 Kappa Variable + Constant-nucleic acid 131 22A02 Kappa Variable + Constant-protein 132 24C05 Heavy Variable + IgG1 Constant-nucleic acid 133 24C05 Heavy Variable + IgG1 Constant-protein 134 24C05 Kappa Variable + Constant-nucleic acid 135 24C05 Kappa Variable + Constant-protein

Example 3—Binding Affinities

The binding affinities and kinetics of the binding of monoclonal antibodies 04D01, 09D03, 11G01, 12A07, 18H02, 22A02 and 24C05 to recombinant human ErbB3/Fc fusion protein (rhErbB3-Fc) were measured by surface plasmon resonance using a Biacore® T100 (Biacore) instrument.

Rabbit anti-mouse IgGs (Biacore, Cat. No. BR-1008-38) were immobilized on carboxymethylated dextran CM4 sensor chips (Biacore, Cat. No. BR-1005-34) by amine coupling (BIAcore, Cat. No. BR-1000-50) using a standard coupling protocol according to vendor's instructions. The analyses were performed at 25° C., using PBS (Invitrogen, Cat. No. 14040-133) containing 0.05% surfactant P20 (Biacore, Cat. No. BR-1000-54) as running buffer.

The antibodies were captured in individual flow cells at a flow rate of 10 μl/minute. Injection time was varied for each antibody to yield an R_(max) between 30 and 60 RU. Buffer or rhErbB3-Fc diluted in running buffer was injected sequentially over a reference surface (no antibody captured) and the active surface (antibody to be tested) for 300 seconds at 60 μl/minute. The dissociation phase was monitored for up to 3600 seconds. The surface was then regenerated with two 60-seconds injection of 10 mM Glycine-HCl, pH 1.7 (made from Glycine pH 1.5 (Biacore, Cat. No. BR-1003-54) and pH 2.0 (Biacore, Cat. No. BR-1003-55)) at a flow rate of 60 μl/minute. The rhErbB3-Fc concentration range tested was 0.125 nM to 20 nM.

Kinetic parameters were determined using the kinetic function of the BIAevaluation software (Biacore) with double reference subtraction. Kinetic parameters for each antibody, k_(a) (association rate constant), k_(d) (dissociation rate constant) and K_(D) (equilibrium dissociation constant) were determined. Kinetic values of the monoclonal antibodies on rhErbB3-Fc at 25° C. are summarized in Table 5.

TABLE 5 Standard Standard Standard Antibody k_(a) (1/Ms) Deviation k_(d) (1/s) Deviation K_(D) (M) Deviation n 04D01 3.8E+05 3.0E+04 9.3E−05 1.9E−05 2.5E−10 5.6E−11 5 09D03 2.7E+05 3.2E+04 2.0E−05 1.2E−05 8.0E−11 5.5E−11 3 11G01 2.7E+05 9.2E+04 2.2E−05 9.6E−06 9.1E−11 5.5E−11 4 12A07 6.2E+05 8.1E+04 1.9E−04 1 0E−04 3 0E−10 1 4E−10 3 18H02 2.8E+05 3.1E+04 2.5E−05 8.8E−06 9.1E−11 3.7E−11 4 22A02 7.0E+05 8.1E+04 2.2E−04 1.4E−04 3.2E−10 2.4E−10 3 24C05 1.5E+06 2.0E+05 9.2E−06 3.0E−06 6.5E−12 2.8E−12 4

The data in Table 5 demonstrate that the antibodies bind rhErbB3 with a K_(D) of about 350 pM or less, 250 pM or less, 200 pM or less, 150 pM or less, 100 pM or less, 50 pM or less, or 10 pM or less.

Example 4—Neutralization Activity

In this example, the antibodies produced in Example 1 were tested for ability to inhibit rhErbB3 binding to NRG1-β1 and NRG1-α1. The antibodies were tested by electrochemiluminescence (ECL) assay for inhibition of hErbB3 binding to NRG1-β1. MA2400 96-well standard binding plates (Meso Scale Discovery, Cat. No. L15XA-6) were coated with 50 μl of 0.5 μg/mL rhErbB3/Fc (R&D systems, Cat. No. 348-RB) in PBS (Invitrogen, Cat. No. 14040-133) for overnight at 4° C. with no agitation. The plates then were washed 3 times with PBS+0.1% Tween20 (Sigma P5927) and blocked with 200 μl of PBS containing 5% BSA (Sera Care Life Sciences, Cat. No. AP-4510-80) for 1.5 hour at room temperature. After washing the plates 3 times with PBS, 25 μl of the antibody dilutions were added to the plates for another hour at room temperature with agitation. Ligand NRG1-β1 (R&D Systems, Cat. No. 377-HB, 26 kDa) was added to the wells at the final concentration of 0.25 μg/ml. The plates were washed three times with PBS and incubated with 25 μl of 1 μg/mL biotinylated antibody against human NRG1-131(R&D systems, Cat. No BAF377) preincubated for one hour with SULTO-TAG Streptavidin (Meso Scale Discovery, Cat. No R32AD-5) for one hour at room temperature with agitation. The plates then were washed 3 times with PBS, and 150 μl of 1× read buffer (Meso Scale Discovery, Cat. No. R92TC-1) was added to each well before the plates were analyzed on a Sector® Imager 2400 (Meso Scale Discovery) instrument.

The interaction of NRG1-β1 with ErbB3 was inhibited by antibodies 04D01, 12A07, 18H02, 22A02 and 24C05 (FIG. 6A). The interaction of NRG1-β1 with rhErbB3 was enhanced by antibody 09D03, but not as well as by antibody 11G01 (FIG. 6B).

The murine anti-human ErbB3 antibody IC₅₀ values for neutralization of NRG1-β1 binding to rhErbB3 for the antibodies (i.e., 04D01, 12A07, 18H02, 22A02 and 24C05) were calculated and are summarized in Table 6.

TABLE 6 IC₅₀ (nM) Standard Antibody Average Deviation n 04D01 0.2232 0.0711 4 12A07 0.2351 0.0530 4 18H02 0.3460 0.0873 4 22A02 0.2418 0.0755 4 24C05 0.3367 0.0764 4

The results show that antibodies 04D01, 12A07, 18H02, 22A02, and 24C05 efficiently neutralized NRG1-β1 binding to rhErbB3. Antibodies 09D03 and 11G01 enhanced hNRG1-β1 binding to hErbB3.

The antibodies were tested by ECL assay for inhibition of hErbB3 binding to the second ErbB3 ligand, NRG1-α1. To assay inhibition of binding of NRG1-α1 to rhErbB3, the same method used for NRG1-β1 was used, except for the following changes: concentrations of plated rhErbB3/Fc (R&D 4518-RB) and of ligand NRG1-α1 (Thermo Scientific, RP-317-P1AX) were 1 μg/ml and 1.5 μg/ml, respectively.

The interaction of NRG1-α1 with rhErbB3 was inhibited by 11G01, 12A07, 18H02, 22A02, and 24C05 IgG1, and was enhanced by antibody 09D03 (FIG. 7).

Example 5—Binding to ErbB3 Domain II

In this example, the antibodies produced in Example 1 were tested for binding to the dimerization domain (domain 2) of hErbB3-ECD. Domain 2 of hErbB3 (118 amino acids, position 210-327) was cloned in place of domain 2 of Her2 (119 amino acids, position AA220-338) into the full-length Her2 receptor. The hybrid construct Her2/3d2 was cloned into pLenti6.3 and packaged by transient transfection of 293T cells into a Lentivirus using the ViraPower™ Lentiviral Support Kit (Invitrogen, Cat. No. K497000). CHO cells were infected with the lentivirus expressing the Her2/3d2 hybrid protein. The binding of the anti-ErbB3 hybridoma supernatants to Her2/3d2 were tested on these engineered CHO cells by ECL with sulfo-tagged anti-mouse antibodies. Data on the binding of the hybridoma supernatants to the chimeric protein Her2/3d2 expressed on the cell surface of CHO cells are summarized in FIG. 8. These results show that antibodies 09D03 and 11G01 bound to the ErbB3 domain II, AA210-327.

Example 6—Anti-Proliferative Activity

This example describes a characterization of the antibodies produced in Example 1 for their ability to inhibit NRG1-β1 dependent proliferation of cells. Antibodies were tested in the BaF/3 cell system engineered to express both human Her2 and ErbB3 and in the human MCF7 breast cancer cells which naturally express both Her2 and ErbB3 and grow in response to NRG1-β1 stimulation.

BaF/3 cells were infected by two lentiviruses engineered to express human Her2 or human ErbB3. Infected cells were selected with blasticidin (15 μg/ml; Invitrogen, Cat. No. R21001) and individual colonies were isolated and tested for expression of both receptors. Her2/ErbB3 expressing clones were maintained in culture under blasticidin selection with [80% RPMI Medium 1640 (GIBCO, Cat. No. 11875-093), 10% fetal bovine serum (GIBCO, Cat. No. 10438-026) and 10% WEHI cell conditioned media {90% ISCOVE's Modified Dulbecco's Medium (GIBCO, Cat. No. 12440053), 10% fetal bovine serum (GIBCO, Cat. No. 10438-026)+2 mM L-glutamine (GIBCO, Cat. No. 25030-081)+0.0025 mM mercaptoethanol (Invitrogen, Cat. No. 21985-023)}]. To screen for antagonistic ErbB3 antibodies, cells were rinsed with PBS, and grown in the absence of blasticidin and WEHI conditioned media. Assays were conducted in a 96-well plate (5,000 cells/well) in the presence of NRG1-131 (100 ng/ml) and various concentrations of antibodies (0.018-5000 ng/ml in 100 μl final volume). MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assays were conducted 3-4 days post NRG1-β1 stimulation.

An example of the dose-dependent inhibition of NRG1-β1 dependent cell proliferation of Her2/ErbB3-BaF/3 by murine anti-human ErbB3 antibodies is shown in FIG. 9. Inhibition data of NRG1-β1 dependent Her2/ErbB3-BaF/3 cell line proliferation with monoclonal antibodies (i.e., 04D01, 09D03, 11G01, 12A07, 18H02, 22A02 and 24C05) are summarized in Table 7.

TABLE 7 Her2/ErbB3-BaF/3, NRG1-β1 dep. Proliferation Antibody IC₅₀ (nM)-Average Standard deviation n 04D01 0.373 0.061 3 09D03 1.395 0.268 3 11G01 1.934 0.116 3 12A07 0.854 0.059 3 18H02 1.930 0.276 3 22A02 1.291 0.151 3 24C05 0.145 0.031 3

The results in Table 7 show that antibodies 04D01, 09D03, 11G01, 12A07, 18H02, 22A02 and 24C05 strongly inhibited NRG1-β1-induced proliferation of BaF/3 cells expressing Her2/ErbB3.

MCF7 cells (ATCC, Cat. No. HTB-22) were maintained as recommended by ATCC. Cells were plated at 5,000 cells/well in a 96-well plate. Cells were starved overnight in the absence of serum. The following day, NRG1-β1 (40 ng/ml) and various concentrations of antibodies (12.8 pg/ml-20 μg/ml in 100 μl final volume) were added to the cells. MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assays were conducted three days post NRG1-β1 stimulation.

An example of the dose-dependent inhibition of NRG1-β1 dependent proliferation of MCF7 cells by murine anti-human ErbB3 antibodies is shown in FIG. 10. Inhibition data of NRG1-β1 dependent MCF7 cell proliferation with antibodies 04D01, 09D03, 11G01, 12A07, 18H02, 22A02 and 24C05 are summarized in Table 8.

TABLE 8 MCF7 cells, NRG1-β1 dependent Proliferation Antibody IC₅₀ (nM)-Average Standard deviation n 04D01 0.47 0.23 3 09D03 2.28 0.60 3 11G01 1.98 1.34 3 12A07 0.74 0.48 3 18H02 1.00 0.20 3 22A02 1.62 0.60 3 24C05 0.39 0.04 3

The results in Table 8 demonstrate that antibodies 04D01, 09D03, 11G01, 12A07, 18H02, 22A02, and 24C05 strongly inhibited NRG1-β1-induced proliferation of MCF7 cells.

The antibodies produced in Example 1 were also tested for their ability to inhibit proliferation of ErbB3 expressing human cancer cells. Breast cancer cells SKBR-3 overexpress Her2 and are sensitive to Her2-specific inhibitory antibodies.

SKBR-3 cells (ATCC, Cat. No. HTB-30) were maintained as recommended by ATCC. Cells were plated at 5,000 cells/well in a 96-well plate in the presence of 5 μg/ml of antibodies but without exogenous NRG1-131. MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assays were conducted after three days in culture.

An example of inhibition of cell proliferation of SKBR-3 cells by murine anti-human ErbB3 antibodies is shown in FIG. 11. The results in FIG. 11 show that antibodies 04D01, 09D03, 11G01, 12A07, 18H02, 22A02 and 24C05 inhibited proliferation of SKBR-3 cells.

Example 7—Inhibition of Downstream Signaling

This example describes a characterization of the antibodies produced in Example 1 for their ability to inhibit NRG1-β1 dependent phosphorylation of ErbB3 and the downstream kinase Akt, as the readout for PI3K activation. These antibodies were also tested for their ability to inhibit steady state phosphorylation of ErbB3 and Akt in exponentially growing cells.

Breast cancer cells SKBR-3 and MCF7 and prostate cancer cells DU145 were maintained as recommended by ATCC. Cells were starved overnight in 0% FBS, treated for one hour with 5 μg/ml of antibody followed by NRG1-β1 stimulation. Lysates were either analyzed by ELISA with the Phospho-ErbB3 kit from R&D Systems (Cat. No DYC1769) or with the Phospho-Akt ELISA kit from Cell Signaling (Cat. No 7143).

An example of the inhibition of the NRG1-β1 induced phosphorylation of ErbB3 in SKBR-3 cells by murine anti-human ErbB3 antibodies is shown in FIG. 12. The results in FIG. 12 demonstrated that antibodies 04D01, 09D03, 11G01, 12A07, 18H02, 22A02 and 24C05 inhibited at least 50% of the phosphorylation of ErbB3 induced by NRG1-β1 in SKBR-3 cells.

An example of the inhibition of the NRG1-β1 induced phosphorylation of Akt in MCF7 and DU145 cells by murine anti-human ErbB3 antibodies is shown in FIG. 13A and FIG. 13B, respectively. The results in FIGS. 13A and 13B demonstrated that antibodies 04D01, 09D03, 11G01, 12A07, 18H02, 22A02 and 24C05 inhibited at least 80% of the phosphorylation of Akt in response to the NRG1-β1 in both MCF7 and DU145 cells.

The capacity of the anti-ErbB3 antibodies to inhibit the steady state phosphorylation status of ErbB3 and Akt in a breast cancer cell line SKBR-3 and a pancreatic cancer cell line BxPC3 were tested by treating these exponentially growing cells for one hour in presence of antibodies at 5 μg/ml.

Western blot analysis of these experiments demonstrated that antibodies 04D01, 09D03, 11G01, 12A07, 18H02, 22A02 and 24C05 inhibited the steady state level of phosphorylation of Akt and ErbB3 in both SKBR-3 and BxPC3 cells.

Example 8—Inhibition of NRG1-β1-Induced EGFR Phosphorylation

In this example, the antibodies produced in Example 1 were tested for their ability to inhibit NRG1-β1 dependent phosphorylation of EGFR in the ovarian cancer cell line NCI/ADR-RES. NCI/ADR-RES cells (DTP/DCTD NCI tumor repository) were starved overnight in 0% FBS, pre-treated with antibody (5 μg/ml) for one hour followed by NRG1-β1 (20 ng/ml) stimulation for 15 minutes. The phosphorylation of EGFR on tyrosine 1068 was analyzed by Western blot. The results of this experiment demonstrated that antibodies 04D01, 09D03, 11G01, 12A07, 18H02, 22A02 and 24C05 inhibited the phosphorylation of EGFR in response to the NRG1-β1 in NCI/ADR-RES cells.

Example 9—Inhibition of EGF-induced Erbb3 Phosphorylation

In this example, the antibodies produced in Example 1 were tested for their ability to inhibit EGF dependent phosphorylation of ErbB3 in the EGFR overexpressing, epidermoid cancer cell line A431. A431 cells (ATCC, Cat. No CRL-1555) were starved overnight in 0% FBS, pre-treated with antibody (5 μg/ml) for one hour followed by EGF (R&D Systems, Cat. No. 236-EG) (50 ng/ml) stimulation for 15 minutes. The phosphorylation of ErbB3 was analyzed by Western blot. The results of this experiment demonstrated that antibodies 04D01, 09D03, 12A07, 18H02, 22A02 and 24C05 inhibited to various extents the phosphorylation of ErbB3 in response to the EGF in A431 cells.

Example 10—Inhibition of NRG1-β1-Induced Her2/ErbB3 Heterodimer Formation

This example describes a characterization of the antibodies produced in Example 1 for their ability to inhibit the formation of the Her2/ErbB3 dimer in response to NRG1-β1 in SKBR-3 cells. Breast cancer cells SKBR-3 were starved overnight in 0% FBS, treated for one hour with 5 μg/ml of antibody followed by NRG1-β1 stimulation (30 ng/ml, 30 min). Lysates were immunoprecipitated with anti-Her2 antibody (R&D Systems, Cat. No. BAF1129) and analyzed by Western blot with polyclonal anti-ErbB3 antibody (Santa Cruz, Cat. No. SC285).

The results of this experiment demonstrated that antibodies 04D01, 09D03, 11G01, 12A07, 18H02, 22A02 and 24C05 inhibited NRG1-β1-induced Her2/ErbB3 dimer formation in SKBR-3 cells.

Example 11—Inhibition of BxPC3 Tumor Xenograft Growth

The ability of murine monoclonal antibodies produced in Example 1 to inhibit tumor growth was tested in a pancreatic BxPC3 xenograft model. Human pancreatic BxPC3 cells were grown in culture in 37° C. in an atmosphere containing 5% CO2, using RMPI medium containing 10% fetal bovine serum. BxPC3 cells were inoculated subcutaneously into the flank of 8-week old female CB.17 SCID mice (Taconic Labs) with 10×10⁶ cells per mouse in 50% matrigel (BD Biosciences, Cat No. 356237). Tumor measurements were taken twice weekly using vernier calipers. Tumor volume was calculated using the formula: width×width×length/2. When tumors reached approximately 200 mm³, the mice were randomized into 9 groups of 10 mice each. One group received PBS and another received human IgG control (huIgG). Each of the other eight groups received one of the antibody, 04D01, 09D03, 18H02, 11G01, 24C05, 22A02, or 12A07. All antibodies were dosed at 20 mg/kg body weight, twice per week, by intra-peritoneal injection for 6 weeks. Tumor volumes and mouse body weights were recorded twice per week. Tumor growth inhibition was analyzed using ANOVA and is expressed as percent inhibition compared to the PBS control.

The results in FIG. 14 show that antibody 24C05 inhibited tumor growth by 76% in this model (p<0.001). Antibodies 04D01, 18H02 and 11G01 also inhibited tumor growth in this model at 64%, 71%, and 72%, respectively (p<0.001). Antibodies 12A07 and 22A02 demonstrated the least activity, i.e., near 40% tumor growth inhibition, while antibody 09D03 gave 60% tumor growth inhibition in this model.

Example 12—Humanization of Anti-ErbB3 Antibodies

A. Construction of Humanized and Chimeric Anti-ErbB3 Antibodies

This Example describes the humanization of the murine antibody designated 24C05, and the characterization of the resulting humanized antibodies. The humanized anti-ErbB3 antibodies were designed using the SUPERHUMANIZATION™ method (Arana Therapeutics Ltd. and Hwang, W. Y. et al. (2005) METHODS 36:35-42) or the CDR grafting method with back mutations (some human framework residues were changed to murine residues) (See e.g., U.S. Pat. Nos. 5,530,101; 5,693,761; 5,693,762; 5,585,089; 6,180,370; 7,022,500). With the exception of heavy chain CDR1, the Kabat CDR definitions were used for CDR grafting onto human frameworks. A combination of Kabat and Chothia definitions were used for grafting heavy CDR1. The designed amino acid sequences were converted to codon-optimized DNA sequences and synthesized by DNA2.0, Inc. to include (in the following order): 5′ HindIII restriction site, Kozak consensus sequence, amino terminal signal sequence, humanized variable region, human IgG1 or Kappa constant region, stop codon, and a 3′ EcoRI restriction site. Additionally, one humanized heavy chain, Sh24C05 Hv3-11 Heavy IgG1, was mutated using overlap extension PCR to enhance humanization, resulting in the Sh24C05 Hv3-11 N62S heavy chain IgG1. A human IgG2 version of the Sh24C05 Hv3-11 N62S heavy chain was also constructed.

The anti-ErbB3 antibody chains humanized according to the SUPERHUMANIZATION™ method, as described herein, are designated with the prefix “Sh” before the antibody chain name. The anti-ErbB3 antibody chains humanized by the CDR grafting method with back mutations, as described herein, are designated with the prefix “Hu” before the antibody chain name.

Chimeric (murine variable region and human constant region) 24C05 heavy (human IgG1) and light (human Kappa) chains were also constructed. The murine variable regions were fused to the human constant region using overlap extension PCR, including (in the following order): 5′ HindIII restriction site, Kozak consensus sequence, amino terminal signal sequence, mouse variable region, human IgG1 or Kappa constant region, stop codon, and 3′ EcoRI restriction site.

The humanized and chimeric heavy chains were subcloned into pEE6.4 (Lonza Biologics) via HindIII and EcoRI sites using In-Fusion™ PCR cloning (Clontech). The humanized and chimeric Kappa light chains were subcloned into pEE14.4 (Lonza Biologics) via HindIII and EcoRI sites using In-Fusion™ PCR cloning.

Humanized antibody chains or chimeric antibody chains were transiently transfected into 293T cells to produce antibody. Antibody was either purified or used in cell culture media supernatant for subsequent in vitro analysis. Binding of the chimeric and humanized antibodies to human ErbB3 was measured as described below. The results are summarized in Table 15.

Additionally, some humanized antibody heavy and light chain combinations were stably expressed in CHOK1SV cells using the GS System™ (Lonza Biologics) in order to produce large quantities of purified humanized antibody. A single expression vector was constructed by combining pEE6.4 and pEE14.4 based vectors. First, pEE6.4 containing full length humanized heavy chain cDNA was digested with NotI and SalI to isolate the hCMV-MIE promoter+full length humanized heavy chain cDNA+SV40 polyA fragment. This fragment was inserted into the pEE14.4 vector already containing full length humanized light chain cDNA via NotI/SalI sites, thus creating an expression vector that simultaneously expresses heavy and light chains. The combined heavy and light chain vector was linearized and transfected into CHOK1SV cells. Stable clones were selected in the presence of methionine sulfoximine.

Each of the possible combinations of the humanized immunoglobulin heavy chain and immunoglobulin light chain variable regions are set forth below in Table 9.

TABLE 9 Light Chain Variable Region Heavy Chain Variable Region Hu24C05 KvA (SEQ ID NO: 174) Hu24C05 HvA (SEQ ID NO: 162) Hu24C05 KvA (SEQ ID NO: 174) Sh24C05 Hv3-21 (SEQ ID NO: 156) Hu24C05 KvA (SEQ ID NO: 174) Sh24C05 Hv3-23 (SEQ ID NO: 158) Hu24C05 KvA (SEQ ID NO: 174) Sh24C05 Hv3-30 (SEQ ID NO: 160) Hu24C05 KvA (SEQ ID NO: 174) Sh24C05 Hv3-7 (SEQ ID NO: 150) Hu24C05 KvA (SEQ ID NO: 174) Sh24C05 Hv3-11 (SEQ ID NO: 152) Hu24C05 KvA (SEQ ID NO: 174) Sh24C05 Hv3-11 N62S (SEQ ID NO: 154) Sh24C05 Kv1-16 (SEQ ID NO: 166) Hu24C05 HvA (SEQ ID NO: 162) Sh24C05 Kv1-16 (SEQ ID NO: 166) Sh24C05 Hv3-21 (SEQ ID NO: 156) Sh24C05 Kv1-16 (SEQ ID NO: 166) Sh24C05 Hv3-23 (SEQ ID NO: 158) Sh24C05 Kv1-16 (SEQ ID NO: 166) Sh24C05 Hv3-30 (SEQ ID NO: 160) Sh24C05 Kv1-16 (SEQ ID NO: 166) Sh24C05 Hv3-7 (SEQ ID NO: 150) Sh24C05 Kv1-16 (SEQ ID NO: 166) Sh24C05 Hv3-11 (SEQ ID NO: 152) Sh24C05 Kv1-16 (SEQ ID NO: 166) Sh24C05 Hv3-11 N62S (SEQ ID NO: 154) Sh24C05 Kv1-17 (SEQ ID NO: 168) Hu24C05 HvA (SEQ ID NO: 162) Sh24C05 Kv1-17 (SEQ ID NO: 168) Sh24C05 Hv3-21 (SEQ ID NO: 156) Sh24C05 Kv1-17 (SEQ ID NO: 168) Sh24C05 Hv3-23 (SEQ ID NO: 158) Sh24C05 Kv1-17 (SEQ ID NO: 168) Sh24C05 Hv3-30 (SEQ ID NO: 160) Sh24C05 Kv1-17 (SEQ ID NO: 168) Sh24C05 Hv3-7 (SEQ ID NO: 150) Sh24C05 Kv1-17 (SEQ ID NO: 168) Sh24C05 Hv3-11 (SEQ ID NO: 152) Sh24C05 Kv1-17 (SEQ ID NO: 168) Sh24C05 Hv3-11 N62S (SEQ ID NO: 154) Sh24C05 Kv1-33 (SEQ ID NO: 170) Hu24C05 HvA (SEQ ID NO: 162) Sh24C05 Kv1-33 (SEQ ID NO: 170) Sh24C05 Hv3-21 (SEQ ID NO: 156) Sh24C05 Kv1-33 (SEQ ID NO: 170) Sh24C05 Hv3-23 (SEQ ID NO: 158) Sh24C05 Kv1-33 (SEQ ID NO: 170) Sh24C05 Hv3-30 (SEQ ID NO: 160) Sh24C05 Kv1-33 (SEQ ID NO: 170) Sh24C05 Hv3-7 (SEQ ID NO: 150) Sh24C05 Kv1-33 (SEQ ID NO: 170) Sh24C05 Hv3-11 (SEQ ID NO: 152) Sh24C05 Kv1-33 (SEQ ID NO: 170) Sh24C05 Hv3-11 N62S (SEQ ID NO: 154) Sh24C05 Kv1-9 (SEQ ID NO: 164) Hu24C05 HvA (SEQ ID NO: 162) Sh24C05 Kv1-9 (SEQ ID NO: 164) Sh24C05 Hv3-21 (SEQ ID NO: 156) Sh24C05 Kv1-9 (SEQ ID NO: 164) Sh24C05 Hv3-23 (SEQ ID NO: 158) Sh24C05 Kv1-9 (SEQ ID NO: 164) Sh24C05 Hv3-30 (SEQ ID NO: 160) Sh24C05 Kv1-9 (SEQ ID NO: 164) Sh24C05 Hv3-7 (SEQ ID NO: 150) Sh24C05 Kv1-9 (SEQ ID NO: 164) Sh24C05 Hv3-11 (SEQ ID NO: 152) Sh24C05 Kv1-9 (SEQ ID NO: 164) Sh24C05 Hv3-11 N625 (SEQ ID NO: 154) Sh24C05 Kv1-39 (SEQ ID NO: 172) Hu24C05 HvA (SEQ ID NO: 162) Sh24C05 Kv1-39 (SEQ ID NO: 172) Sh24C05 Hv3-21 (SEQ ID NO: 156) Sh24C05 Kv1-39 (SEQ ID NO: 172) Sh24C05 Hv3-23 (SEQ ID NO: 158) Sh24C05 Kv1-39 (SEQ ID NO: 172) Sh24C05 Hv3-30 (SEQ ID NO: 160) Sh24C05 Kv1-39 (SEQ ID NO: 172) Sh24C05 Hv3-7 (SEQ ID NO: 150) Sh24C05 Kv1-39 (SEQ ID NO: 172) Sh24C05 Hv3-11 (SEQ ID NO: 152) Sh24C05 Kv1-39 (SEQ ID NO: 172) Sh24C05 Hv3-11 N62S (SEQ ID NO: 154)

The nucleic acid sequences encoding and the protein sequences defining variable regions of the humanized 24C05 antibodies are summarized below (amino terminal signal peptide sequences are not shown). CDR sequences (Kabat definition) are shown in bold and are underlined in the amino acid sequences.

Nucleic Acid Sequence Encoding the Sh24C05 Hv3-7 Heavy Chain Variable Region (SEQ ID NO: 149)

  1 gaggttcagc tggtggaatc tggcggtggg cttgtacaac caggaggctc cctcagactg  61 agttgtgccg cttcagggtt cacattctcc gactatgcga tgtcatgggt gcgccaagca 121 cccgggaaag gactggagtg ggttgccact atcagcgatg gcggaacgta tacctattac 181 cctgacaatg tgaagggtcg gttcaccatt tccagggata acgcaaagaa cagtctctac 241 ctgcagatga acagcctgag ggctgaggac accgccgtct actactgcgc ccgagaatgg 301 ggagattatg atgggtttga ctattggggc cagggcactt tggtgacagt cagttct

Protein Sequence Defining the Sh24C05 Hv3-7 Heavy Chain Variable Region (SEQ ID NO: 150)

 1 evqlvesggg lvqpggslrl scaasgftfs  dyams wvrqa pgkglewva t isdggtytyy 61  pdnvkg rfti srdnaknsly lqmnslraed tavyycar ew gdydgfdy wg qgtlvtvss

Nucleic Acid Sequence Encoding the Sh24C05 Hv3-11 Heavy Chain Variable Region (SEQ ID NO: 151)

  1 caagttcagc tggtggaatc tggcggtggg cttgtaaagc caggaggctc cctcagactg  61 agttgtgccg cttcagggtt cacattctcc gactatgcga tgtcatggat caggcaagca 121 cccgggaaag gactggagtg ggttagcact atcagcgatg gcggaacgta tacctattac 181 cctgacaatg tgaagggtcg gttcaccatt tccagggata acgcaaagaa cagtctctac 241 cttcagatga acagcctgag ggctgaggac accgccgtct actactgcgc ccgagaatgg 301 ggagattatg atgggtttga ctattggggc cagggcactt tggtgacagt cagttct

Protein Sequence Defining the Sh24C05 Hv3-11 Heavy Chain Variable Region (SEQ ID NO: 152)

 1 qvqlvesggg lvkpggslrl scaasgftfs  dyams wirqa pgkglewvs t isdggtytyy 61  pdnvkg rfti srdnaknsly lqmnslraed tavyycar ew gdydgfdy wg qgtlvtvss

Nucleic Acid Sequence Encoding the Sh24C05 Hv3-11 N62S Heavy Chain Variable Region (SEQ ID NO: 153)

  1 caagttcagc tggtggaatc tggcggtggg cttgtaaagc caggaggctc cctcagactg  61 agttgtgccg cttcagggtt cacattctcc gactatgcga tgtcatggat caggcaagca 121 cccgggaaag gactggagtg ggttagcact atcagcgatg gcggaacgta tacctattac 181 cctgactccg tgaagggtcg gttcaccatt tccagggata acgcaaagaa cagtctctac 241 cttcagatga acagcctgag ggctgaggac accgccgtct actactgcgc ccgagaatgg 301 ggagattatg atgggtttga ctattggggc cagggcactt tggtgacagt cagttct

Protein Sequence Defining the Sh24C05 Hv3-11 N62S Heavy Chain Variable Region (SEQ ID NO: 154)

 1 qvqlvesggg lvkpggslrl scaasgftfs  dyams wirqa pgkglewvs t isdggtytyy 61  pdsvkg rfti srdnaknsly lqmnslraed tavyycar ew gdydgfdy wg qgtlvtvss

Nucleic Acid Sequence Encoding the Sh24C05 Hv3-21 Heavy Chain Variable Region (SEQ ID NO: 155)

1 gaggttcagc tggtggaatc tggcggtggg cttgtaaagc caggaggctc cctcagactg 61 agttgtgccg cttcagggtt cacattctcc gactatgcga tgtcatgggt gcgccaagca 121 cccgggaaag gactggagtg ggttagcact atcagcgatg gcggaacgta tacctattac 181 cctgacaatg tgaagggtcg gttcaccatt tccagggata acgcaaagaa cagtctctat 241 ttgcagatga acagcctgag ggctgaggac accgccgtct actactgcgc ccgagaatgg 301 ggagattatg atgggtttga ctattggggc cagggcactt tggtgacagt cagttct

Protein Sequence Defining the Sh24C05 Hv3-21 Heavy Chain Variable Region (SEQ ID NO: 156)

1 evqlvesggg lvkpggslrl scaasgftfs  dyams wvrqa pgkglewvs t isdggtytyy    61 pdnvkg rfti srdnaknsly lqmnslraed tavyycar ew gdydgfdy wg qgtlvtvss

Nucleic Acid Sequence Encoding the Sh24C05 Hv3-23 Heavy Chain Variable Region (SEQ ID NO: 157)

1 gaggttcagc ttctggaatc tggcggtggg cttgtacagc caggaggctc cctcagactg 61 agttgtgccg cttcagggtt cacattctcc gactatgcga tgtcatgggt gcgccaagca 121 cccgggaaag gactggagtg ggtttcaact atcagcgatg gcggaacgta tacctattac 181 cctgacaatg tgaagggtcg gttcaccatt tccagggata acagcaagaa cacactctat 241 ctccagatga acagcctgag ggctgaggac accgccgtct actactgcgc ccgagaatgg 301 ggagattatg atgggtttga ctattggggc cagggcactt tggtgacagt cagttct

Protein Sequence Defining the Sh24C05 Hv3-23 Heavy Chain Variable Region (SEQ ID NO: 158)

1 evqllesggg lvqpggslrl scaasgftfs  dyams wvrqa pgkglewvs t isdggtytyy 61 pdnvkg rfti srdnskntly lqmnslraed tavyycar ew gdydgfdy wg qgtlvtvss

Nucleic Acid Sequence Encoding the Sh24C05 Hv3-30 Heavy Chain Variable Region (SEQ ID NO: 159)

1 caggttcagc tggtggaatc tggcggtggg gtagtacaac caggacggtc cctcagactg 61 agttgtgccg cttcagggtt cacattctcc gactatgcga tgtcatgggt gcgccaagca 121 cccgggaaag gactggagtg ggttgccact atcagcgatg gcggaacgta tacctattac 181 cctgacaatg tgaagggtcg gttcaccatt tccagggata actcaaagaa caccctctat 241 ctccaaatga gtagcctgag ggctgaggac accgccgtct actactgcgc ccgagaatgg 301 ggagattatg atgggtttga ctattggggc cagggcactt tggtgacagt cagttct

Protein Sequence Defining the Sh24C05 Hv3-30 Heavy Chain Variable Region (SEQ ID NO: 160)

1 qvqlvesggg vvqpgrslrl scaasgftfs  dyams wvrqa pgkglewva t isdggtytyy 61 pdnvkg rfti srdnskntly lqmsslraed tavyycar ew gdydgfdy wg qgtlvtvss

Nucleic Acid Sequence Encoding the Hu24C05 HvA Heavy Chain Variable Region (SEQ ID NO: 161)

1 gaggttcagc tggtggaatc tggcggtggg cttgtaaagc caggaggctc cctcagactg 61 agttgtgccg cttcagggtt cacattctcc gactatgcga tgtcatgggt gcgccaagca 121 cccgggaaag gactggagtg ggttgccact atcagcgatg gcggaacgta tacctattac 181 cctgacaatg tgaagggtcg gttcaccatt tccagggata acgcaaagaa cagtctctac 241 cttcagatga acagcctgag ggctgaggac accgccgtct actactgcgc ccgagaatgg 301 ggagattatg atgggtttga ctattggggc cagggcactt tggtgacagt cagttct

Protein Sequence Defining the Hu24C05 HvA Heavy Chain Variable Region (SEQ ID NO: 162)

1 evqlvesggg lvkpggslrl scaasgftfs  dyams wvrqa pgkglewva t isdggtytyy 61 pdnvkg rfti srdnaknsly lqmnslraed tavyycar ew gdydgfdy wg qgtlvtvss

Nucleic Acid Sequence Encoding the Sh24C05 Kv1-9 Kappa Chain Variable Region (SEQ ID NO: 163)

1 gatattcagt tgacccaatc acctagcttc ctctcagctt ccgtgggcga cagagttacc 61 ataacctgtc gggcaagcca ggagatttct gggtacctgt cctggtacca acagaagccc 121 ggaaaagccc ctaagctgtt gatctatgct gcgtcaacct tggatagcgg tgtcccgagt 181 cgattctccg gttctggctc cggaacagag ttcactctga caatttctag ccttcagcca 241 gaagatttcg ccacgtacta ttgcctccag tacgacagct atccctatac atttgggcag 301 ggcactaaac tggagatcaa a

Protein Sequence Defining the Sh24C05 Kv1-9 Kappa Chain Variable Region (SEQ ID NO: 164)

1 diqltqspsf lsasvgdrvt itc rasqeis gyls wyqqkp gkapklliy a astlds gvps 61 rfsgsgsgte ftltisslqp edfatyyc lq ydsypyt fgq gtkleik

Nucleic Acid Sequence Encoding the Sh24C05 Kv1-16 Kappa Chain Variable Region (SEQ ID NO: 165)

1 gatattcaga tgacccaatc acctagcagt ctctcagctt ccgtgggcga cagagttacc 61 ataacctgtc gggcaagcca ggagatttct gggtacctgt cctggtttca acagaagccc 121 ggaaaggccc cgaagagctt gatctatgct gcgtcaacct tggatagcgg tgtcccgagt 181 cgattctccg gttctggctc cggaaccgac tttactctga caatttctag ccttcagcca 241 gaagatttcg ccacgtacta ttgcctccag tacgacagct atccctatac atttgggcag 301 ggcactaaac tggagatcaa a

Protein Sequence Defining the Sh24C05 Kv1-16 Kappa Chain Variable Region (SEQ ID NO: 166)

1 diqmtqspss lsasvgdrvt itc rasqeis gyls wfqqkp gkapksliy a astlds gvps 61 rfsgsgsgtd ftltisslqp edfatyyc lq ydsypyt fgq gtkleik

Nucleic Acid Sequence Encoding the Sh24C05 Kv1-17 Kappa Chain Variable Region (SEQ ID NO: 167)

1 gatattcaga tgacccaatc acctagcagt ctctcagctt ccgtgggcga cagagttacc 61 ataacctgtc gggcaagcca ggagatttct gggtacctgt cctggtatca acagaagccc 121 ggaaaagccc caaagaggtt gatctatgct gcgtcaacct tggatagcgg tgtcccgagt 181 cgattctccg gttctggctc cggaaccgag ttcactctga caatttctag ccttcagcca 241 gaagatttcg ccacgtacta ttgcctccag tacgacagct atccctatac atttgggcag 301 ggcactaaac tggagatcaa a

Protein Sequence Defining the Sh24C05 Kv1-17 Kappa Chain Variable Region (SEQ ID NO: 168)

1 diqmtqspss lsasvgdrvt itc rasqeis gyls wyqqkp gkapkrliy a astlds gvps 61 rfsgsgsgte ftltisslqp edfatyyc lq ydsypyt fgq gtkleik

Nucleic Acid Sequence Encoding the Sh24C05 Kv1-33 Kappa Chain Variable Region (SEQ ID NO: 169)

1 gatattcaga tgacccaatc acctagcagt ctctcagctt ccgtgggcga cagagttacc 61 ataacctgtc gggcaagcca ggagatttct gggtacctgt cctggtacca acagaagccc 121 ggaaaggccc ccaagctgtt gatctatgct gcgtcaacct tggatagcgg tgtcccgagt 181 cgattctccg gttctggctc cggaacagac tttactttta caatttctag ccttcagcca 241 gaggacatcg ccacgtacta ttgcctccag tacgacagct atccctatac atttgggcag 301 ggcactaaac tggagatcaa a

Protein Sequence Defining the Sh24C05 Kv1-33 Kappa Chain Variable Region (SEQ ID NO: 170)

 1 diqmtqspss lsasvgdrvt itc rasqeis gyls wyqqkp gkapklliy a astlds gvps 61 rfsgsgsgtd ftftisslqp ediatyyc lq ydsypyt fgq gtkleik 

Nucleic Acid Sequence Encoding the Sh24C05 Kv1-39 Kappa Chain Variable Region (SEQ ID NO: 171)

  1 gatattcaga tgacccaatc acctagcagt ctctcagctt ccgtgggcga cagagttacc  61 ataacctgtc gggcaagcca ggagatttct gggtacctgt cctggtatca acagaagccc 121 ggaaaagccc ctaagctgtt gatctatgct gcgtcaacct tggatagcgg tgtcccgagt 181 cgattctccg gttctggctc cggaactgac ttcactctga caatttctag ccttcagcca 241 gaagatttcg ccacgtacta ttgcctccag tacgacagct atccctatac atttgggcag  301 ggcactaaac tggagatcaa a 

Protein Sequence Defining the Sh24C05 Kv1-39 Kappa Chain Variable Region (SEQ ID NO: 172)

 1 diqmtqspss lsasvgdrvt itcr asqeis gyls wyqqkp gkapklliy a astlds gvps 61 rfsgsgsgtd ftltisslqp edfatyyc lq ydsypyt fgq gtkleik 

Nucleic Acid Sequence Encoding the Hu24C05 KvA Kappa Chain Variable Region (SEQ ID NO: 173)

  1 gatattcaga tgacccaatc acctagcagt ctctcagctt ccgtgggcga cagagttacc  61 ataacctgtc gggcaagcca ggagatttct gggtacctgt cctggctgca acagaagccc 121 ggaggcgcca tcaagaggtt gatctatgct gcgtcaacct tggatagcgg tgtcccgagt 181 cgattctccg gttctggctc cggaagtgac tacactctga caatttctag ccttcagcca 241 gaagatttcg ccacgtacta ttgcctccag tacgacagct atccctatac atttgggcag 301 ggcactaaac tggagatcaa a 

Protein Sequence Defining the Hu24C05 KvA Kappa Chain Variable Region (SEQ ID NO: 174)

 1 diqmtqspss lsasvgdrvt itc rasqeis gyls wlqqkp ggaikrliy a astlds gvps 61 rfsgsgsgsd ytltisslqp edfatyyc lq ydsypyt fgq gtkleik 

The amino acid sequences defining the immunoglobulin heavy chain variable regions for the antibodies produced in Example 12 are aligned in FIG. 15. Amino terminal signal peptide sequences (for proper expression/secretion) are not shown. CDR₁, CDR₂, and CDR₃ (Kabat definition) are identified by boxes.

The amino acid sequences defining the immunoglobulin light chain variable regions for the antibodies in Example 12 are aligned in FIG. 16. Amino terminal signal peptide sequences (for proper expression/secretion) are not shown. CDR₁, CDR₂ and CDR₃ are identified by boxes.

Table 10 is a concordance chart showing the SEQ ID NO. of each sequence discussed in this Example.

TABLE 10 SEQ. ID NO. Nucleic Acid or Protein 149 Sh24C05 Hv3-7 Heavy Chain Variable Region-nucleic acid 150 Sh24C05 Hv3-7 Heavy Chain Variable Region-protein 57 Sh24C05 Hv3-7 Heavy Chain CDR₁ 58 Sh24C05 Hv3-7 Heavy Chain CDR₂ 59 Sh24C05 Hv3-7 Heavy Chain CDR₃ 151 Sh24C05 Hv3-11 Heavy Chain Variable Region-nucleic acid 152 Sh24C05 Hv3-11 Heavy Chain Variable Region-protein 57 Sh24C05 Hv3-11 Heavy Chain CDR₁ 58 Sh24C05 Hv3-11 Heavy Chain CDR₂ 59 Sh24C05 Hv3-11 Heavy Chain CDR₃ 153 Sh24C05 Hv3-11 N62S Heavy Chain Variable Region- nucleic acid 154 Sh24C05 Hv3-11 N62S Heavy Chain Variable Region- protein 57 Sh24C05 Hv3-11 N62S Heavy Chain CDR₁ 148 Sh24C05 Hv3-11 N62S Heavy Chain CDR₂ 59 Sh24C05 Hv3-11 N62S Heavy Chain CDR₃ 155 Sh24C05 Hv3-21 Heavy Chain Variable Region-nucleic acid 156 Sh24C05 Hv3-21 Heavy Chain Variable Region-protein 57 Sh24C05 Hv3-21 Heavy Chain CDR₁ 58 Sh24C05 Hv3-21 Heavy Chain CDR₂ 59 Sh24C05 Hv3-21 Heavy Chain CDR₃ 157 Sh24C05 Hv3-23 Heavy Chain Variable Region-nucleic acid 158 Sh24C05 Hv3-23 Heavy Chain Variable Region-protein 57 Sh24C05 Hv3-23 Heavy Chain CDR₁ 58 Sh24C05 Hv3-23 Heavy Chain CDR₂ 59 Sh24C05 Hv3-23 Heavy Chain CDR₃ 159 Sh24C05 Hv3-30 Heavy Chain Variable Region-nucleic acid 160 Sh24C05 Hv3-30 Heavy Chain Variable Region-protein 57 Sh24C05 Hv3-30 Heavy Chain CDR₁ 58 Sh24C05 Hv3-30 Heavy Chain CDR₂ 59 Sh24C05 Hv3-30 Heavy Chain CDR₃ 161 Hu24C05 HvA Heavy Chain Variable Region-nucleic acid 162 Hu24C05 HvA Heavy Chain Variable Region-protein 57 Hu24C05 HvA Heavy Chain CDR₁ 58 Hu24C05 HvA Heavy Chain CDR₂ 59 Hu24C05 HvA Heavy Chain CDR₃ 163 Sh24C05 Kv1-9 Light (kappa) Chain Variable Region- nucleic acid 164 Sh24C05 Kv1-9 Light (kappa) Chain Variable Region- protein 60 Sh24C05 Kv1-9 Light (kappa) Chain CDR₁ 61 Sh24C05 Kv1-9 Light (kappa) Chain CDR₂ 62 Sh24C05 Kv1-9 Light (kappa) Chain CDR₃ 165 Sh24C05 Kv1-16 Light (kappa) Chain Variable Region- nucleic acid 166 Sh24C05 Kv1-16 Light (kappa) Chain Variable Region- protein 60 Sh24C05 Kv1-16 Light (kappa) Chain CDR₁ 61 Sh24C05 Kv1-16 Light (kappa) Chain CDR₂ 62 Sh24C05 Kv1-16 Light (kappa) Chain CDR₃ 167 Sh24C05 Kv1-17 Light (kappa) Chain Variable Region- nucleic acid 168 Sh24C05 Kv1-17 Light (kappa) Chain Variable Region- protein 60 Sh24C05 Kv1-17 Light (kappa) Chain CDR₁ 61 Sh24C05 Kv1-17 Light (kappa) Chain CDR₂ 62 Sh24C05 Kv1-17 Light (kappa) Chain CDR₃ 169 Sh24C05 Kv1-33 Light (kappa) Chain Variable Region- nucleic acid 170 Sh24C05 Kv1-33 Light (kappa) Chain Variable Region- protein 60 Sh24C05 Kv1-33 Light (kappa) Chain CDR₁ 61 Sh24C05 Kv1-33 Light (kappa) Chain CDR₂ 62 Sh24C05 Kv1-33 Light (kappa) Chain CDR₃ 171 Sh24C05 Kv1-39 Light (kappa) Chain Variable Region- nucleic acid 172 Sh24C05 Kv1-39 Light (kappa) Chain Variable Region- protein 60 Sh24C05 Kv1-39 Light (kappa) Chain CDR₁ 61 Sh24C05 Kv1-39 Light (kappa) Chain CDR₂ 62 Sh24C05 Kv1-39 Light (kappa) Chain CDR₃ 173 Hu24C05 KvA Light (kappa) Chain Variable Region- nucleic acid 174 Hu24C05 KvA Light (kappa) Chain Variable Region- protein 60 Hu24C05 KvA Light (kappa) Chain CDR₁ 61 Hu24C05 KvA Light (kappa) Chain CDR₂ 62 Hu24C05 KvA Light (kappa) Chain CDR₃

Humanized monoclonal antibody heavy chain CDR sequences (Kabat, Chothia, and IMGT definitions) are shown in Table 11.

TABLE 11 CDR1 CDR2 CDR3 Kabat 24C05 DYAMS TISDGGTYTYYPDNVKG EWGDYDGFDY (SEQ ID NO: 57) (SEQ ID NO: 58) (SEQ ID NO: 59) Sh24C05 DYAMS TISDGGTYTYYPDNVKG EWGDYDGFDY Hv3-7 (SEQ ID NO: 57) (SEQ ID NO: 58) (SEQ ID NO: 59) Sh24C05 DYAMS TISDGGTYTYYPDNVKG EWGDYDGFDY Hv3-11 (SEQ ID NO: 57) (SEQ ID NO: 58) (SEQ ID NO: 59) Sh24C05 DYAMS TISDGGTYTYYPDSVKG EWGDYDGFDY Hv3-11 (SEQ ID NO: 57) (SEQ ID NO: 148) (SEQ ID NO: 59) N62S Sh24C05 DYAMS TISDGGTYTYYPDNVKG EWGDYDGFDY Hv3-21 (SEQ ID NO: 57) (SEQ ID NO: 58) (SEQ ID NO: 59) Sh24C05 DYAMS TISDGGTYTYYPDNVKG EWGDYDGFDY Hv3-23 (SEQ ID NO: 57) (SEQ ID NO: 58) (SEQ ID NO: 59) Sh24C05 DYAMS TISDGGTYTYYPDNVKG EWGDYDGFDY Hv3-30 (SEQ ID NO: 57) (SEQ ID NO: 58) (SEQ ID NO: 59) Hu24C05 DYAMS TISDGGTYTYYPDNVKG EWGDYDGFDY HvA (SEQ ID NO: 57) (SEQ ID NO: 58) (SEQ ID NO: 59) Chothia 24C05 GFTFSDY SDGGTY EWGDYDGFDY (SEQ ID NO: 75) (SEQ ID NO: 76) (SEQ ID NO: 59) Sh24C05 GFTFSDY SDGGTY EWGDYDGFDY Hv3-7 (SEQ ID NO: 75) (SEQ ID NO: 76) (SEQ ID NO: 59) Sh24C05 GFTFSDY SDGGTY EWGDYDGFDY Hv3-11 (SEQ ID NO: 75) (SEQ ID NO: 76) (SEQ ID NO: 59) Sh24C05 GFTFSDY SDGGTY EWGDYDGFDY Hv3-11 (SEQ ID NO: 75) (SEQ ID NO: 76) (SEQ ID NO: 59) N62S Sh24C05 GFTFSDY SDGGTY EWGDYDGFDY Hv3-21 (SEQ ID NO: 75) (SEQ ID NO: 76) (SEQ ID NO: 59) Sh24C05 GFTFSDY SDGGTY EWGDYDGFDY Hv3-23 (SEQ ID NO: 75) (SEQ ID NO: 76) (SEQ ID NO: 59) Sh24C05 GFTFSDY SDGGTY EWGDYDGFDY Hv3-30 (SEQ ID NO: 75) (SEQ ID NO: 76) (SEQ ID NO: 59) Hu24C05 GFTFSDY SDGGTY EWGDYDGFDY HvA (SEQ ID NO: 75) (SEQ ID NO: 76) (SEQ ID NO: 59) IMGT 24C05 GFTFSDYA ISDGGTYT AREWGDYDGFDY (SEQ ID NO: 94) (SEQ ID NO: 95) (SEQ ID NO: 96) Sh24C05 GFTFSDYA ISDGGTYT AREWGDYDGFDY Hv3-7 (SEQ ID NO: 94) (SEQ ID NO: 95) (SEQ ID NO: 96) Sh24C05 GFTFSDYA ISDGGTYT AREWGDYDGFDY Hv3-11 (SEQ ID NO: 94) (SEQ ID NO: 95) (SEQ ID NO: 96) Sh24C05 GFTFSDYA ISDGGTYT AREWGDYDGFDY Hv3-11 (SEQ ID NO: 94) (SEQ ID NO: 95) (SEQ ID NO: 96) N62S Sh24C05 GFTFSDYA ISDGGTYT AREWGDYDGFDY Hv3-21 (SEQ ID NO: 94) (SEQ ID NO: 95) (SEQ ID NO: 96) Sh24C05 GFTFSDYA ISDGGTYT AREWGDYDGFDY Hv3-23 (SEQ ID NO: 94) (SEQ ID NO: 95) (SEQ ID NO: 96) Sh24C05 GFTFSDYA ISDGGTYT AREWGDYDGFDY Hv3-30 (SEQ ID NO: 94) (SEQ ID NO: 95) (SEQ ID NO: 96) Hu24C05 GFTFSDYA ISDGGTYT AREWGDYDGFDY HvA (SEQ ID NO: 94) (SEQ ID NO: 95) (SEQ ID NO: 96)

Humanized monoclonal antibody Kappa light chain CDR sequences (Kabat, Chothia, and IMGT definitions) are shown in Table 12.

TABLE 12 CDR1 CDR2 CDR3 Kabat/Chothia 24C05 RASQEISGYLS AASTLDS LQYDSYPYT (SEQ ID NO: 60) (SEQ ID NO: 61) (SEQ ID NO: 62) Sh24C05 RASQEISGYLS AASTLDS LQYDSYPYT Kv1-9 (SEQ ID NO: 60) (SEQ ID NO: 61) (SEQ ID NO: 62) Sh24C05 RASQEISGYLS AASTLDS LQYDSYPYT Kv1-16 (SEQ ID NO: 60) (SEQ ID NO: 61) (SEQ ID NO: 62) Sh24C05 RASQEISGYLS AASTLDS LQYDSYPYT Kv1-17 (SEQ ID NO: 60) (SEQ ID NO: 61) (SEQ ID NO: 62) Sh24C05 RASQEISGYLS AASTLDS LQYDSYPYT Kv1-33 (SEQ ID NO: 60) (SEQ ID NO: 61) (SEQ ID NO: 62) Sh24C05 RASQEISGYLS AASTLDS LQYDSYPYT Kv1-39 (SEQ ID NO: 60) (SEQ ID NO: 61) (SEQ ID NO: 62) Flu24C05  RASQEISGYLS AASTLDS LQYDSYPYT KvA (SEQ ID NO: 60) (SEQ ID NO: 61) (SEQ ID NO: 62) IMGT 24C05 QEISGY AAS LQYDSYPYT (SEQ ID NO: 101) (SEQ ID NO: 62) Sh24C05 QEISGY AAS LQYDSYPYT Kv1-9 (SEQ ID NO: 101) (SEQ ID NO: 62) Sh24C05 QEISGY AAS LQYDSYPYT Kv1-16 (SEQ ID NO: 101) (SEQ ID NO: 62) Sh24C05 QEISGY AAS LQYDSYPYT Kv1-17 (SEQ ID NO: 101) (SEQ ID NO: 62) Sh24C05 QEISGY AAS LQYDSYPYT Kv1-33 (SEQ ID NO: 101) (SEQ ID NO: 62) Sh24C05 QEISGY AAS LQYDSYPYT Kv1-39 (SEQ ID NO: 101) (SEQ ID NO: 62) Hu24C05 QEISGY AAS LQYDSYPYT KvA (SEQ ID NO: 101) (SEQ ID NO: 62)

In Tables 11 and 12, the longest CDR sequences for the immunoglobulin heavy chain and light chain are shown in bold.

To create the complete chimeric and humanized heavy or kappa chain antibody sequences, each variable sequence above is combined with its respective human constant region. For example, a complete heavy chain comprises a heavy variable sequence followed by a human IgG1 heavy chain constant sequence or a human IgG2 heavy chain constant sequence. A complete kappa chain comprises a kappa variable sequence followed by the human kappa light chain constant sequence.

Nucleic Acid Sequence Encoding the Human IgG1 Heavy Chain Constant Region (SEQ ID NO: 175)

  1 gcctcaacaa aaggaccaag tgtgttccca ctcgccccta gcagcaagag tacatccggg  61 ggcactgcag cactcggctg cctcgtcaag gattattttc cagagccagt aaccgtgagc 121 tggaacagtg gagcactcac ttctggtgtc catacttttc ctgctgtcct gcaaagctct 181 ggcctgtact cactcagctc cgtcgtgacc gtgccatctt catctctggg cactcagacc 241 tacatctgta atgtaaacca caagcctagc aatactaagg tcgataagcg ggtggaaccc 301 aagagctgcg acaagactca cacttgtccc ccatgccctg cccctgaact tctgggcggt 361 cccagcgtct ttttgttccc accaaagcct aaagatactc tgatgataag tagaacaccc 421 gaggtgacat gtgttgttgt agacgtttcc cacgaggacc cagaggttaa gttcaactgg 481 tacgttgatg gagtcgaagt acataatgct aagaccaagc ctagagagga gcagtataat 541 agtacatacc gtgtagtcag tgttctcaca gtgctgcacc aagactggct caacggcaaa 601 gaatacaaat gcaaagtgtc caacaaagca ctcccagccc ctatcgagaa gactattagt 661 aaggcaaagg ggcagcctcg tgaaccacag gtgtacactc tgccacccag tagagaggaa 721 atgacaaaga accaagtctc attgacctgc ctggtgaaag gcttctaccc cagcgacatc 781 gccgttgagt gggagagtaa cggtcagcct gagaacaatt acaagacaac ccccccagtg 841 ctggatagtg acgggtcttt ctttctgtac agtaagctga ctgtggacaa gtcccgctgg 901 cagcagggta acgtcttcag ctgttccgtg atgcacgagg cattgcacaa ccactacacc 961 cagaagtcac tgagcctgag cccagggaag 

Protein Sequence Defining the Human IgG1 Heavy Chain Constant Region (SEQ ID NO: 176)

  1 astkgpsvfp lapsskstsg gtaalgclvk dyfpepvtvs wnsgaltsgv htfpavlqss  61 glyslssvvt vpssslgtqt yicnvnhkps ntkvdkrvep kscdkthtcp pcpapellgg 121 psvflfppkp kdtlmisrtp evtcvvvdvs hedpevkfnw yvdgvevhna ktkpreeqyn 181 styrvvsvlt vlhqdwlngk eykckvsnka lpapiektis kakgqprepq vytlppsree 241 mtknqvsltc lvkgfypsdi avewesngqp ennykttppv ldsdgsffly skltvdksrw 301 qqgnvfscsv mhealhnhyt qkslslspgk 

Nucleic Acid Sequence Encoding the Human IgG2 Heavy Chain Constant Region (SEQ ID NO: 177)

  1 gcctccacca agggcccatc ggtcttcccc ctggcgccct gctccaggag cacctccgag  61 agcacagcgg ccctgggctg cctggtcaag gactacttcc ccgaaccggt gacggtgtcg 121 tggaactcag gcgctctgac cagcggcgtg cacaccttcc cagctgtcct acagtcctca 181 ggactctact ccctcagcag cgtggtgacc gtgccctcca gcaacttcgg cacccagacc 241 tacacctgca acgtagatca caagcccagc aacaccaagg tggacaagac agttgagcgc 301 aaatgttgtg tcgagtgccc accgtgccca gcaccacctg tggcaggacc gtcagtcttc 361 ctcttccccc caaaacccaa ggacaccctc atgatctccc ggacccctga ggtcacgtgc 421 gtggtggtgg acgtgagcca cgaagacccc gaggtccagt tcaactggta cgtggacggc 481 gtggaggtgc ataatgccaa gacaaagcca cgggaggagc agttcaacag cacgttccgt 541 gtggtcagcg tcctcaccgt tgtgcaccag gactggctga acggcaagga gtacaagtgc 601 aaggtctcca acaaaggcct cccagccccc atcgagaaaa ccatctccaa aaccaaaggg 661 cagccccgag aaccacaggt gtacaccctg cccccatccc gggaggagat gaccaagaac 721 caggtcagcc tgacctgcct ggtcaaaggc ttctacccca gcgacatcgc cgtggagtgg 781 gagagcaatg ggcagccgga gaacaactac aagaccacac ctcccatgct ggactccgac 841 ggctccttct tcctctacag caagctcacc gtggacaaga gcaggtggca gcaggggaac 901 gtcttctcat gctccgtgat gcatgaggct ctgcacaacc actacacgca gaagagcctc 961 tccctgtctc cgggtaaa 

Protein Sequence Defining the Human IgG2 Heavy Chain Constant Region (SEQ ID NO: 178)

  1 astkgpsvfp lapcsrstse staalgclvk dyfpepvtvs wnsgaltsgv htfpavlqss  61 glyslssvvt vpssnfgtqt ytcnvdhkps ntkvdktver kccvecppcp appvagpsvf 121 lfppkpkdtl misrtpevtc vvvdvshedp evqfnwyvdg vevhnaktkp reeqfnstfr 181 vvsvltvvhq dwlngkeykc kvsnkglpap iektisktkg qprepqvytl ppsreemtkn 241 qvsltclvkg fypsdiavew esngqpenny kttppmldsd gsfflysklt vdksrwqqgn 301 vfscsvmhea lhnhytqksl slspgk 

Nucleic Acid Sequence Encoding the Human Kappa Light Chain Constant Region (SEQ ID NO: 179)

  1 cgcacagttg ctgcccccag cgtgttcatt ttcccaccta gcgatgagca gctgaaaagc  61 ggtactgcct ctgtcgtatg cttgctcaac aacttttacc cacgtgaggc taaggtgcag 121 tggaaagtgg ataatgcact tcaatctgga aacagtcaag agtccgtgac agaacaggac 181 agcaaagact caacttattc actctcttcc accctgactc tgtccaaggc agactatgaa 241 aaacacaagg tatacgcctg cgaggttaca caccagggtt tgtctagtcc tgtcaccaag 301 tccttcaata ggggcgaatg t 

Protein Sequence Defining the Human Kappa Light Chain Constant Region (SEQ ID NO: 180)

 1 rtvaapsvfi fppsdeqlks gtasvvclln nfypreakvq wkvdnalqsg nsqesvteqd 61 skdstyslss tltlskadye khkvyacevt hqglsspvtk sfnrgec 

The following sequences represent the actual or contemplated full length heavy and light chain sequences (i.e., containing both the variable and constant regions sequences) for each antibody described in this Example. Signal sequences for proper secretion of the antibodies are also included at the 5′ end of the DNA sequences or the amino terminal end of the protein sequences. It is also contemplated herein that the variable region sequences can be ligated to other constant region sequences to produce active full length IgG heavy and light chains.

Nucleic Acid Sequence Encoding the Full Length Chimeric 24C05 Heavy Chain (Mouse Heavy Chain Variable Region and Human IgG1 Constant Region) (SEQ ID NO: 181)

   1 atgaacttcg ggctcagctt gatgttcctt gtccttgtct taaaaggtgt ccagtgtgag   61 gtgcagctgg tggaatctgg gggaggctta gtgaagcctg gagggtccct gaaactctcc  121 tgtgcagcct ctggattcac tttcagtgac tatgccatgt cttgggttcg ccagactccg  181 gaaaagaggc tggagtgggt cgcaaccatt agtgatggtg gtacttacac ctactatcca  241 gacaatgtaa agggccgatt caccatctcc agagacaatg ccaagaacaa cctgtacctg  301 caaatgagcc atctgaagtc tgaggacaca gccatgtatt actgtgcaag agaatggggt  361 gattacgacg gatttgacta ctggggccaa ggcaccactc tcacagtctc ctcggcctca  421 acaaaaggac caagtgtgtt cccactcgcc cctagcagca agagtacatc cgggggcact  481 gcagcactcg gctgcctcgt caaggattat tttccagagc cagtaaccgt gagctggaac  541 agtggagcac tcacttctgg tgtccatact tttcctgctg tcctgcaaag ctctggcctg  601 tactcactca gctccgtcgt gaccgtgcca tcttcatctc tgggcactca gacctacatc  661 tgtaatgtaa accacaagcc tagcaatact aaggtcgata agcgggtgga acccaagagc  721 tgcgacaaga ctcacacttg tcccccatgc cctgcccctg aacttctggg cggtcccagc  781 gtctttttgt tcccaccaaa gcctaaagat actctgatga taagtagaac acccgaggtg  841 acatgtgttg ttgtagacgt ttcccacgag gacccagagg ttaagttcaa ctggtacgtt  901 gatggagtcg aagtacataa tgctaagacc aagcctagag aggagcagta taatagtaca  961 taccgtgtag tcagtgttct cacagtgctg caccaagact ggctcaacgg caaagaatac 1021 aaatgcaaag tgtccaacaa agcactccca gcccctatcg agaagactat tagtaaggca 1081 aaggggcagc ctcgtgaacc acaggtgtac actctgccac ccagtagaga ggaaatgaca 1141 aagaaccaag tctcattgac ctgcctggtg aaaggcttct accccagcga catcgccgtt 1201 gagtgggaga gtaacggtca gcctgagaac aattacaaga caaccccccc agtgctggat 1261 agtgacgggt ctttctttct gtacagtaag ctgactgtgg acaagtcccg ctggcagcag 1321 ggtaacgtct tcagctgttc cgtgatgcac gaggcattgc acaaccacta cacccagaag 1381 tcactgagcc tgagcccagg gaag 

Protein Sequence Defining the Full Length Chimeric 24C05 Heavy Chain (Mouse Heavy Chain Variable Region and Human IgG1 Constant Region) (SEQ ID NO: 182)

  1 mnfglslmfl vlvlkgvqce vqlvesgggl vkpggslkls caasgftfsd yamswvrqtp  61 ekrlewvati sdggtytyyp dnvkgrftis rdnaknnlyl qmshlksedt amyycarewg 121 dydgfdywgq gttltvssas tkgpsvfpla psskstsggt aalgclvkdy fpepvtvswn 181 sgaltsgvht fpavlgssgl yslssvvtvp ssslgtqtyi cnvnhkpsnt kvdkrvepks 241 cdkthtcppc papellggps vflfppkpkd tlmisrtpev tcvvvdvshe dpevkfnwyv 301 dgvevhnakt kpreeqynst yrvvsvltvl hqdwlngkey kckvsnkalp apiektiska 361 kgqprepqvy tlppsreemt knqvsltclv kgfypsdiav ewesngqpen nykttppvld 421 sdgsfflysk ltvdksrwqq gnvfscsvmh ealhnhytqk slslspgk 

Nucleic Acid Sequence Encoding the Full Length Chimeric 24C05 Light Chain (Mouse Kappa Chain Variable Region and Human Kappa Constant Region) (SEQ ID NO: 183)

  1 atggacatga gggttcctgc tcacgttttt ggcttcttgt tgctctggtt tccaggtacc  61 agatgtgaca tccagatgac ccagtctcca tcctccttat ctgcctctct gggagaaaga 121 gtcagtctca cttgtcgggc aagtcaggaa attagtggtt acttaagctg gcttcagcag 181 aaaccagatg gaactattaa acgcctgatc tacgccgcat ccactttaga ttctggtgtc 241 ccaaaaaggt tcagtggcag taggtctggg tcagattatt ctctcaccat cggcagcctt 301 gagtctgaag atcttgcaga ctattactgt ctacaatatg atagttatcc gtacacgttc 361 ggagggggga ccaagctgga aataaaacgc acagtcgccg ctccctccgt gttcatcttt 421 ccaccaagtg atgagcaact gaagtctggt actgcttcag tcgtgtgtct gctgaacaat 481 ttctaccctc gagaagccaa agtccaatgg aaggtagaca acgcactgca gtccggcaat 541 agccaagaat cagttaccga acaggattca aaggacagta catattccct gagcagcact 601 ctgaccctgt caaaggccga ttacgagaaa cacaaggtct atgcttgcga agtgacacat 661 cagggactgt ccagcccagt gacaaaatct tttaaccgtg gggagtgt

Protein Sequence Defining the Full Length Chimeric 24C05 Light Chain (Mouse Kappa Chain Variable Region and Human Kappa Constant Region) (SEQ ID NO: 184)

  1 mdmrvpahvf gflllwfpgt rcdiqmtqsp sslsaslger vsltcrasqe isgylswlqq  61 kpdgtikrli yaastldsgv pkrfsgsrsg sdysltigsl esedladyyc lqydsypytf 121 gggtkleikr tvaapsvfif ppsdeqlksg tasvvcllnn fypreakvqw kvdnalqsgn 181 sqesvteqds kdstyslsst ltlskadyek hkvyacevth qglsspvtks fnrgec

Nucleic Acid Sequence Encoding the Full Length Humanized sh24C05 Hv3-7 Heavy Chain (Humanized Heavy Chain Variable Region and Human IgG1 Constant Region) (SEQ ID NO: 185)

   1 atggacatga gagttcctgc tcagctgctc gggttgctgt tgctttggct ccggggtgct   61 aggtgcgagg ttcagctggt ggaatctggc ggtgggcttg tacaaccagg aggctccctc  121 agactgagtt gtgccgcttc agggttcaca ttctccgact atgcgatgtc atgggtgcgc  181 caagcacccg ggaaaggact ggagtgggtt gccactatca gcgatggcgg aacgtatacc  241 tattaccctg acaatgtgaa gggtcggttc accatttcca gggataacgc aaagaacagt  301 ctctacctgc agatgaacag cctgagggct gaggacaccg ccgtctacta ctgcgcccga  361 gaatggggag attatgatgg gtttgactat tggggccagg gcactttggt gacagtcagt  421 tctgcctcaa caaaaggacc aagtgtgttc ccactcgccc ctagcagcaa gagtacatcc  481 gggggcactg cagcactcgg ctgcctcgtc aaggattatt ttccagagcc agtaaccgtg  541 agctggaaca gtggagcact cacttctggt gtccatactt ttcctgctgt cctgcaaagc  601 tctggcctgt actcactcag ctccgtcgtg accgtgccat cttcatctct gggcactcag  661 acctacatct gtaatgtaaa ccacaagcct agcaatacta aggtcgataa gcgggtggaa  721 cccaagagct gcgacaagac tcacacttgt cccccatgcc ctgcccctga acttctgggc  781 ggtcccagcg tctttttgtt cccaccaaag cctaaagata ctctgatgat aagtagaaca  841 cccgaggtga catgtgttgt tgtagacgtt tcccacgagg acccagaggt taagttcaac  901 tggtacgttg atggagtcga agtacataat gctaagacca agcctagaga ggagcagtat  961 aatagtacat accgtgtagt cagtgttctc acagtgctgc accaagactg gctcaacggc 1021 aaagaataca aatgcaaagt gtccaacaaa gcactcccag cccctatcga gaagactatt 1081 agtaaggcaa aggggcagcc tcgtgaacca caggtgtaca ctctgccacc cagtagagag 1141 gaaatgacaa agaaccaagt ctcattgacc tgcctggtga aaggcttcta ccccagcgac 1201 atcgccgttg agtgggagag taacggtcag cctgagaaca attacaagac aaccccccca 1261 gtgctggata gtgacgggtc tttctttctg tacagtaagc tgactgtgga caagtcccgc 1321 tggcagcagg gtaacgtctt cagctgttcc gtgatgcacg aggcattgca caaccactac 1381 acccagaagt cactgagcct gagcccaggg aag

Protein Sequence Defining the Full Length Humanized Sh24C05 Hv3-7 Heavy Chain (Humanized Heavy Chain Variable Region and Human IgG1 Constant Region) (SEQ ID NO: 186)

  1 mdmrvpaqll gllllwlrga rcevqlvesg gglvqpggsl rlscaasgft fsdyamswvr  61 qapgkglewv atisdggtyt yypdnvkgrf tisrdnakns lylqmnslra edtavyycar 121 ewgdydgfdy wgqgtivtvs sastkgpsvf plapssksts ggtaalgclv kdyfpepvtv 181 swnsgaltsg vhtfpavlqs sglyslssvv tvpssslgtq tyicnvnhkp sntkvdkrve 241 pkscdkthtc ppcpapellg gpsvflfppk pkdtlmisrt pevtcvvvdv shedpevkfn 301 wyvdgvevhn aktkpreeqy nstyrvvsvl tvlhqdwlng keykckvsnk alpapiekti 361 skakgqprep qvytlppsre emtknqvslt clvkgfypsd iavewesngq pennykttpp 421 vldsdgsffl yskltvdksr wqqgnvfscs vmhealhnhy tqkslslspg k

Nucleic Acid Sequence Encoding the Full Length Humanized Sh24C05 Hv3-11 Heavy Chain (Humanized Heavy Chain Variable Region and Human IgG1 Constant Region) (SEQ ID NO: 187)

   1 atggacatga gagttcctgc tcagctgctc gggttgctgt tgctttggct ccggggtgct   61 aggtgccaag ttcagctggt ggaatctggc ggtgggcttg taaagccagg aggctccctc  121 agactgagtt gtgccgcttc agggttcaca ttctccgact atgcgatgtc atggatcagg  181 caagcacccg ggaaaggact ggagtgggtt agcactatca gcgatggcgg aacgtatacc  241 tattaccctg acaatgtgaa gggtcggttc accatttcca gggataacgc aaagaacagt  301 ctctaccttc agatgaacag cctgagggct gaggacaccg ccgtctacta ctgcgcccga  361 gaatggggag attatgatgg gtttgactat tggggccagg gcactttggt gacagtcagt  421 tctgcctcaa caaaaggacc aagtgtgttc ccactcgccc ctagcagcaa gagtacatcc  481 gggggcactg cagcactcgg ctgcctcgtc aaggattatt ttccagagcc agtaaccgtg  541 agctggaaca gtggagcact cacttctggt gtccatactt ttcctgctgt cctgcaaagc  601 tctggcctgt actcactcag ctccgtcgtg accgtgccat cttcatctct gggcactcag  661 acctacatct gtaatgtaaa ccacaagcct agcaatacta aggtcgataa gcgggtggaa  721 cccaagagct gcgacaagac tcacacttgt cccccatgcc ctgcccctga acttctgggc  781 ggtcccagcg tctttttgtt cccaccaaag cctaaagata ctctgatgat aagtagaaca  841 cccgaggtga catgtgttgt tgtagacgtt tcccacgagg acccagaggt taagttcaac  901 tggtacgttg atggagtcga agtacataat gctaagacca agcctagaga ggagcagtat  961 aatagtacat accgtgtagt cagtgttctc acagtgctgc accaagactg gctcaacggc 1021 aaagaataca aatgcaaagt gtccaacaaa gcactcccag cccctatcga gaagactatt 1081 agtaaggcaa aggggcagcc tcgtgaacca caggtgtaca ctctgccacc cagtagagag 1141 gaaatgacaa agaaccaagt ctcattgacc tgcctggtga aaggcttcta ccccagcgac 1201 atcgccgttg agtgggagag taacggtcag cctgagaaca attacaagac aaccccccca 1261 gtgctggata gtgacgggtc tttctttctg tacagtaagc tgactgtgga caagtcccgc 1321 tggcagcagg gtaacgtctt cagctgttcc gtgatgcacg aggcattgca caaccactac 1381 acccagaagt cactgagcct gagcccaggg aag

Protein Sequence Defining the Full Length Humanized Sh24C05 Hv3-11 Heavy Chain (Humanized Heavy Chain Variable Region and Human IgG1 Constant Region) (SEQ ID NO: 188)

  1 mdmrvpaqll gllllwlrga rcqvglvesg gglvkpggsl rlscaasgft fsdyamswir  61 qapgkglewv stisdggtyt yypdnvkgrf tisrdnakns lylqmnslra edtavyycar 121 ewgdydgfdy wgqgtlvtvs sastkgpsvf plapssksts ggtaalgclv kdyfpepvtv 181 swnsgaltsg vhtfpavlqs sglyslssvv tvpssslgtq tyicnvnhkp sntkvdkrve 241 pkscdkthtc ppcpapellg gpsvflfppk pkdtlmisrt pevtcvvvdv shedpevkfn 301 wyvdgvevhn aktkpreeqy nstyrvvsvl tvlhqdwlng keykckvsnk alpapiekti 361 skakgqprep qvytlppsre emtknqvslt clvkgfypsd iavewesngq pennykttpp 421 vldsdgsffl yskltvdksr wqqgnvfscs vmhealhnhy tqkslslspg k

Nucleic Acid Sequence Encoding the Full Length Humanized Sh24C05 Hv3-11 N62S IgG1 Heavy Chain (Humanized Heavy Chain Variable Region and Human IgG1 Constant Region) (SEQ ID NO: 189)

   1 atggacatga gagttcctgc tcagctgctc gggttgctgt tgctttggct ccggggtgct   61 aggtgccaag ttcagctggt ggaatctggc ggtgggcttg taaagccagg aggctccctc  121 agactgagtt gtgccgcttc agggttcaca ttctccgact atgcgatgtc atggatcagg  181 caagcacccg ggaaaggact ggagtgggtt agcactatca gcgatggcgg aacgtatacc  241 tattaccctg actccgtgaa gggtcggttc accatttcca gggataacgc aaagaacagt  301 ctctaccttc agatgaacag cctgagggct gaggacaccg ccgtctacta ctgcgcccga  361 gaatggggag attatgatgg gtttgactat tggggccagg gcactttggt gacagtcagt  421 tctgcctcaa caaaaggacc aagtgtgttc ccactcgccc ctagcagcaa gagtacatcc  481 gggggcactg cagcactcgg ctgcctcgtc aaggattatt ttccagagcc agtaaccgtg  541 agctggaaca gtggagcact cacttctggt gtccatactt ttcctgctgt cctgcaaagc  601 tctggcctgt actcactcag ctccgtcgtg accgtgccat cttcatctct gggcactcag  661 acctacatct gtaatgtaaa ccacaagcct agcaatacta aggtcgataa gcgggtggaa  721 cccaagagct gcgacaagac tcacacttgt cccccatgcc ctgcccctga acttctgggc  781 ggtcccagcg tctttttgtt cccaccaaag cctaaagata ctctgatgat aagtagaaca  841 cccgaggtga catgtgttgt tgtagacgtt tcccacgagg acccagaggt taagttcaac  901 tggtacgttg atggagtcga agtacataat gctaagacca agcctagaga ggagcagtat  961 aatagtacat accgtgtagt cagtgttctc acagtgctgc accaagactg gctcaacggc 1021 aaagaataca aatgcaaagt gtccaacaaa gcactcccag cccctatcga gaagactatt 1081 agtaaggcaa aggggcagcc tcgtgaacca caggtgtaca ctctgccacc cagtagagag 1141 gaaatgacaa agaaccaagt ctcattgacc tgcctggtga aaggcttcta ccccagcgac 1201 atcgccgttg agtgggagag taacggtcag cctgagaaca attacaagac aaccccccca 1261 gtgctggata gtgacgggtc tttctttctg tacagtaagc tgactgtgga caagtcccgc 1321 tggcagcagg gtaacgtctt cagctgttcc gtgatgcacg aggcattgca caaccactac 1381 acccagaagt cactgagcct gagcccaggg aag

Protein Sequence Defining the Full Length Humanized Sh24C05 Hv3-11 N62S IgG1 Heavy Chain (Humanized Heavy Chain Variable Region and Human IgG1 Constant Region) (SEQ ID NO: 190)

  1 mdmrvpaqll gllllwlrga rcqvqlvesg gglvkpggsl rlscaasgft fsdyamswir  61 qapgkglewv stisdggtyt yypdsvkgrf tisrdnakns lylqmnslra edtavyycar 121 ewgdydgfdy wgqgtivtvs sastkgpsvf plapssksts ggtaalgclv kdyfpepvtv 181 swnsgaltsg vhtfpavlqs sglyslssvv tvpssslgtq tyicnvnhkp sntkvdkrve 241 pkscdkthtc ppcpapellg gpsvflfppk pkdtlmisrt pevtcvvvdv shedpevkfn 301 wyvdgvevhn aktkpreeqy nstyrvvsvl tvlhqdwlng keykckvsnk alpapiekti 361 skakgqprep qvytlppsre emtknqvslt clvkgfypsd iavewesngq pennykttpp 421 vldsdgsffl yskltvdksr wqqgnvfscs vmhealhnhy tqkslslspg k

Nucleic Acid Sequence Encoding the Full Length Humanized Sh24C05 Hv3-11 N62S IgG2 Heavy Chain (Humanized Heavy Chain Variable Region and Human IgG2 Constant Region) (SEQ ID NO: 191)

   1 atggacatga gagttcctgc tcagctgctc gggttgctgt tgctttggct ccggggtgct   61 aggtgccaag ttcagctggt ggaatctggc ggtgggcttg taaagccagg aggctccctc  121 agactgagtt gtgccgcttc agggttcaca ttctccgact atgcgatgtc atggatcagg  181 caagcacccg ggaaaggact ggagtgggtt agcactatca gcgatggcgg aacgtatacc  241 tattaccctg actccgtgaa gggtcggttc accatttcca gggataacgc aaagaacagt  301 ctctaccttc agatgaacag cctgagggct gaggacaccg ccgtctacta ctgcgcccga  361 gaatggggag attatgatgg gtttgactat tggggccagg gcactttggt gacagtcagt  421 tctgcctcca ccaagggccc atcggtcttc cccctggcgc cctgctccag gagcacctcc  481 gagagcacag cggccctggg ctgcctggtc aaggactact tccccgaacc ggtgacggtg  541 tcgtggaact caggcgctct gaccagcggc gtgcacacct tcccagctgt cctacagtcc  601 tcaggactct actccctcag cagcgtggtg accgtgccct ccagcaactt cggcacccag  661 acctacacct gcaacgtaga tcacaagccc agcaacacca aggtggacaa gacagttgag  721 cgcaaatgtt gtgtcgagtg cccaccgtgc ccagcaccac ctgtggcagg accgtcagtc  781 ttcctcttcc ccccaaaacc caaggacacc ctcatgatct cccggacccc tgaggtcacg  841 tgcgtggtgg tggacgtgag ccacgaagac cccgaggtcc agttcaactg gtacgtggac  901 ggcgtggagg tgcataatgc caagacaaag ccacgggagg agcagttcaa cagcacgttc  961 cgtgtggtca gcgtcctcac cgttgtgcac caggactggc tgaacggcaa ggagtacaag 1021 tgcaaggtct ccaacaaagg cctcccagcc cccatcgaga aaaccatctc caaaaccaaa 1081 gggcagcccc gagaaccaca ggtgtacacc ctgcccccat cccgggagga gatgaccaag 1141 aaccaggtca gcctgacctg cctggtcaaa ggcttctacc ccagcgacat cgccgtggag 1201 tgggagagca atgggcagcc ggagaacaac tacaagacca cacctcccat gctggactcc 1261 gacggctcct tcttcctcta cagcaagctc accgtggaca agagcaggtg gcagcagggg 1321 aacgtcttct catgctccgt gatgcatgag gctctgcaca accactacac gcagaagagc 1381 ctctccctgt ctccgggtaa a

Protein Sequence Defining the Full Length Humanized Sh24C05 Hv3-11 N62S IgG2 Heavy Chain (Humanized Heavy Chain Variable Region and Human IgG2 Constant Region) (SEQ ID NO: 192)

  1 mdmrvpaqll gllllwlrga rcqvqlvesg gglvkpggsl rlscaasgft fsdyamswir  61 qapgkglewv stisdggtyt yypdsvkgrf tisrdnakns lylqmnslra edtavyycar 121 ewgdydgfdy wgqgtlvtvs sastkgpsvf plapcsrsts estaalgclv kdyfpepvtv 181 swnsgaltsg vhtfpavlqs sglyslssvv tvpssnfgtq tytcnvdhkp sntkvdktve 241 rkccvecppc pappvagpsv flfppkpkdt lmisrtpevt cvvvdvshed pevqfnwyvd 301 gvevhnaktk preeqfnstf rvvsvltvvh qdwlngkeyk ckvsnkglpa piektisktk 361 gqprepqvyt lppsreemtk nqvsltclvk gfypsdiave wesngqpenn ykttppmlds 421 dgsfflyskl tvdksrwqqg nvfscsvmhe alhnhytqks lslspgk

Nucleic Acid Sequence Encoding the Full Length Humanized Sh24C05 Hv3-21 Heavy Chain (Humanized Heavy Chain Variable Region and Human IgG1 Constant Region) (SEQ ID NO: 193)

   1 atggacatga gagttcctgc tcagctgctc gggttgctgt tgctttggct ccggggtgct   61 aggtgcgagg ttcagctggt ggaatctggc ggtgggcttg taaagccagg aggctccctc  121 agactgagtt gtgccgcttc agggttcaca ttctccgact atgcgatgtc atgggtgcgc  181 caagcacccg ggaaaggact ggagtgggtt agcactatca gcgatggcgg aacgtatacc  241 tattaccctg acaatgtgaa gggtcggttc accatttcca gggataacgc aaagaacagt  301 ctctatttgc agatgaacag cctgagggct gaggacaccg ccgtctacta ctgcgcccga  361 gaatggggag attatgatgg gtttgactat tggggccagg gcactttggt gacagtcagt  421 tctgcctcaa caaaaggacc aagtgtgttc ccactcgccc ctagcagcaa gagtacatcc  481 gggggcactg cagcactcgg ctgcctcgtc aaggattatt ttccagagcc agtaaccgtg  541 agctggaaca gtggagcact cacttctggt gtccatactt ttcctgctgt cctgcaaagc  601 tctggcctgt actcactcag ctccgtcgtg accgtgccat cttcatctct gggcactcag  661 acctacatct gtaatgtaaa ccacaagcct agcaatacta aggtcgataa gcgggtggaa  721 cccaagagct gcgacaagac tcacacttgt cccccatgcc ctgcccctga acttctgggc  781 ggtcccagcg tctttttgtt cccaccaaag cctaaagata ctctgatgat aagtagaaca  841 cccgaggtga catgtgttgt tgtagacgtt tcccacgagg acccagaggt taagttcaac  901 tggtacgttg atggagtcga agtacataat gctaagacca agcctagaga ggagcagtat  961 aatagtacat accgtgtagt cagtgttctc acagtgctgc accaagactg gctcaacggc 1021 aaagaataca aatgcaaagt gtccaacaaa gcactcccag cccctatcga gaagactatt 1081 agtaaggcaa aggggcagcc tcgtgaacca caggtgtaca ctctgccacc cagtagagag 1141 gaaatgacaa agaaccaagt ctcattgacc tgcctggtga aaggcttcta ccccagcgac 1201 atcgccgttg agtgggagag taacggtcag cctgagaaca attacaagac aaccccccca 1261 gtgctggata gtgacgggtc tttctttctg tacagtaagc tgactgtgga caagtcccgc 1321 tggcagcagg gtaacgtctt cagctgttcc gtgatgcacg aggcattgca caaccactac 1381 acccagaagt cactgagcct gagcccaggg aag

Protein Sequence Defining the Full Length Humanized 24C05 Hv3-21 Heavy Chain (Humanized Heavy Chain Variable Region and Human IgG1 Constant Region) (SEQ ID NO: 194)

  1 mdmrvpaqll gllllwlrga rcevqlvesg gglvkpggsl rlscaasgft fsdyamswvr  61 qapgkglewv stisdggtyt yypdnvkgrf tisrdnakns lylqmnslra edtavyycar 121 ewgdydgfdy wgqgtlvtvs sastkgpsvf plapssksts ggtaalgclv kdyfpepvtv 181 swnsgaltsg vhtfpavlqs sglyslssvv tvpssslgtq tyicnvnhkp sntkvdkrve 241 pkscdkthtc ppcpapellg gpsvflfppk pkdtlmisrt pevtcvvvdv shedpevkfn 301 wyvdgvevhn aktkpreeqy nstyrvvsvl tvlhqdwlng keykckvsnk alpapiekti 361 skakgqprep qvytlppsre emtknqvslt clvkgfypsd iavewesngq pennykttpp 421 vldsdgsffl yskltvdksr wqqgnvfscs vmhealhnhy tqkslslspg k

Nucleic Acid Sequence Encoding the Full Length Humanized Sh24C05 Hv3-23 Heavy Chain (Humanized Heavy Chain Variable Region and Human IgG1 Constant Region) (SEQ ID NO: 195)

   1 atggacatga gagttcctgc tcagctgctc gggttgctgt tgctttggct ccggggtgct   61 aggtgcgagg ttcagcttct ggaatctggc ggtgggcttg tacagccagg aggctccctc  121 agactgagtt gtgccgcttc agggttcaca ttctccgact atgcgatgtc atgggtgcgc  181 caagcacccg ggaaaggact ggagtgggtt tcaactatca gcgatggcgg aacgtatacc  241 tattaccctg acaatgtgaa gggtcggttc accatttcca gggataacag caagaacaca  301 ctctatctcc agatgaacag cctgagggct gaggacaccg ccgtctacta ctgcgcccga  361 gaatggggag attatgatgg gtttgactat tggggccagg gcactttggt gacagtcagt  421 tctgcctcaa caaaaggacc aagtgtgttc ccactcgccc ctagcagcaa gagtacatcc  481 gggggcactg cagcactcgg ctgcctcgtc aaggattatt ttccagagcc agtaaccgtg  541 agctggaaca gtggagcact cacttctggt gtccatactt ttcctgctgt cctgcaaagc  601 tctggcctgt actcactcag ctccgtcgtg accgtgccat cttcatctct gggcactcag  661 acctacatct gtaatgtaaa ccacaagcct agcaatacta aggtcgataa gcgggtggaa  721 cccaagagct gcgacaagac tcacacttgt cccccatgcc ctgcccctga acttctgggc  781 ggtcccagcg tctttttgtt cccaccaaag cctaaagata ctctgatgat aagtagaaca  841 cccgaggtga catgtgttgt tgtagacgtt tcccacgagg acccagaggt taagttcaac  901 tggtacgttg atggagtcga agtacataat gctaagacca agcctagaga ggagcagtat  961 aatagtacat accgtgtagt cagtgttctc acagtgctgc accaagactg gctcaacggc 1021 aaagaataca aatgcaaagt gtccaacaaa gcactcccag cccctatcga gaagactatt 1081 agtaaggcaa aggggcagcc tcgtgaacca caggtgtaca ctctgccacc cagtagagag 1141 gaaatgacaa agaaccaagt ctcattgacc tgcctggtga aaggcttcta ccccagcgac 1201 atcgccgttg agtgggagag taacggtcag cctgagaaca attacaagac aaccccccca 1261 gtgctggata gtgacgggtc tttctttctg tacagtaagc tgactgtgga caagtcccgc 1321 tggcagcagg gtaacgtctt cagctgttcc gtgatgcacg aggcattgca caaccactac 1381 acccagaagt cactgagcct gagcccaggg aag

Protein Sequence Defining the Full Length Humanized Sh24C05 Hv3-23 Heavy Chain (Humanized Heavy Chain Variable Region and Human IgG1 Constant Region) (SEQ ID NO: 196)

  1 mdmrvpaqll gllllwlrga rcevqllesg gglvqpggsl rlscaasgft fsdyamswvr  61 qapgkglewv stisdggtyt yypdnvkgrf tisrdnsknt lylqmnslra edtavyycar 121 ewgdydgfdy wgqgtlvtvs sastkgpsvf plapssksts ggtaalgclv kdyfpepvtv 181 swnsgaltsg vhtfpavlqs sglyslssvv tvpssslgtq tyicnvnhkp sntkvdkrve 241 pkscdkthtc ppcpapellg gpsvflfppk pkdtlmisrt pevtcvvvdv shedpevkfn 301 wyvdgvevhn aktkpreeqy nstyrvvsvl tvlhqdwlng keykckvsnk alpapiekti 361 skakgqprep qvytlppsre emtknqvslt clvkgfypsd iavewesngq pennykttpp 421 vldsdgsffl yskltvdksr wqqgnvfscs vmhealhnhy tqkslslspg k

Nucleic Acid Sequence Encoding the Full Length Humanized Sh24C05 Hv3-30 Heavy Chain (Humanized Heavy Chain Variable Region and Human IgG1 Constant Region) (SEQ ID NO: 197)

   1 atggacatga gagttcctgc tcagctgctc gggttgctgt tgctttggct ccggggtgct   61 aggtgccagg ttcagctggt ggaatctggc ggtggggtag tacaaccagg acggtccctc  121 agactgagtt gtgccgcttc agggttcaca ttctccgact atgcgatgtc atgggtgcgc  181 caagcacccg ggaaaggact ggagtgggtt gccactatca gcgatggcgg aacgtatacc  241 tattaccctg acaatgtgaa gggtcggttc accatttcca gggataactc aaagaacacc  301 ctctatctcc aaatgagtag cctgagggct gaggacaccg ccgtctacta ctgcgcccga  361 gaatggggag attatgatgg gtttgactat tggggccagg gcactttggt gacagtcagt  421 tctgcctcaa caaaaggacc aagtgtgttc ccactcgccc ctagcagcaa gagtacatcc  481 gggggcactg cagcactcgg ctgcctcgtc aaggattatt ttccagagcc agtaaccgtg  541 agctggaaca gtggagcact cacttctggt gtccatactt ttcctgctgt cctgcaaagc  601 tctggcctgt actcactcag ctccgtcgtg accgtgccat cttcatctct gggcactcag  661 acctacatct gtaatgtaaa ccacaagcct agcaatacta aggtcgataa gcgggtggaa  721 cccaagagct gcgacaagac tcacacttgt cccccatgcc ctgcccctga acttctgggc  781 ggtcccagcg tctttttgtt cccaccaaag cctaaagata ctctgatgat aagtagaaca  841 cccgaggtga catgtgttgt tgtagacgtt tcccacgagg acccagaggt taagttcaac  901 tggtacgttg atggagtcga agtacataat gctaagacca agcctagaga ggagcagtat  961 aatagtacat accgtgtagt cagtgttctc acagtgctgc accaagactg gctcaacggc 1021 aaagaataca aatgcaaagt gtccaacaaa gcactcccag cccctatcga gaagactatt 1081 agtaaggcaa aggggcagcc tcgtgaacca caggtgtaca ctctgccacc cagtagagag 1141 gaaatgacaa agaaccaagt ctcattgacc tgcctggtga aaggcttcta ccccagcgac 1201 atcgccgttg agtgggagag taacggtcag cctgagaaca attacaagac aaccccccca 1261 gtgctggata gtgacgggtc tttctttctg tacagtaagc tgactgtgga caagtcccgc 1321 tggcagcagg gtaacgtctt cagctgttcc gtgatgcacg aggcattgca caaccactac 1381 acccagaagt cactgagcct gagcccaggg aag

Protein Sequence Defining the Full Length Humanized of Sh24C05 Hv3-30 Heavy Chain (Humanized Heavy Chain Variable Region and Human IgG1 Constant Region) (SEQ ID NO: 198)

  1 mdmrvpaqll gllllwlrga rcqvqlvesg ggvvqpgrsl rlscaasgft fsdyamswvr  61 qapgkglewv atisdggtyt yypdnvkgrf tisrdnsknt lylqmsslra edtavyycar 121 ewgdydgfdy wgqgtlvtvs sastkgpsvf plapssksts ggtaalgclv kdyfpepvtv 181 swnsgaltsg vhtfpavlqs sglyslssvv tvpssslgtq tyicnvnhkp sntkvdkrve 241 pkscdkthtc ppcpapellg gpsvflfppk pkdtlmisrt pevtcvvvdv shedpevkfn 301 wyvdgvevhn aktkpreeqy nstyrvvsvl tvlhqdwlng keykckvsnk alpapiekti 361 skakgqprep qvytlppsre emtknqvslt clvkgfypsd iavewesngq pennykttpp 421 vldsdgsffl yskltvdksr wqqgnvfscs vmhealhnhy tqkslslspg k

Nucleic Acid Sequence Encoding the Full Length Humanized Hu24C05 HvA Heavy Chain (Humanized Heavy Chain Variable Region and Human IgG1 Constant Region) (SEQ ID NO: 199)

   1 atggacatga gagttcctgc tcagctgctc gggttgctgt tgctttggct ccggggtgct   61 aggtgcgagg ttcagctggt ggaatctggc ggtgggcttg taaagccagg aggctccctc  121 agactgagtt gtgccgcttc agggttcaca ttctccgact atgcgatgtc atgggtgcgc  181 caagcacccg ggaaaggact ggagtgggtt gccactatca gcgatggcgg aacgtatacc  241 tattaccctg acaatgtgaa gggtcggttc accatttcca gggataacgc aaagaacagt  301 ctctaccttc agatgaacag cctgagggct gaggacaccg ccgtctacta ctgcgcccga  361 gaatggggag attatgatgg gtttgactat tggggccagg gcactttggt gacagtcagt  421 tctgcctcaa caaaaggacc aagtgtgttc ccactcgccc ctagcagcaa gagtacatcc  481 gggggcactg cagcactcgg ctgcctcgtc aaggattatt ttccagagcc agtaaccgtg  541 agctggaaca gtggagcact cacttctggt gtccatactt ttcctgctgt cctgcaaagc  601 tctggcctgt actcactcag ctccgtcgtg accgtgccat cttcatctct gggcactcag  661 acctacatct gtaatgtaaa ccacaagcct agcaatacta aggtcgataa gcgggtggaa  721 cccaagagct gcgacaagac tcacacttgt cccccatgcc ctgcccctga acttctgggc  781 ggtcccagcg tctttttgtt cccaccaaag cctaaagata ctctgatgat aagtagaaca  841 cccgaggtga catgtgttgt tgtagacgtt tcccacgagg acccagaggt taagttcaac  901 tggtacgttg atggagtcga agtacataat gctaagacca agcctagaga ggagcagtat  961 aatagtacat accgtgtagt cagtgttctc acagtgctgc accaagactg gctcaacggc 1021 aaagaataca aatgcaaagt gtccaacaaa gcactcccag cccctatcga gaagactatt 1081 agtaaggcaa aggggcagcc tcgtgaacca caggtgtaca ctctgccacc cagtagagag 1141 gaaatgacaa agaaccaagt ctcattgacc tgcctggtga aaggcttcta ccccagcgac 1201 atcgccgttg agtgggagag taacggtcag cctgagaaca attacaagac aaccccccca 1261 gtgctggata gtgacgggtc tttctttctg tacagtaagc tgactgtgga caagtcccgc 1321 tggcagcagg gtaacgtctt cagctgttcc gtgatgcacg aggcattgca caaccactac 1381 acccagaagt cactgagcct gagcccaggg aag

Protein Sequence Defining the Full Length Humanized Hu24C05 HvA Heavy Chain (Humanized Heavy Chain Variable Region and Human IgG1 Constant Region) (SEQ ID NO: 200)

  1 mdmrvpaqll gllllwlrga rcevqlvesg gglvkpggsl rlscaasgft fsdyamswvr  61 qapgkglewv atisdggtyt yypdnvkgrf tisrdnakns lylqmnslra edtavyycar 121 ewgdydgfdy wgqgtlvtvs sastkgpsvf plapssksts ggtaalgclv kdyfpepvtv 181 swnsgaltsg vhtfpavlqs sglyslssvv tvpssslgtq tyicnvnhkp sntkvdkrve 241 pkscdkthtc ppcpapellg gpsvflfppk pkdtlmisrt pevtcvvvdv shedpevkfn 301 wyvdgvevhn aktkpreeqy nstyrvvsvl tvlhqdwlng keykckvsnk alpapiekti 361 skakgqprep qvytlppsre emtknqvslt clvkgfypsd iavewesngq pennykttpp 421 vldsdgsffl yskltvdksr wqqgnvfscs vmhealhnhy tqkslslspg k

Nucleic Acid Sequence Encoding the Full Length Humanized Sh24C05 Kv1-9 Light Chain (Humanized Kappa Chain Variable Region and Human Constant Region) (SEQ ID NO: 201)

  1 atggacatga gggtgcccgc tcaactgctg gggctgctgc tgctgtggct gagaggagct  61 cgttgcgata ttcagttgac ccaatcacct agcttcctct cagcttccgt gggcgacaga 121 gttaccataa cctgtcgggc aagccaggag atttctgggt acctgtcctg gtaccaacag 181 aagcccggaa aagcccctaa gctgttgatc tatgctgcgt caaccttgga tagcggtgtc 241 ccgagtcgat tctccggttc tggctccgga acagagttca ctctgacaat ttctagcctt 301 cagccagaag atttcgccac gtactattgc ctccagtacg acagctatcc ctatacattt 361 gggcagggca ctaaactgga gatcaaacgc acagttgctg cccccagcgt gttcattttc 421 ccacctagcg atgagcagct gaaaagcggt actgcctctg tcgtatgctt gctcaacaac 481 ttttacccac gtgaggctaa ggtgcagtgg aaagtggata atgcacttca atctggaaac 541 agtcaagagt ccgtgacaga acaggacagc aaagactcaa cttattcact ctcttccacc 601 ctgactctgt ccaaggcaga ctatgaaaaa cacaaggtat acgcctgcga ggttacacac 661 cagggtttgt ctagtcctgt caccaagtcc ttcaataggg gcgaatgt

Protein Sequence Defining the Full Length Humanized Sh24C05 Kv1-9 Light Chain (Humanized Kappa Chain Variable Region and Human Constant Region) (SEQ ID NO: 202)

  1 mdmrvpaqll gllllwlrga rcdiqltqsp sflsasvgdr vtitcrasqe isgylswyqq  61 kpgkapklli yaastldsgv psrfsgsgsg teftltissl qpedfatyyc lqydsypytf 121 gqgtkleikr tvaapsvfif ppsdeqlksg tasvvcllnn fypreakvqw kvdnalqsgn 181 sqesvteqds kdstyslsst ltlskadyek hkvyacevth qglsspvtks fnrgec

Nucleic Acid Sequence Encoding the Full Length Humanized Sh24C05 Kv1-16 Light Chain (Humanized Kappa Chain Variable Region and Human Constant Region) (SEQ ID NO: 203)

  1 atggacatga gggtgcccgc tcaactgctg gggctgctgc tgctgtggct gagaggagct  61 cgttgcgata ttcagatgac ccaatcacct agcagtctct cagcttccgt gggcgacaga 121 gttaccataa cctgtcgggc aagccaggag atttctgggt acctgtcctg gtttcaacag 181 aagcccggaa aggccccgaa gagcttgatc tatgctgcgt caaccttgga tagcggtgtc 241 ccgagtcgat tctccggttc tggctccgga accgacttta ctctgacaat ttctagcctt 301 cagccagaag atttcgccac gtactattgc ctccagtacg acagctatcc ctatacattt 361 gggcagggca ctaaactgga gatcaaacgc acagttgctg cccccagcgt gttcattttc 421 ccacctagcg atgagcagct gaaaagcggt actgcctctg tcgtatgctt gctcaacaac 481 ttttacccac gtgaggctaa ggtgcagtgg aaagtggata atgcacttca atctggaaac 541 agtcaagagt ccgtgacaga acaggacagc aaagactcaa cttattcact ctcttccacc 601 ctgactctgt ccaaggcaga ctatgaaaaa cacaaggtat acgcctgcga ggttacacac 661 cagggtttgt ctagtcctgt caccaagtcc ttcaataggg gcgaatgt

Protein Sequence Defining the Full Length Humanized Sh24C05 Kv1-16 Light Chain (Humanized Kappa Chain Variable Region and Human Constant Region) (SEQ ID NO: 204)

  1 mdmrvpaqll gllllwlrga rcdiqmtqsp sslsasvgdr vtitcrasqe isgylswfqq  61 kpgkapksli yaastldsgv psrfsgsgsg tdftltissl qpedfatyyc lqydsypytf 121 gqgtkleikr tvaapsvfif ppsdeqlksg tasvvcllnn fypreakvqw kvdnalqsgn 181 sqesvteqds kdstyslsst ltlskadyek hkvyacevth qglsspvtks fnrgec

Nucleic Acid Sequence Encoding the Full Length Humanized Sh24C05 Kv1-17 Light Chain (Humanized Kappa Chain Variable Region and Human Constant Region) (SEQ ID NO: 205)

  1 atggacatga gggtgcccgc tcaactgctg gggctgctgc tgctgtggct gagaggagct  61 cgttgcgata ttcagatgac ccaatcacct agcagtctct cagcttccgt gggcgacaga 121 gttaccataa cctgtcgggc aagccaggag atttctgggt acctgtcctg gtatcaacag 181 aagcccggaa aagccccaaa gaggttgatc tatgctgcgt caaccttgga tagcggtgtc 241 ccgagtcgat tctccggttc tggctccgga accgagttca ctctgacaat ttctagcctt 301 cagccagaag atttcgccac gtactattgc ctccagtacg acagctatcc ctatacattt 361 gggcagggca ctaaactgga gatcaaacgc acagttgctg cccccagcgt gttcattttc 421 ccacctagcg atgagcagct gaaaagcggt actgcctctg tcgtatgctt gctcaacaac 481 ttttacccac gtgaggctaa ggtgcagtgg aaagtggata atgcacttca atctggaaac 541 agtcaagagt ccgtgacaga acaggacagc aaagactcaa cttattcact ctcttccacc 601 ctgactctgt ccaaggcaga ctatgaaaaa cacaaggtat acgcctgcga ggttacacac 661 cagggtttgt ctagtcctgt caccaagtcc ttcaataggg gcgaatgt

Protein Sequence Defining the Full Length Humanized Sh24C05 Kv1-17 Light Chain (Humanized Kappa Chain Variable Region and Human Constant Region) (SEQ ID NO: 206)

  1 mdmrvpaqll gllllwlrga rcdiqmtqsp sslsasvgdr vtitcrasqe isgylswyqq  61 kpgkapkrli yaastldsgv psrfsgsgsg teftltissl qpedfatyyc lqydsypytf 121 gqgtkleikr tvaapsvfif ppsdeqlksg tasvvcllnn fypreakvqw kvdnalqsgn 181 sqesvteqds kdstyslsst ltlskadyek hkvyacevth qglsspvtks fnrgec

Nucleic Acid Sequence Encoding the Full Length Humanized sh24C05 Kv1-33 Light Chain (Humanized Kappa Chain Variable Region and Human Constant Region) (SEQ ID NO: 207)

  1 atggacatga gggtgcccgc tcaactgctg gggctgctgc tgctgtggct gagaggagct  61 cgttgcgata ttcagatgac ccaatcacct agcagtctct cagcttccgt gggcgacaga 121 gttaccataa cctgtcgggc aagccaggag atttctgggt acctgtcctg gtaccaacag 181 aagcccggaa aggcccccaa gctgttgatc tatgctgcgt caaccttgga tagcggtgtc 241 ccgagtcgat tctccggttc tggctccgga acagacttta cttttacaat ttctagcctt 301 cagccagagg acatcgccac gtactattgc ctccagtacg acagctatcc ctatacattt 361 gggcagggca ctaaactgga gatcaaacgc acagttgctg cccccagcgt gttcattttc 421 ccacctagcg atgagcagct gaaaagcggt actgcctctg tcgtatgctt gctcaacaac 481 ttttacccac gtgaggctaa ggtgcagtgg aaagtggata atgcacttca atctggaaac 541 agtcaagagt ccgtgacaga acaggacagc aaagactcaa cttattcact ctcttccacc 601 ctgactctgt ccaaggcaga ctatgaaaaa cacaaggtat acgcctgcga ggttacacac 661 cagggtttgt ctagtcctgt caccaagtcc ttcaataggg gcgaatgt

Protein Sequence Defining the Full Length Humanized Sh24C05 Kv1-33 Light Chain (Humanized Kappa Chain Variable Region and Human Constant Region) (SEQ ID NO: 208)

  1 mdmrvpaqll gllllwlrga rcdiqmtqsp sslsasvgdr vtitcrasqe isgylswyqq  61 kpgkapklli yaastldsgv psrfsgsgsg tdftftissl qpediatyyc lqydsypytf 121 gqgtkleikr tvaapsvfif ppsdeqlksg tasvvcllnn fypreakvqw kvdnalqsgn 181 sqesvteqds kdstyslsst ltlskadyek hkvyacevth qglsspvtks fnrgec

Nucleic Acid Sequence Encoding the Full Length Humanzied Sh24C05 Kv1-39 Light Chain (Humanized Kappa Chain Variable Region and Human Constant Region) (SEQ ID NO: 209)

  1 atggacatga gggtgcccgc tcaactgctg gggctgctgc tgctgtggct gagaggagct  61 cgttgcgata ttcagatgac ccaatcacct agcagtctct cagcttccgt gggcgacaga 121 gttaccataa cctgtcgggc aagccaggag atttctgggt acctgtcctg gtatcaacag 181 aagcccggaa aagcccctaa gctgttgatc tatgctgcgt caaccttgga tagcggtgtc 241 ccgagtcgat tctccggttc tggctccgga actgacttca ctctgacaat ttctagcctt 301 cagccagaag atttcgccac gtactattgc ctccagtacg acagctatcc ctatacattt 361 gggcagggca ctaaactgga gatcaaacgc acagttgctg cccccagcgt gttcattttc 421 ccacctagcg atgagcagct gaaaagcggt actgcctctg tcgtatgctt gctcaacaac 481 ttttacccac gtgaggctaa ggtgcagtgg aaagtggata atgcacttca atctggaaac 541 agtcaagagt ccgtgacaga acaggacagc aaagactcaa cttattcact ctcttccacc 601 ctgactctgt ccaaggcaga ctatgaaaaa cacaaggtat acgcctgcga ggttacacac 661 cagggtttgt ctagtcctgt caccaagtcc ttcaataggg gcgaatgt

Protein Sequence Defining the Full Length Humanized Sh24C05 Kv1-39 Light Chain (Humanized Kappa Chain Variable Region and Human Constant Region) (SEQ ID NO: 210)

  1 mdmrvpaqll gllllwlrga rcdiqmtqsp sslsasvgdr vtitcrasqe isgylswyqq  61 kpgkapklli yaastldsgv psrfsgsgsg tdftltissl qpedfatyyc lqydsypytf 121 gqgtkleikr tvaapsvfif ppsdeqlksg tasvvcllnn fypreakvqw kvdnalqsgn 181 sqesvteqds kdstyslsst ltlskadyek hkvyacevth qglsspvtks fnrgec

Nucleic Acid Sequence Encoding the Full Length Humanized Hu24C05 KvA Light Chain (Humanized Kappa Chain Variable Region and Human Constant Region) (SEQ ID NO: 211)

  1 atggacatga gggtgcccgc tcaactgctg gggctgctgc tgctgtggct gagaggagct  61 cgttgcgata ttcagatgac ccaatcacct agcagtctct cagcttccgt gggcgacaga 121 gttaccataa cctgtcgggc aagccaggag atttctgggt acctgtcctg gctgcaacag 181 aagcccggag gcgccatcaa gaggttgatc tatgctgcgt caaccttgga tagcggtgtc 241 ccgagtcgat tctccggttc tggctccgga agtgactaca ctctgacaat ttctagcctt 301 cagccagaag atttcgccac gtactattgc ctccagtacg acagctatcc ctatacattt 361 gggcagggca ctaaactgga gatcaaacgc acagttgctg cccccagcgt gttcattttc 421 ccacctagcg atgagcagct gaaaagcggt actgcctctg tcgtatgctt gctcaacaac 481 ttttacccac gtgaggctaa ggtgcagtgg aaagtggata atgcacttca atctggaaac 541 agtcaagagt ccgtgacaga acaggacagc aaagactcaa cttattcact ctcttccacc 601 ctgactctgt ccaaggcaga ctatgaaaaa cacaaggtat acgcctgcga ggttacacac 661 cagggtttgt ctagtcctgt caccaagtcc ttcaataggg gcgaatgt

Protein Sequence Defining the Full Length Humanized Hu24C05 KvA Light Chain (Humanized Kappa Chain Variable Region and Human Constant Region) (SEQ ID NO: 212)

  1 mdmrvpaqll gllllwlrga rcdiqmtqsp sslsasvgdr vtitcrasqe isgylswlqq  61 kpggaikrli yaastldsgv psrfsgsgsg sdytltissl qpedfatyyc lqydsypytf 121 gqgtkleikr tvaapsvfif ppsdeqlksg tasvvcllnn fypreakvqw kvdnalqsgn 181 sqesvteqds kdstyslsst ltlskadyek hkvyacevth qglsspvtks fnrgec

For convenience, Table 13 provides a concordance chart showing the SEQ ID NO. of each sequence discussed in this Example.

TABLE 13 SEQ ID NO. Nucleic Acid or Protein 175 Human IgG1 constant-nucleic acid 176 Human IgG1 constant-protein 177 Human IgG2 constant-nucleic acid 178 Human IgG2 constant-protein 179 Human Kappa constant-nucleic acid 180 Human Kappa constant-protein 181 Chimeric 24C05 Mouse Heavy Chain Variable + Human IgG1 constant-nucleic acid 182 Chimeric 24C05 Mouse Heavy Chain Variable + Human IgG1 constant-protein 183 Chimeric 24C05 Mouse Light Chain Variable + Human Kappa constant-nucleic acid 184 Chimeric 24C05 Mouse Light Chain Variable + Human Kappa constant-protein 185 Humanized Sh24C05 Hv3-7 Heavy Human Variable + Human IgG1 constant- nucleic acid 186 Humanized Sh24C05 Hv3-7 Heavy Human Variable + Human IgG1 constant- protein 187 Humanized Sh24C05 Hv3-11 Heavy Human Variable + Human IgG1 constant- nucleic acid 188 Humanized Sh24C05 Hv3-11 Heavy Human Variable + Human IgG1 constant- protein 189 Humanized Sh24C05 Hv3-11 N62S IgG1 Heavy Human Variable + Human IgG1 constant-nucleic acid 190 Humanized Sh24C05 Hv3-11 N62S IgG1 Heavy Human Variable + Human IgG1 constant-protein 191 Humanized Sh24C05 Hv3-11 N62S IgG2 Heavy Human Variable + Human IgG2 constant-nucleic acid 192 Humanized Sh24C05 Hv3-11 N62S IgG2 Heavy Human Variable + Human IgG2 constant-protein 193 Humanized Sh24C05 Hv3-21Heavy Human Variable + Human IgG1 constant- nucleic acid 194 Humanized Sh24C05 Hv3-21 Heavy Human Variable + Human IgG1 constant- protein 195 Humanized Sh24C05 Hv3-23 Heavy Human Variable + Human IgG1 constant- nucleic acid 196 Humanized Sh24C05 Hv3-23 Heavy Human Variable + Human IgG1 constant- protein 197 Humanized Sh24C05 Hv3-30 Heavy Human Variable + Human IgG1 constant- nucleic acid 198 Humanized Sh24C05 Hv3-30 Heavy Human Variable + Human IgG1 constant- protein 199 Humanized Hu24C05 HvA Heavy Human Variable + Human IgG1 constant-nucleic acid 200 Humanized Hu24C05 HvA Heavy Human Variable + Human IgG1 constant-protein 201 Humanized Sh24C05 Kv1-9 Human Variable + Human Kappa constant-nucleic acid 202 Humanized Sh24C05 Kv1-9 Human Variable + Human Kappa constant-protein 203 Humanized Sh24C05 Kv1-16 Human Variable + Human Kappa constant-nucleic acid 204 Humanized Sh24C05 Kv1-16 Human Variable + Human Kappa constant-protein 205 Humanized Sh24C05 Kv1-17 Human Variable + Human Kappa constant-nucleic acid 206 Humanized Sh24C05 Kv1-17 Human Variable + Human Kappa constant-protein 207 Humanized Sh24C05 Kv1-33 Human Variable + Human Kappa constant-nucleic acid 208 Humanized Sh24C05 Kv1-33 Human Variable + Human Kappa constant-protein 209 Humanized Sh24C05 Kv1-39 Human Variable + Human Kappa constant-nucleic acid 210 Humanized Sh24C05 Kv1-39 Human Variable + Human Kappa constant-protein 211 Humanized Hu24C05 KvA Human Variable + Human Kappa constant-nucleic acid 212 Humanized Hu24C05 KvA Human Variable + Human Kappa constant-protein

Table 14 below shows antibodies containing chimeric immunoglobulin heavy and light chains and each of the possible combinations of the full-length humanized immunoglobulin heavy and light chains.

TABLE 14 Antibody Name Light Chain Heavy Chain Sh24C05-1 24C05 Chimeric Kappa GP203 24C05 Chimeric Heavy (SEQ ID NO: 184) IgG1 (SEQ ID NO: 182) Sh24C05-14 Hu24C05 KvA Kappa Hu24C05 HvA IgG1 (SEQ ID NO: 212) (SEQ ID NO: 200) Sh24C05-15 Hu24C05 KvA Kappa Sh24C05 Hv3-21 Heavy IgG1 (SEQ ID NO: 212) (SEQ ID NO: 194) Sh24C05-16 Hu24C05 KvA Kappa Sh24C05 Hv3-23 Heavy IgG1 (SEQ ID NO: 212) (SEQ ID NO: 196) Sh24C05-17 Hu24C05 KvA Kappa Sh24C05 Hv3-30 Heavy IgG1 (SEQ ID NO: 212) (SEQ ID NO: 198) Sh24C05-18 Hu24C05 KvA Kappa Sh24C05 Hv3-7 Heavy IgG1 (SEQ ID NO: 212) (SEQ ID NO: 186) Sh24C05-19 Hu24C05 KvA Kappa Sh24C05 Hv3-11 Heavy IgG1 (SEQ ID NO: 212) (SEQ ID NO: 188) Sh24C05-19 Hu24C05 KvA Kappa Sh24C05 Hv3-11 N62S Heavy N62S IgG1 (SEQ ID NO: 212) IgG1 (SEQ ID NO: 190) Sh24C05-19 Hu24C05 KvA Kappa Sh24C05 Hv3-11 N62S Heavy N62S IgG2 (SEQ ID NO: 212) IgG2 (SEQ ID NO: 192) Sh24C05-20 Sh24C05 Kv1-16 Kappa Hu24C05 HvA IgG1 (SEQ ID NO: 204) (SEQ ID NO: 200) Sh24C05-21 Sh24C05 Kv1-16 Kappa Sh24C05 Hv3-21 Heavy IgG1 (SEQ ID NO: 204) (SEQ ID NO: 194) Sh24C05-22 Sh24C05 Kv1-16 Kappa Sh24C05 Hv3-23 Heavy IgG1 (SEQ ID NO: 204) (SEQ ID NO: 196) Sh24C05-23 Sh24C05 Kv1-16 Kappa Sh24C05 Hv3-30 Heavy IgG1 (SEQ ID NO: 204) (SEQ ID NO: 198) Sh24C05-24 Sh24C05 Kv1-16 Kappa Sh24C05 Hv3-7 Heavy IgG1 (SEQ ID NO: 204) (SEQ ID NO: 186) Sh24C05-25 Sh24C05 Kv1-16 Kappa Sh24C05 Hv3-11 Heavy IgG1 (SEQ ID NO: 204) (SEQ ID NO: 188) Sh24C05-25 Sh24C05 Kv1-16 Kappa Sh24C05 Hv3-11 N62S Heavy N62S IgG1 (SEQ ID NO: 204) IgG1 (SEQ ID NO: 190) Sh24C05-25 Sh24C05 Kv1-16 Kappa Sh24C05 Hv3-11 N62S Heavy N62S IgG2 (SEQ ID NO: 204) IgG2 (SEQ ID NO: 192) Sh24C05-26 Sh24C05 Kv1-17 Kappa Hu24C05 HvA IgG1 (SEQ ID NO: 206) (SEQ ID NO: 200) Sh24C05-27 Sh24C05 Kv1-17 Kappa Sh24C05 Hv3-21 Heavy IgG1 (SEQ ID NO: 206) (SEQ ID NO: 194) Sh24C05-28 Sh24C05 Kv1-17 Kappa Sh24C05 Hv3-23 Heavy IgG1 (SEQ ID NO: 206) (SEQ ID NO: 196) Sh24C05-29 Sh24C05 Kv1-17 Kappa Sh24C05 Hv3-30 Heavy IgG1 (SEQ ID NO: 206) (SEQ ID NO: 198) Sh24C05-30 Sh24C05 Kv1-17 Kappa Sh24C05 Hv3-7 Heavy IgG1 (SEQ ID NO: 206) (SEQ ID NO: 186) Sh24C05-31 Sh24C05 Kv1-17 Kappa Sh24C05 Hv3-11 Heavy IgG1 (SEQ ID NO: 206) (SEQ ID NO: 188) Sh24C05-31 Sh24C05 Kv1-17 Kappa Sh24C05 Hv3-11 N62S Heavy N62S IgG1 (SEQ ID NO: 206) IgG1 (SEQ ID NO: 190) Sh24C05-31 Sh24C05 Kv1-17 Kappa Sh24C05 Hv3-11 N62S Heavy N62S IgG2 (SEQ ID NO: 206) IgG2 (SEQ ID NO: 192) Sh24C05-32 Sh24C05 Kv1-33 Kappa Hu24C05 HvA IgG1 (SEQ ID NO: 208) (SEQ ID NO: 200) Sh24C05-33 Sh24C05 Kv1-33 Kappa Sh24C05 Hv3-21 Heavy IgG1 (SEQ ID NO: 208) (SEQ ID NO: 194) Sh24C05-34 Sh24C05 Kv1-33 Kappa Sh24C05 Hv3-23 Heavy IgG1 (SEQ ID NO: 208) (SEQ ID NO: 196) Sh24C05-35 Sh24C05 Kv1-33 Kappa Sh24C05 Hv3-30 Heavy IgG1 (SEQ ID NO: 208) (SEQ ID NO: 198) Sh24C05-36 Sh24C05 Kv1-33 Kappa Sh24C05 Hv3-7 Heavy IgG1 (SEQ ID NO: 208) (SEQ ID NO: 186) Sh24C05-37 Sh24C05 Kv1-33 Kappa Sh24C05 Hv3-11 Heavy IgG1 (SEQ ID NO: 208) (SEQ ID NO: 188) Sh24C05-37 Sh24C05 Kv1-33 Kappa Sh24C05 Hv3-11 N62S Heavy N62S IgG1 (SEQ ID NO: 208) IgG1 (SEQ ID NO: 190) Sh24C05-37 Sh24C05 Kv1-33 Kappa Sh24C05 Hv3-11 N62S Heavy N62S IgG2 (SEQ ID NO: 208) IgG2 (SEQ ID NO: 192) Sh24C05-38 Sh24C05 Kv1-9 Kappa Hu24C05 HvA IgG1 (SEQ ID NO: 202) (SEQ ID NO: 200) Sh24C05-39 Sh24C05 Kv1-9 Kappa Sh24C05 Hv3-21 Heavy IgG1 (SEQ ID NO: 202) (SEQ ID NO: 194) Sh24C05-40 Sh24C05 Kv1-9 Kappa Sh24C05 Hv3-23 Heavy IgG1 (SEQ ID NO: 202) (SEQ ID NO: 196) Sh24C05-41 Sh24C05 Kv1-9 Kappa Sh24C05 Hv3-30 Heavy IgG1 (SEQ ID NO: 202) (SEQ ID NO: 198) Sh24C05-42 Sh24C05 Kv1-9 Kappa Sh24C05 Hv3-7 Heavy IgG1 (SEQ ID NO: 202) (SEQ ID NO: 186) Sh24C05-43 Sh24C05 Kv1-9 Kappa Sh24C05 Hv3-11 Heavy IgG1 (SEQ ID NO: 202) (SEQ ID NO: 188) Sh24C05-43 Sh24C05 Kv1-9 Kappa Sh24C05 Hv3-11 N62S Heavy N62S IgG1 (SEQ ID NO: 202) IgG1 (SEQ ID NO: 190) Sh24C05-43 Sh24C05 Kv1-9 Kappa Sh24C05 Hv3-11 N62SHeavy N62S IgG2 (SEQ ID NO: 202) IgG2 (SEQ ID NO: 192) Sh24C05-44 Sh24C05 Kv1-39 Kappa Hu24C05 HvA IgG1 (SEQ ID NO: 210) (SEQ ID NO: 200) Sh24C05-45 Sh24C05 Kv1-39 Kappa Sh24C05 Hv3-21 Heavy IgG1 (SEQ ID NO: 210) (SEQ ID NO: 194) Sh24C05-46 Sh24C05 Kv1-39 Kappa Sh24C05 Hv3-23 Heavy IgG1 (SEQ ID NO: 210) (SEQ ID NO: 196) Sh24C05-47 Sh24C05 Kv1-39 Kappa Sh24C05 Hv3-30 Heavy IgG1 (SEQ ID NO: 210) (SEQ ID NO: 198) Sh24C05-48 Sh24C05 Kv1-39 Kappa Sh24C05 Hv3-7 Heavy IgG1 (SEQ ID NO: 210) (SEQ ID NO: 186) Sh24C05-49 Sh24C05 Kv1-39 Kappa Sh24C05 Hv3-11 Heavy IgG1 (SEQ ID NO: 210) (SEQ ID NO: 188) Sh24C05-49 Sh24C05 Kv1-39 Kappa Sh24C05 Hv3-11 N62S Heavy N62S IgG1 (SEQ ID NO: 210) IgG1 (SEQ ID NO: 190) Sh24C05-49 Sh24C05 Kv1-39 Kappa Sh24C05 Hv3-11 N62S Heavy N62S IgG2 (SEQ ID NO: 210) IgG2 (SEQ ID NO: 192)

The antibody construct containing the full length chimeric heavy and light chains is designated below:

-   -   Chimeric 24C05=Full Length Chimeric 24C05 Heavy Chain (Mouse         Variable Region and Human IgG1 Constant Region) (SEQ ID NO: 182)         plus Full Length Chimeric 24C05 Light Chain (Mouse Variable         Region and Human Kappa Constant Region) (SEQ ID NO: 184)

Four of the possible antibody constructs containing the full length immunoglobulin heavy and light chains containing humanized variable regions are designated below:

-   -   Sh24C05-25 N62S IgG1=Humanized Sh24C05 Hv3-11 N62S Heavy Chain         Variable Region and Human IgG1 Constant Region (SEQ ID NO: 190)         plus Sh24C05 Kv1-16 Light Chain Variable Region and Human Kappa         Constant Region (SEQ ID NO: 204)     -   Sh24C05-25 N62S IgG2=Humanized Sh24C05 Hv3-11 N62S Heavy Chain         Variable Region and Human IgG2 Constant Region (SEQ ID NO: 192)         plus Sh24C05 Kv1-16 Light Chain Variable Region and Human Kappa         Constant Region (SEQ ID NO: 204)     -   Sh24C05-31 N62S IgG1=Humanized Sh24C05 Hv3-11 N62S Heavy Chain         Variable Region and Human IgG1 Constant Region (SEQ ID NO: 190)         plus Sh24C05 Kv1-17 Light Chain Variable Region and Human Kappa         Constant Region (SEQ ID NO: 206)

Sh24C05-31 N62S IgG2=Humanized Sh24C05 Hv3-11 N62S Heavy Chain Variable Region and Human IgG2 Constant Region (SEQ ID NO: 192) plus Sh24C05 Kv1-17 Light Chain Variable Region and Human Kappa Constant Region (SEQ ID NO: 206)

B. Binding Affinities of Humanized and Chimeric Anti-ErbB3 Monoclonal Antibodies

The binding affinities and kinetics of interaction of monoclonal antibodies produced in Example 12 against recombinant human ErbB3 monomeric protein (cleaved rhErbB3) were measured by surface plasmon resonance using a Biacore® T100 (Biacore) instrument. Monomeric ErbB3 was obtained by protease cleavage of rhErbB3-Fc (R&D Systems, Cat. No. 348-RB).

Goat anti-human IgG Fc (Jackson ImmunoResearch, Catalog No. 109-005-098) was immobilized on carboxymethylated dextran CM4 sensor chips (Biacore, Catalog No. BR-1005-34) by amine coupling (Biacore, Catalog No. BR-1000-50) using a standard coupling protocol according to the vendor's instructions. The analyses were performed at 37° C. using PBS (Invitrogen, Catalog No. 14040-133) containing 0.05% surfactant P20 (Biacore, Catalog No. BR-1000-54) as running buffer.

The antibodies were captured in individual flow cells at a flow rate of 60 μl/minute. Injection time was varied for each antibody to yield an R_(max) between 30 and 60 RU. Buffer or cleaved rhErbB3 diluted in running buffer was injected sequentially over a reference surface (no antibody captured) and the active surface (antibody to be tested) for 300 seconds at 60 μl/minute. The dissociation phase was monitored for up to 1200 seconds. The surface was then regenerated with two 60 second injections of Glycine pH 2.25 (made from Glycine pH 2.0 (Biacore, Catalog No. BR-1003-55) and pH 2.5 (Biacore, Catalog No. BR-1003-56)) at 60 μl/minute. For the initial screening, only one or two concentrations of cleaved rhErbB3 were tested, typically 5.0 and 1.25 nM (results are summarized in Table 15).

Kinetic parameters were determined using the kinetic function of the BIAevaluation software (Biacore) with double reference subtraction. Kinetic parameters for each antibody, k_(a) (association rate constant), k_(d) (dissociation rate constant) and K_(D) (equilibrium dissociation constant) were determined. The initial monoclonal antibodies were screened using cell culture media supernatant containing secreted antibody, and kinetic values of the monoclonal antibodies on cleaved rhErbB3 at 37° C. are summarized in Table 15.

TABLE 15 Antibody k_(a) (1/Ms) k_(d) (1/s) K_(D) (M) n Sh24C05-1 2.52E+06 4.48E−04 1.78E−10 3 Sh24C05-14 2.88E+06 4.98E−04 1.73E−10 2 Sh24C05-15 2.67E+06 4.99E−04 1.87E−10 2 Sh24C05-16 2.75E+06 4.04E−04 1.47E−10 2 Sh24C05-17 2.79E+06 4.17E−04 1.50E−10 2 Sh24C05-18 2.88E+06 4.63E−04 1.61E−10 2 Sh24C05-19 3.00E+06 2.55E−04 8.55E−11 2 Sh24C05-20 2.67E+06 5.91E−04 2.21E−10 2 Sh24C05-21 3.11E+06 6.62E−04 2.20E−10 2 Sh24C05-22 2.79E+06 6.01E−04 2.16E−10 2 Sh24C05-23 2.79E+06 7.21E−04 2.63E−10 2 Sh24C05-24 2.90E+06 6.28E−04 2.18E−10 2 Sh24C05-25 2.63E+06 4.59E−04 1.75E−10 2 Sh24C05-26 3.36E+06 7.39E−04 2.20E−10 2 Sh24C05-27 3.34E+06 7.98E−04 2.40E−10 2 Sh24C05-28 3.26E+06 6.14E−04 1.89E−10 2 Sh24C05-29 3.25E+06 5.88E−04 1.82E−10 2 Sh24C05-30 4.48E+06 7.87E−04 1.90E−10 2 Sh24C05-31 3.47E+06 2.92E−04 8.65E−11 2 Sh24C05-32 9.98E+06 6.02E−03 6.03E−10 1 Sh24C05-33 4.02E+06 4.33E−03 1.08E−09 1 Sh24C05-34 1.09E+07 6.00E−03 5.52E−10 1 Sh24C05-35 8.44E+06 5.53E−03 6.55E−10 1 Sh24C05-36 5.18E+06 4.34E−03 8.37E−10 1 Sh24C05-37 5.94E+06 2.00E−03 3.74E−10 2 Sh24C05-38 2.71E+07 1.54E−02 5.67E−10 1 Sh24C05-39 1.18E+07 9.67E−03 8.19E−10 1 Sh24C05-40 2.11E+07 1.06E−02 5.03E−10 1 Sh24C05-41 1.81E+07 1.21E−02 6.69E−10 1 Sh24C05-42 7.35E+06 6.82E−03 9.27E−10 1 Sh24C05-43 6.16E+06 3.58E−03 5.82E−10 1 Sh24C05-44 7.96E+06 5.12E−03 6.44E−10 1 Sh24C05-45 8.57E+06 6.06E−03 7.07E−10 1 Sh24C05-46 7.99E+06 4.40E−03 5.51E−10 1 Sh24C05-47 7.98E+06 4.41E−03 5.53E−10 1 Sh24C05-48 8.72E+06 4.90E−03 5.62E−10 1 Sh24C05-49 4.08E+06 1.70E−03 4.16E−10 2

The results in Table 15 demonstrate that the chimeric and each of the humanized 24C05 antibodies have fast association rates (k_(a)), very slow disassociation rates (10 and very high affinities (K_(D)). In particular, the antibodies have affinities ranging from about 87 pM to about 1 nM.

The binding affinities and kinetics of certain purified monoclonal antibodies were also determined. To further characterize certain antibodies, the surface plasmon resonance experiments described above were conducted using concentrations of cleaved rhErbB3 between 0.3125 nM and 5.0 nM (a 2-fold serial dilution).

The kinetic values of certain purified monoclonal antibodies (i.e., Sh24C05-1, Sh24C05-25, Sh24C05-25 N62S IgG1, Sh24C05-25 N62S IgG2, Sh24C05-31, Sh24C05-31 N62S IgG1, and Sh24C05-31 N62S IgG2) on cleaved rhErbB3 at 37° C. are summarized in Table 16.

TABLE 16 Antibody k_(a) (1/Ms) k_(d) (1/s) K_(D) (M) n Sh24C05-1 3.5E+06 4.4E−04 1.4E−10 3 Sh24C05-25 4.0E+06 5.0E−04 1.3E−10 4 Sh24C05-25 N62S 2.9E+06 4.5E−04 1.6E−10 4 IgG1 Sh24C05-25 N62S 2.7E+06 3.4E−04 1.2E−10 4 IgG2 Sh24C05-31 4.7E+06 2.8E−04 6.3E−11 3 Sh24C05-31 N62S 3.5E+06 2.7E−04 7.6E−11 6 IgG1 Sh24C05-31 N62S 3.2E+06 2.4E−04 7.4E−11 3 IgG2

The results in Table 16 demonstrate the purified antibodies have a have affinities ranging from about 63 pM to about 160 pM when tested at 37° C.

C. Comparison of Other Anti-ErbB3 Antibodies

Three human antibodies that inhibit the function of human ErbB3 were constructed and expressed using published information. One antibody, referred to as Ab #6, was constructed as a human IgG2/Lambda antibody based the disclosure of Schoeberl et al., US 2009/0291085 (Merrimack Pharmaceuticals, Inc.). Two additional antibodies, referred to as U1-53 and U1-59, were constructed as human IgG1/Kappa antibodies based on the disclosure of Rothe et al., US 2008/0124345 (U3 Pharma AG and Amgen, Inc.).

Kinetic parameters for the Ab #6, U1-53, and U1-59 antibodies were determined by Biacore at 37° C. using cleaved rhErbB3 (monomer) as described above (See Section B. Binding Affinities of Humanized and Chimeric Anti-ErbB3 Monoclonal Antibodies). Both Biacore sensorgrams (FIG. 17) and kinetic values (Table 17) are displayed for each antibody.

TABLE 17 Antibody k_(a) (1/Ms) k_(d) (1/s) K_(D) (M) n Sh24C05-31 N62S  3.5+06 2.7E−04 7.6E−11 6 IgG1 Ab#6 9.3E+05 1.9E−04 2.3E−10 3 U1-59 1.8E+06 9.4E−04 5.3E−10 3 U1-53 — — — —

The results in Table 17 demonstrate that the overall equilibrium dissociation constant (K_(D)) for the Sh24C05-31 N62S IgG1 (76 pM) was smaller (i.e., higher affinity) than the K_(D) for the Ab #6 and U1-59 antibodies (230 pM (p<0.01) and 530 pM (p<0.0005), respectively). The equilibrium dissociation constant (K_(D)) for U1-53 could not determined because of poor curve fits (see FIG. 17, which shows a fast K_(off) rate of U1-53). The K_(D) of Ab #6, U1-53, and U1-59 antibodies can also be compared with other humanized 24C05 variants by comparing Tables 16 and 17.

Therefore, the affinity for Sh24C05-31 N62S IgG1 is significantly higher than the affinity of Ab #6 and U1-59 as disclosed herein.

Example 13—Neutralization Activity of the Humanized Anti-ErbB3 Antibodies

In this example, the humanized antibodies produced in Example 12 were tested for their ability to inhibit rhErbB3 binding to NRG1-β1 by ECL assay. Multi-array 96-well standard binding plates (Meso Scale Discovery, Cat. No. L15XA-3) were coated with 50 μl of 0.5 μg/mL rhErbB3/Fc (R&D systems, Cat. No. 348-RB) in PBS (Invitrogen, Cat. No. 14040-133) for one hour at room temperature with no agitation. The plates then were washed three times with PBS+0.1% Tween20 (Sigma P5927) and blocked with 200 μl of 100% Horse Serum, heat inactivated (GIBCO, Cat. No. 26050-088) for 1.5 hours at room temperature. After washing the plates three times with PBS+0.1% Tween, 25 μl of the antibody dilutions were added to the plates for another hour at room temperature with agitation. Ligand NRG1-β1 (R&D Systems, Cat. No. 377-HB, 26 kDa) was added to the wells at a final concentration of 0.25 μg/ml. The plates were washed three times with PBS+0.1% Tween and incubated with 25 μl of 1 μg/mL biotinylated antibody against human NRG1-131 (R&D systems, Cat. No BAF377) preincubated for one hour with SULTO-TAG Streptavidin (Meso Scale Discovery, Cat. No R32AD-5) for one hour at room temperature with agitation. The plates then were washed three times with PBS+0.1% Tween, and 150 μl of 1× read buffer (Meso Scale Discovery, Cat. No. R92TC-1) was added to each well before the plates were analyzed on a Sector® Imager 2400 (Meso Scale Discovery) instrument.

The interaction of NRG1-β1 with rhErbB3 was inhibited by antibodies Sh24C05-25 N62S-IgG1, Sh24C05-25 N62S-IgG2, Sh24C05-31 N62S-IgG1, and Sh24C05-31 N62S-IgG2 (FIG. 18A). The Ab #6 IgG2 antibody as described in Schoeberl et al. (supra) and the U1-53 and U1-59 antibodies as described in Rothe et al. (supra) were also tested for their ability to inhibit ErbB3 binding to NRG1-β1. As shown in FIG. 18B, each of the Ab #6 IgG2, U1-53, and U1-59 antibodies inhibited ErbB3 binding to NRG1-β1.

The IC₅₀ values for neutralization of NRG1-β1 binding to hErbB3 for the humanized 24C05 antibodies (i.e., Sh24C05-25 N62S-IgG1, Sh24C05-25 N62S-IgG2, Sh24C05-31 N62S-IgG1, and Sh24C05-31 N62S-IgG2) were calculated and are summarized in Table 18. The IC₅₀ values for the NRG1-β1 neutralization activity of the anti-ErbB3 human antibodies Ab #6 IgG2, U1-53 and U1-59 are also shown in Table 18.

TABLE 18 IC50 (nM) Antibody Average Standard Deviation n Sh24C05-25 N62S-IgG1 0.1219 0.0173 4 Sh24C05-25 N62S-IgG2 0.1117 0.0154 4 Sh24C05-31 N62S-IgG1 0.1242 0.0391 5 Sh24C05-31 N62S-IgG2 0.0860 0.0588 4 U1-53 0.1128 0.0615 3 U1-59 0.3181 0.0274 3 Ab#6 IgG2 1.5161 0.5883 5

The results in Table 18 demonstrate that antibodies Sh24C05-25 N62S-IgG1, Sh24C05-25 N62S-IgG2, Sh24C05-31 N62S-IgG1, and Sh24C05-31 N62S-IgG2 efficiently neutralized NRG1-β1 binding to rhErbB3. While the anti-ErbB3 human antibodies Ab #6 IgG2, U1-53 and U1-59 also showed neutralization activity, the humanized Sh24C05 antibodies (i.e., Sh24C05-25 N62S-IgG1, Sh24C05-25 N62S-IgG2, Sh24C05-31 N62S-IgG1, and Sh24C05-31 N62S-IgG2) had superior neutralization capacity than U1-59 or Ab #6 IgG2.

Example 14—Anti-Proliferative Activity

In this example, the humanized antibodies produced in Example 12 were tested for their ability to inhibit NRG1-131 dependent proliferation of cells in the BaF/3 cell system engineered to express both human Her2 and ErbB3.

BaF/3 cells expressing Her2 and ErbB3 receptors as described in Example 6 were treated with anti-ErbB3 antibodies in the absence of WEHI conditioned media but in the presence of NRG1-β1 (100 ng/ml). Assays were conducted in a 96-well plate (5,000 cells/well) in the presence of NRG1-131 (100 ng/ml) and various concentrations of antibodies (0.018-5000 ng/ml in 100 μl of final volume). MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assays were conducted 3-4 days post NRG1-β1 stimulation.

The results demonstrate that Sh24C05-25 N62S-IgG1, Sh24C05-25 N62S-IgG2, Sh24C05-31 N62S-IgG1, and Sh24C05-31 N62S-IgG2 inhibited NRG induced Her2/ErbB3-BaF/3 cell proliferation in a dose dependent manner (FIG. 19A).

The IC₅₀ values for the inhibition of NRG1-β1 dependent Her2/ErbB3-BaF/3 cell line proliferation with the humanized 24C05 antibodies (i.e., Sh24C05-25 N62S-IgG1, Sh24C05-25 N62S-IgG2, Sh24C05-31 N62S-IgG1, Sh24C05-31 N62S-IgG2) were calculated and are summarized in Table 19.

TABLE 19 Her2/ErbB3-BaF/3, NRG1-β1 Dependent Proliferation Antibody IC₅₀ (nM)-Average Standard deviation n Sh24C05-25 N62S-IgG1 0.0981 0.0187 2 Sh24C05-25 N62S-IgG2 0.2482 0.0124 2 Sh24C05-31 N62S-IgG1 0.1245 0.0181 5 Sh24C05-31 N62S-IgG2 0.2392 0.0217 2 U1-53 0.8128 0.0268 3 U1-59 0.8364 0.0434 5 Ab#6 IgG2 6.3015 0.8577 2

The results in Table 19 demonstrate that antibodies Sh24C05-25 N62S-IgG1, Sh24C05-25 N62S-IgG2, Sh24C05-31 N62S-IgG1, and Sh24C05-31 N62S-IgG2 strongly inhibited NRG1-β1-induced proliferation of BaF/3 cells expressing Her2/ErbB3.

The inhibitory activity of anti-ErbB3 Ab #6 IgG2, U1-53 and U1-59 antibodies were also tested in the NRG1-β1 dependent Her2/ErbB3-BaF/3 cells proliferation assay. As shown in FIG. 19B, the results demonstrate that the Ab #6 IgG2, U1-53 and U1-59 antibodies inhibited NRG induced Her2/ErbB3-BaF/3 cell proliferation in a dose dependent manner. Inhibition data of NRG1-β1 dependent Her2/ErbB3-BaF/3 cell proliferation with antibodies Ab #6 IgG2, U1-53 and U1-59 are summarized in Table 19. The results in Table 19 demonstrate that antibodies Ab #6 IgG2, U1-53, and U1-59 inhibited NRG1-β1-induced proliferation of Her2/ErbB3-BaF/3 cells. A comparison of the inhibitory activity of the tested anti-ErbB3 antibodies in the NRG1-131 dependent Her2/ErbB3-BaF/3 cells proliferation assay indicates that the inhibitory activity of the humanized Sh24C05 antibodies is superior to the inhibitory activity of the Ab #6 IgG2, U1-53 and U1-59 antibodies (e.g., the IC₅₀ was 0.1245 nM for Sh24C05-31 N62S-IgG1 compared to 0.8128 nM for U1-53).

Example 15—Inhibition of Downstream Signaling in SKBR-3 Cells

This example describes a characterization of the humanized antibodies produced in Example 12 for their ability to degrade total ErbB3 and inhibit phosphorylation of ErbB3 in exponentially growing SKBR-3 cells.

The breast cancer SKBR-3 cells were maintained as recommended by ATCC. Cells maintained in full serum condition were treated for 1, 2, 4 or 6 hours with 40 μg/ml of anti-ErbB3 antibody (i.e., Sh24C05-25 N62S-IgG1, Sh24C05-25 N62S-IgG2, Sh24C05-31 N62S-IgG1, and Sh24C05-31 N62S-IgG2). Lysates were either analyzed by ELISA with the Total-ErbB3 and the Phospho-ErbB3 kit from R&D Systems (Cat. No DYC234 and Cat. No DYC1769, respectively).

The results demonstrate that anti-ErbB3 antibodies Sh24C05-25 N62S-IgG1, Sh24C05-25 N62S-IgG2, Sh24C05-31 N62S-IgG1, and Sh24C05-31 N62S-IgG2 inhibit at least 50% of the phosphorylation of ErbB3 in exponentially growing SKBR-3 cells (FIG. 20).

The results also demonstrate that anti-ErbB3 antibodies Sh24C05-25 N62S-IgG1, Sh24C05-25 N62S-IgG2, Sh24C05-31 N62S-IgG1, and Sh24C05-31 N62S-IgG2 degraded at least 50% of the total ErbB3 receptor present in exponentially growing SKBR-3 cells (FIG. 21).

Example 16—Inhibition of BxPC3 Tumor Xenograft Growth

The ability of the humanized monoclonal antibodies produced in Example 12 to inhibit tumor growth were tested in a BxPC3 pancreatic xenograft model. Human pancreatic BxPC3 cells were grown in culture in 37° C. in an atmosphere containing 5% CO2, using RMPI medium containing 10% fetal bovine serum. BxPC3 cells were inoculated subcutaneously into the flank of 8-week old female CB.17 SCID mice (Taconic Labs) with 10×10⁶ cells per mouse in 50% matrigel (BD Biosciences, Cat No. 356237). Tumor measurements were taken twice weekly using vernier calipers. Tumor volume was calculated using the formula: width×width×length/2. When tumors reached approximately 200 mm³, the mice were randomized into 8 groups of 10 mice each. One group received PBS, another received huIgG control, and another received muIgG control. Each of the remaining five groups received one of the antibodies (i.e., murine 24C05, Sh24C05-25 N62S-IgG1, Sh24C05-25 N62S-IgG2, Sh24C05-31 N62S-IgG1 or Sh24C05-31 N62S-IgG2). All of the antibodies were dosed at 2 mg/kg body weight, twice per week, by intra-peritoneal injection for 7 weeks. Tumor volumes and mouse body weights were recorded twice per week. Tumor growth inhibition was analyzed using ANOVA and is expressed as percent inhibition compared to the PBS control.

The tested humanized antibodies were active in vivo. All four humanized anti-ErbB3 antibodies had similar efficacy in the BxPC3 model when dosed at 2 mg/kg, ranging from 75-80% tumor growth inhibition (p<0.001) (i.e., Sh24C05-25 N62S-IgG1, 75%; Sh24C05-25 N62S-IgG2, 76%; Sh24C05-31 N62S-IgG1, 79%; and Sh24C05-31 N62S-IgG2, 80%) at day 28 of the study (FIG. 22). The murine antibody demonstrated 65% tumor growth inhibition in this study (p<0.05). These results suggest similar potency and activity of the four humanized antibodies in this model.

The ability of the humanized monoclonal antibodies U1-53, U1-59, and Ab #6 IgG2 to inhibit tumor growth were also tested in a BxPC3 xenograft model. Using the protocol described above, BxPC3 tumors were generated in CB.17 SCID mice. When tumors reached approximately 200 mm³, the mice were randomized into 11 groups of 10 mice each. One group received PBS and another received huIgG control. Each of the other nine groups received one of the humanized antibodies (i.e., Sh24C05-31 N62S-IgG1, U1-53, U1-59, or Ab #6 IgG2). The antibodies were dosed either at 0.5 mg/kg, 1 mg/kg, or 5 mg/kg body weight, twice per week, by intra-peritoneal injection for 7 weeks. Tumor volumes and mouse body weights were recorded twice per week. Tumor growth inhibition was analyzed using ANOVA and is expressed as percent inhibition compared to the PBS control.

Tumor growth inhibition data determined at day 29 following treatment with one of the humanized antibodies (i.e., Sh24C05-31 N62S-IgG1, U1-59, or Ab #6 IgG2) is shown in Table 20.

TABLE 20 Tumor ANOVA ANOVA Growth Analysis Analysis Treatment Inhibition (Compared (Compared Gr. Agent mg/kg (%) to PBS) to hIgG) 1 PBS — NA NA NA 2 hIgG 5 29.2 NS NS Sh24C05-31 3 N62S-IgG1 0.5 63.3 P < 0.001 P < 0.01  Sh24C05-31 4 N62S-IgG1 1 75.0 P < 0.001 P < 0.001 Sh24C05-31 5 N62S-IgG1 5 76.5 P < 0.001 P < 0.001 6 Ab#6 IgG2 0.5 31.5 P < 0.05  NS 7 Ab#6 IgG2 1 2.1 NS NS 8 Ab#6 IgG2 5 40.6 P < 0.001 NS 9 U1-59 0.5 32.6 P < 0.01  NS 10 U1-59 1 52.9 P < 0.001 NS 11 U1-59 5 60.3 P < 0.001 P < 0.05 

The results demonstrate that Sh24C05-31 N62S-IgG1 showed the greatest tumor growth inhibition by day 29 (76.5%, p<0.001) at a dose of 5 mg/kg in the BxPC3 pancreatic xenograft model. The U1-59 and Ab #6 IgG2 antibodies demonstrated approximately 60% and 41% tumor growth inhibition at a dose of 5 mg/kg in the BxPC3 model, respectively (P<0.001).

The results also demonstrate that Sh24C05-31 N62S-IgG1 showed the greatest tumor growth inhibition by day 29 at a dose of 0.5 mg/kg (63.3%, p<0.001) and at a dose of 1 mg/kg (75.0%, p<0.001) in the BxPC3 pancreatic xenograft model. The U1-59 and AB #6 IgG2 antibodies demonstrate approximately 33% (p<0.01) and 31% (p<0.05) tumor growth inhibition at a dose of 0.5 mg/kg in the BxPC3 model, respectively. The U1-59 and AB #6 IgG2 antibodies demonstrated approximately 53% (p<0.001) and 2% (not significant) tumor growth inhibition at a dose of 1.0 mg/kg in the BxPC3 model, respectively.

Example 17—Inhibition of Calu-3 Tumor Xenograft Growth

The ability of the humanized monoclonal antibodies produced in Example 12 to inhibit tumor growth was tested in a Calu-3 non-small cell lung cancer xenograft model. The ability of the humanized monoclonal antibodies U1-59 and Ab #6 IgG2, as described in Example 12, to inhibit tumor growth were also tested in the same model.

Human Non-Small Cell Lung Cancer Calu-3 cells were grown in culture in 37° C. in an atmosphere containing 5% CO2, using EMEM medium containing 10% fetal bovine serum. Calu-3 cells were inoculated subcutaneously into the flank of 8-week old female NCR nude mice (Taconic Labs) with 10×10⁶ cells per mouse in 50% matrigel (BD Biosciences, Cat No. 356237). Tumor measurements were taken twice weekly using vernier calipers. Tumor volume was calculated using the formula: width×width×length/2.

When tumors reached approximately 200 mm³, the mice were randomized into 11 groups of 10 mice each. One group received PBS and another received muIgG control. Each of the other nine groups received one of the humanized antibodies (i.e., Sh24C05-31 N62S-IgG1, U1-59, or Ab #6 IgG2) at a dose of either 5 mg/kg, 10 mg/kg or 20 mg/kg body weight, twice per week, by intra-peritoneal injection for 4 weeks. Tumor volumes and mouse body weights were recorded twice per week. Tumor growth inhibition was analyzed using ANOVA and is expressed as percent inhibition compared to the PBS control.

Tumor growth inhibition data determined at day 26 following treatment with one of the humanized antibodies (i.e., Sh24C05-31 N62S-IgG1, U1-59, or Ab #6 IgG2) is shown in Table 21.

TABLE 21 Tumor ANOVA ANOVA Growth Analysis Analysis Treatment Inhibition (Compared (Compared Gr. Agent mg/kg (%) to PBS) to hIgG) 1 PBS — NA NA NA 2 muIgG 20 −1.2 NS NA 3 Sh24C05-31 5 62.3 P < 0.001 P < 0.001 N62S-IgG1 4 Sh24C05-31 10 62.0 P < 0.001 P < 0.001 N62S-IgG1 5 Sh24C05-31 20 69.0 P < 0.001 P < 0.001 N62S-IgG1 6 Ab# IgG2 5 24.7 NS NS 7 Ab# IgG2 10 35.9 P < 0.01  P < 0.01  8 Ab# IgG2 20 48.4 P < 0.001 P < 0.001 9 U1-59 5 47.8 P < 0.001 P < 0.001 10 U1-59 10 56.7 P < 0.001 P < 0.001 11 U1-59 20 57.7 P < 0.001 P < 0.001

The results using the Calu-3 non-small cell lung cancer xenograft model demonstrate that Sh24C05-31 N62S-IgG1 showed the greatest tumor growth inhibition by day 26 at all doses tested (i.e., 5 mg/kg, 10 mg/kg, and 20 mg/kg of body weight).

For example, at the 10 mg/kg dose, Sh24C05-31 N62S-IgG1 showed the greatest tumor growth inhibition by day 26 (62%, P<0.001) when compared to Ab #6 IgG2 (36%, NS) or U1-59 (57%, P<0.001). At the 20 mg/kg dose, Sh24C05-31 N62S-IgG1 also showed the greatest tumor growth inhibition by day 26 (69%, P<0.001) when compared to Ab #6 IgG2 (48%, P<0.001) or U1-59 (58%, P<0.001).

Example 18—Inhibition of MDA-MB-453 Tumor Xenograft Growth

The ability of the humanized monoclonal antibodies produced in Example 12 to inhibit tumor growth were tested in a MDA-MB-453 breast xenograft model (which is a HER2 positive breast model). The ability of the humanized monoclonal antibodies U1-59 and Ab #6 IgG2, as described in Example 12, to inhibit tumor growth were also tested in the same model.

Human Breast MDA-MB-453 cells were grown in culture in 37° C. in an atmosphere containing 0% CO2, using Leibovitz ATCC medium (Cat No. 30-2008) containing 10% fetal bovine serum. MDA-MB-453 cells were inoculated subcutaneously into the flank of 8-week old female NOD SCID mice (Taconic Labs) with 20×10⁶ cells per mouse in 50% matrigel (BD Biosciences, Cat No. 356237). Tumor measurements were taken twice weekly using vernier calipers. Tumor volume was calculated using the formula: width×width×length/2.

When tumors reached approximately 200 mm³, the mice were randomized into 7 groups of 10 mice each. One group received PBS and another received huIgG control. Each of the other nine groups received one of the humanized antibodies (i.e., Sh24C05-31 N62S-IgG1, U1-59, or Ab #6 IgG2). Sh24C05-31 N62S-IgG1 was dosed either at 5 mg/kg, 10 mg/kg, or 20 mg/kg body weight, twice per week, by intra-peritoneal injection for more than 10 weeks; U1-59, or Ab #6 were dosed at 10 mg/kg with the same frequency. Tumor volumes and mouse body weights were recorded twice per week. Tumor growth inhibition was analyzed using ANOVA and is expressed as percent inhibition compared to the PBS control.

Tumor growth inhibition data determined at day 71 following treatment with one of the humanized antibodies (i.e., Sh24C05-31 N62S-IgG1, U1-59, or Ab #6 IgG2) is shown in Table 22.

TABLE 22 Tumor ANOVA ANOVA Growth Analysis Analysis Treatment Inhibition (Compared (Compared Gr. Agent mg/kg (%) to PBS) to hIgG) 1 PBS — NA NA NA 2 hIgG 20 28.87 p < 0.001 p < 0.001 Sh24C05-31 3 N62S-IgG1  5 86.57 p < 0.001 p < 0.001 Sh24C05-31 4 N62S-IgG1 10 84.09 p < 0.001 p < 0.001 Sh24C05-31 5 N62S-IgG1 20 85.26 p < 0.001 p < 0.001 6 Ab#6 IgG2 10 62.48 p < 0.001 p < 0.001 7 U1-59 10 83.93 p < 0.001 p < 0.001

The results using the MDA-MB-453 xenograft model demonstrate that Sh24C05-31 N62S-IgG1 showed potent tumor growth inhibition by day 71 at all doses tested (i.e., 5 mg/kg, 10 mg/kg, and 20 mg/kg of body weight).

The results also demonstrate that at the 10 mg/kg dose, Sh24C05-31 N62S-IgG1 showed greater tumor growth inhibition by day 71 (84%, P<0.001) when compared to Ab #6 IgG2 (62%, P<0.001). Sh24C05-31 N62S-IgG1 showed equivalent tumor growth inhibition as U1-59 at the same dose.

INCORPORATION BY REFERENCE

The entire disclosure of each of the patent documents and scientific articles referred to herein is incorporated by reference for all purposes.

EQUIVALENTS

The invention may be embodied in other specific forms without departing from the spirit or essential characteristics thereof. The foregoing embodiments are therefore to be considered in all respects illustrative rather than limiting on the invention described herein. Scope of the invention is thus indicated by the appended claims rather than by the foregoing description, and all changes that come within the meaning and the range of equivalency of the claims are intended to be embraced therein. 

1. An isolated antibody that binds human ErbB3 comprising an immunoglobulin heavy chain variable region and an immunoglobulin light chain variable region selected from the group consisting of: (a) (i) an immunoglobulin heavy chain variable region comprising a CDR_(H1) comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 57 (24C05) and SEQ ID NO: 75 (24C05), a CDR_(H2) comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 58 (24C05) and SEQ ID NO: 148 (Sh24C05 Hv3-11 N62S), and a CDR_(H3) comprising the amino acid sequence of SEQ ID NO:59 (24C05); and (ii) an immunoglobulin light chain variable region comprising a CDR_(L1) comprising the amino acid sequence of SEQ ID NO: 60 (24C05), a CDR_(L2) comprising the amino acid sequence of SEQ ID NO: 61 (24C05), and a CDR_(L3) comprising the amino acid sequence of SEQ ID NO: 62 (24C05); (b) (i) an immunoglobulin heavy chain variable region comprising a CDR_(H1) comprising the amino acid sequence of SEQ ID NO: 5 (04D01), a CDR_(H2) comprising the amino acid sequence of SEQ ID NO: 6 (04D01), and a CDR_(H3) comprising the amino acid sequence of SEQ ID NO: 7 (04D01); and (ii) an immunoglobulin light chain variable region comprising a CDR_(L1) comprising the s amino acid sequence of SEQ ID NO: 8 (04D01), a CDR_(L2) comprising the amino acid sequence of SEQ ID NO: 9 (04D01), and a CDR_(L3) comprising the amino acid sequence of SEQ ID NO: 10 (04D01); (c) (i) an immunoglobulin heavy chain variable region comprising a CDR_(H1) comprising the amino acid sequence of SEQ ID NO: 15 (09D03), a CDR_(H2) comprising the amino acid sequence of SEQ ID NO: 16 (09D03), and a CDR_(H3) comprising the amino acid sequence of SEQ ID NO: 17 (09D03); and (ii) an immunoglobulin light chain variable region comprising a CDR_(L1) comprising the amino acid sequence of SEQ ID NO: 18 (09D03), a CDR_(L2) comprising the amino acid sequence of SEQ ID NO: 19 (09D03), and a CDR_(L3) comprising the amino acid sequence of SEQ ID NO: 20 (09D03); (d) (i) an immunoglobulin heavy chain variable region comprising a CDR_(H1) comprising the s amino acid sequence of SEQ ID NO: 25 (11G01), a CDR_(H2) comprising the amino acid sequence of SEQ ID NO: 26 (11G01), and a CDR_(H3) comprising the amino acid sequence of SEQ ID NO: 27 (11G01); and (ii) an immunoglobulin light chain variable region comprising a CDR_(L1) comprising the amino acid sequence of SEQ ID NO: 28 (11G01), a CDR_(L2) comprising the amino acid sequence of SEQ ID NO: 9 (11G01), and a CDR_(L3) comprising the amino acid sequence of SEQ ID NO: 29 (11G01); (e) (i) an immunoglobulin heavy chain variable region comprising a CDR_(H1) comprising the amino acid sequence of SEQ ID NO: 34 (12A07), a CDR_(H2) comprising the amino acid sequence of SEQ ID NO: 35 (12A07), and a CDR_(H3) comprising the amino acid sequence of SEQ ID NO: 36 (12A07); and (ii) an immunoglobulin light chain variable region comprising a CDR_(L1) comprising the amino acid sequence of SEQ ID NO: 8 (12A07), a CDR_(L2) comprising the amino acid sequence of SEQ ID NO: 9 (12A07), and a CDR_(L3) comprising the amino acid sequence of SEQ ID NO: 10 (12A07); (f) (i) an immunoglobulin heavy chain variable region comprising a CDR_(H1) comprising the amino acid sequence of SEQ ID NO: 41 (18H02), a CDR_(H2) comprising the amino acid sequence of SEQ ID NO: 42 (18H02), and a CDR_(H3) comprising the amino acid sequence of SEQ ID NO: 43 (18H02); and (ii) an immunoglobulin light chain variable region comprising a CDR_(L1) comprising the amino acid sequence of SEQ ID NO: 44 (18H02), a CDR_(L2) comprising the amino acid sequence of SEQ ID NO: 45 (18H02), and a CDR_(L3) comprising the amino acid sequence of SEQ ID NO: 46 (18H02); and (g) (i) an immunoglobulin heavy chain variable region comprising a CDR_(H1) comprising the amino acid sequence of SEQ ID NO: 51 (22A02), a CDR_(H3) comprising the amino acid sequence of SEQ ID NO: 52 (22A02), and a CDR_(H3) comprising the amino acid sequence of SEQ ID NO: 36 (22A02); and (ii) an immunoglobulin light chain variable region comprising a CDR_(L1) comprising the amino acid sequence of SEQ ID NO: 8 (22A02), a CDR_(L2) comprising the amino acid sequence of SEQ ID NO: 9 (22A02), and a CDR_(L3) comprising the amino acid sequence of SEQ ID NO: 10 (22A02).
 2. (canceled)
 3. The antibody of claim 1, wherein the immunoglobulin heavy chain variable region comprises a CDR_(H1) comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 57 (24C05) and SEQ ID NO: 75 (24C05), a CDR_(H3) comprising the amino acid sequence of SEQ ID NO: 148 (Sh24C05 Hv3-11 N62S), and a CDR_(H3) comprising the amino acid sequence of SEQ ID NO:59 (24C05); and wherein the immunoglobulin light chain variable region comprises a CDR_(L1) comprising the amino acid sequence of SEQ ID NO: 60 (24C05), a CDR_(L2) comprising the amino acid sequence of SEQ ID NO: 61 (24C05), and a CDR_(L3) comprising the amino acid sequence of SEQ ID NO: 62 (24C05).
 4. The antibody of claim 1, wherein the CDR sequences are interposed between human and humanized framework sequences.
 5. The antibody of claim 1, wherein the antibody is an antigen-binding fragment.
 6. An isolated nucleic acid comprising a nucleotide sequence encoding an immunoglobulin heavy chain variable region of claim
 1. 7. An isolated nucleic acid comprising a nucleotide sequence encoding an immunoglobulin light chain variable region of claim
 1. 8. An expression vector comprising the nucleic acid of claim
 6. 9. An expression vector comprising the nucleic acid of claim
 7. 10. (canceled)
 11. A host cell comprising the expression vector of claim
 8. 12. A host cell comprising the expression vector of claim
 9. 13-16. (canceled)
 17. An isolated antibody that binds human ErbB3 comprising an immunoglobulin heavy chain variable region and an immunoglobulin light chain variable region selected from the group consisting of: (a) an immunoglobulin heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 54 (24C05), and an immunoglobulin light chain variable region comprising the amino acid sequence of SEQ ID NO: 56 (24C05); (b) an immunoglobulin heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 154 (Sh24C05 Hv3-11 N62S), and an immunoglobulin light chain variable region comprising the amino acid sequence of SEQ ID NO: 168 (Sh24C05 Kv1-17); (c) an immunoglobulin heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 154 (Sh24C05 Hv3-11 N62S), and an immunoglobulin light chain variable region comprising the amino acid sequence of SEQ ID NO: 166 (Sh24C05 Kv1-16); (d) an immunoglobulin heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 2 (04D01), and an immunoglobulin light chain variable region comprising the amino acid sequence of SEQ ID NO: 4 (04D01); (e) an immunoglobulin heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 12 (09D03), and an immunoglobulin light chain variable region comprising the amino acid sequence of SEQ ID NO: 14 (09D03); (f) an immunoglobulin heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 22 (11G01), and an immunoglobulin light chain variable region comprising the amino acid sequence of SEQ ID NO: 24 (11G01); (g) an immunoglobulin heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 31 (12A07), and an immunoglobulin light chain variable region comprising the amino acid sequence of SEQ ID NO: 33 (12A07); (h) an immunoglobulin heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 38 (18H02), and an immunoglobulin light chain variable region comprising the amino acid sequence of SEQ ID NO: 40 (18H02); and (i) an immunoglobulin heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 48 (22A02), and an immunoglobulin light chain variable region comprising the amino acid sequence of SEQ ID NO: 50 (22A02).
 18. (canceled)
 19. The antibody of claim 17, wherein the immunoglobulin heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 154 (Sh24C05 Hv3-11 N62S), and the immunoglobulin light chain variable region comprises the amino acid sequence of SEQ ID NO: 168 (Sh24C05 Kv1-17). 20-31. (canceled)
 32. An isolated antibody that binds human ErbB3 comprising an immunoglobulin heavy chain and an immunoglobulin light chain selected from the group consisting of: (a) an immunoglobulin heavy chain comprising the amino acid sequence of SEQ ID NO: 133 (24C05), and an immunoglobulin light chain comprising the amino acid sequence of SEQ ID NO: 135 (24C05); (b) an immunoglobulin heavy chain comprising the amino acid sequence of SEQ ID NO: 190 (Sh24C05 Hv3-11 N62S IgG1), and an immunoglobulin light chain comprising the amino acid sequence of SEQ ID NO: 206 (Sh24C05 Kv1-17 kappa); (c) an immunoglobulin heavy chain comprising the amino acid sequence of SEQ ID NO: 190 (Sh24C05 Hv3-11 N62S IgG1), and an immunoglobulin light chain comprising the amino acid sequence of SEQ ID NO: 204 (Sh24C05 Kv1-16 kappa); (d) an immunoglobulin heavy chain comprising the amino acid sequence of SEQ ID NO: 109 (04D01), and an immunoglobulin light chain comprising the amino acid sequence of SEQ ID NO: 111 (04D01); (e) an immunoglobulin heavy chain comprising the amino acid sequence of SEQ ID NO: 113 (09D03), and an immunoglobulin light chain comprising the amino acid sequence of SEQ ID NO: 115 (09D03); (f) an immunoglobulin heavy chain comprising the amino acid sequence of SEQ ID NO: 117 (11G01), and an immunoglobulin light chain comprising the amino acid sequence of SEQ ID NO: 119 (11G01); (g) an immunoglobulin heavy chain comprising the amino acid sequence of SEQ ID NO: 121 (12A07), and an immunoglobulin light chain comprising the amino acid sequence of SEQ ID NO: 123 (12A07); (h) an immunoglobulin heavy chain comprising the amino acid sequence of SEQ ID NO: 125 (18H02), and an immunoglobulin light chain comprising the amino acid sequence of SEQ ID NO: 127 (1811024); and (i) an immunoglobulin heavy chain comprising the amino acid sequence of SEQ ID NO: 129 (22A02), and an immunoglobulin light chain comprising the amino acid sequence of SEQ ID NO: 131 (22A02).
 33. (canceled)
 34. The antibody of claim 32, wherein the immunoglobulin heavy chain comprises the amino acid sequence of SEQ ID NO: 190 (Sh24C05 Hv3-11 N62S IgG1), and the immunoglobulin light chain comprises the amino acid sequence of SEQ ID NO: 206 (Sh24C05 Kv1-17 kappa).
 35. The antibody of claim 32, wherein the immunoglobulin heavy chain comprises the amino acid sequence of SEQ ID NO: 190 (Sh24C05 Hv3-11 N62S IgG1), and the immunoglobulin light chain comprises the amino acid sequence of SEQ ID NO: 204 (Sh24C05 Kv1-16 kappa).
 36. The antibody of claim 17, wherein the antibody is an antigen binding fragment. 37-47. (canceled)
 48. The antibody of claim 1, wherein the antibody has a K_(D) of 200 pM or lower as measured by surface plasmon resonance.
 49. A method of inhibiting or reducing proliferation of a tumor cell comprising exposing the cell to an effective amount of the antibody of claim 1 to inhibit or reduce proliferation of the tumor cell.
 50. A method of inhibiting or reducing tumor growth in a mammal, the method comprising exposing the mammal to an effective amount of the antibody of claim 1 to inhibit or reduce proliferation of the tumor.
 51. A method of treating cancer in a mammal, the method comprising administering an effective amount of the antibody of claim 1 to a mammal in need thereof. 52-54. (canceled) 